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Recent studies have shown that osteoblasts (OBs), the bone-forming cells of the 
skeleton, play a central role in regulating systemic glucose metabolism, with 
dysregulation of insulin signalling in OBs eliciting profound effects on glucose 
homeostasis. mTORC1 is the primary nutrient sensor in eukaryotic cells that 
coordinates anabolic and catabolic processes to control cell growth. mTORC1 is a 
crucial mediator and prolonged mTORC1 activation leads to insulin resistance 
suggesting modulation of mTORC1 function in OBs may affect glucose homeostasis. 
Furthermore, as aberrant activation of mTORC1 signalling leads to the development of 
insulin resistance, a chronic pathology associated with the development of type 2 
diabetes mellitus (T2DM), aberrant mTORC1 signalling in OBs may contribute to the 
development of T2DM and associated diseases. 
This project investigated the role of OB-specific mTORC1 in the regulation of systemic 
glucose and energy metabolism. To achieve this, mice with conditional deletion of 
Rptor, an essential component of mTORC1, in pre-OBs were utilised (Rptorob
-/-
). The 
metabolic phenotype of these mice was evaluated using a complementary suite of 
metabolic tests, coupled with detailed assessment of the effect of OB-specific mTORC1 
disruption on insulin-responsive tissues. The role of skeletal mTORC1 signalling in the 
development of insulin resistance in response to an obesogenic high fat diet (HFD; 40% 
calories from fat) was also explored. 
Rptorob
-/-
 mice exhibited enhanced insulin secretion and sensitivity when fed with a 
normal diet. While both sexes were markedly lean and showed a preference for fat 
utilisation and elevated ketone body levels, sex-dependent differences in body 
composition and energy metabolism were observed. Specifically, a significant decrease 
in fat mass, white adipocyte size and an increase in glucose tolerance was observed in 
male, but not female, Rptorob
-/-
 mice compared to controls. Mechanistically, these 
improved metabolic indices were found to occur independently of osteocalcin, the major 
bone secretagogue, and instead were likely attributable to elevated adiponectin levels 
arising from increased bone marrow adiposity.  
When placed on HFD for 12 weeks, Rptorob
-/- 
mice were resistant to diet-induced weight 
gain and displayed a significant reduction in fat mass, adipocyte hypertrophy and 
hepatic steatosis.  Rptorob
-/- 
mice had significantly lower fasting glucose and insulin 
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levels and exhibited increased tolerance to glucose and improved insulin sensitivity. 
The obesity-resistant phenotype of Rptorob
-/- 
mice was independent of food intake, 
physical activity or lipid absorption. Instead, Rptorob
-/- 
mice maintained greater substrate 
flexibility and exhibited browning of white adipose. 
RNA-sequencing and gene set enrichment analysis revealed positively enriched gene 
sets for glycolysis and insulin signalling pathways in the bones of Rptorob
-/- 
mice. 
Consistent with this, potentiated insulin signalling was observed in Rptorob
-/- 
bone and 
Rptor knockout OBs in vitro where a profound increase in basal and insulin-dependent 
glucose uptake was observed. 
The studies detailed in this thesis demonstrate that suppression of skeletal mTORC1 
signalling in mice leads to a dramatic improvement in glucose metabolism and 
protection from diet-induced obesity and insulin resistance. Collectively, these results 
point to a critical role for the mTORC1 complex in osteoblasts in integrating whole-
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The skeleton has recently emerged as a critical insulin target tissue that regulates whole 
body glucose metabolism and male reproductive function. While our understanding of 
these new regulatory axes remains in its infancy, the bone-specific protein, osteocalcin, 
has been shown to be centrally involved. Undercarboxylated osteocalcin acts as a 
secretagogue in a feed-forward loop to stimulate pancreatic β-cell proliferation and 
insulin secretion, improve insulin sensitivity and promote testosterone production. 
Importantly, dysregulation of insulin signalling in bone causes a reduction in serum 
osteocalcin levels that is associated with elevated blood glucose and reduced serum 
insulin levels, suggesting the significant role of the skeleton in the development of diet-
induced insulin resistance. Insulin signalling is negatively regulated by the mammalian 
target of rapamycin complex 1 (mTORC1) which becomes hyper-activated in response 
to nutrient overload. Loss- and gain-of function models suggest that mTORC1 function 
in bone is essential for normal skeletal development; however, the role of this complex 
in the regulation of glucose metabolism remains to be determined. This review 
highlights our current understanding of the role played by osteocalcin in the skeletal 
regulation of glucose metabolism and fertility. In particular, it examines data emerging 
from transgenic mouse models which have revealed a pancreas-bone-testis regulatory 
axis and discusses recent human studies which seek to corroborate findings from mouse 
models with clinical observations. Moreover, we review recent studies which suggest 
dysregulation of insulin signalling in bone leads to the development of insulin resistance 




Bone is a specialized connective tissue that provides mechanical support for organs, acts 
as an anchor site for muscles to facilitate locomotion, protects vital organs, houses the 
hematopoietic bone marrow and serves as a metabolic reservoir for calcium and 
phosphate to maintain mineral homeostasis. In healthy adults, old bone is constantly 
being resorbed by osteoclasts (OCs) and new bone is formed by osteoblasts (OBs) in a 
coordinated process known as bone remodeling
1
. Under normal physiological 
conditions, the two phases of bone remodelling (i.e. bone resorption and bone 
formation) occur in a sequential and balanced manner to maintain a net balance in bone 
volume.  
Maintenance of skeletal integrity comes at a high cost in terms of energy demand. This 
is best illustrated in anorexia nervosa, where reduced food intake leads to impaired bone 
growth in children and low bone mass in adults
2,3
. Conversely, obesity is associated 
with an increase in bone density and protection against osteoporosis in males
4
. 
Moreover, osteoporosis is positively associated with sarcopenia, whereas increased 
muscle mass is associated with increased bone mass and reduced fracture risk in post-
menopausal women
5
. Skeletal integrity and bone growth are also influenced by sex 
steroid hormones; gonadal failure in both genders triggers bone loss, and the absence of 
sex hormones in post-menopausal women leads to osteoporosis
6,7
. Taken together, these 
clinical observations highlight the existence of an interconnected regulatory network 
coordinating bone growth, energy metabolism and reproductive function. 
The OB-specific protein, osteocalcin (OCN), has recently been identified as a hormone 
that regulates glucose homeostasis, energy expenditure, male fertility, brain 
development and cognition. OCN is regulated by insulin signalling in OBs (Figure 1.1) 
and, in a feed-forward loop, OCN stimulates pancreatic β-cell proliferation and insulin 
secretion and improves insulin sensitivity in peripheral tissues. This newly assigned 
metabolic role for the skeleton raises important questions as to the normal physiological 
and pathophysiological regulation of glucose metabolism by the skeleton. This review 
focuses on the role played by OCN in the skeletal regulation of glucose metabolism and 
male fertility and highlights the importance of the skeleton in the regulation of whole-
body metabolism. Furthermore, this review describes recent studies which suggest that 
dysregulation of insulin signalling in bone leads to the development of insulin resistance 






Figure 1.1 Insulin signalling in osteoblasts promotes osteocalcin bio-activation. In 
the absence of insulin, FOXO1, in cooperation with ATF4, activates Esp gene 
expression and the production of OST-PTP, which in turn negatively regulates InsR 
signalling. FoxO1 also increases expression of Opg, a decoy receptor for RANKL, 
which inhibits osteoclast differentiation and bone resorption by interrupting the 
interaction between RANKL and RANK, a receptor for RANKL. Simultaneously, 
FOXO1 and TWIST2 act on RUNX2 to prevent Bglap, gene encoding OCN expression, 
and OCN production. Activation of insulin signalling inhibits FOXO1 and TWIST2 
which promotes OCN production and activation (via decarboxylation). Insulin 
suppresses OPG production, which stimulates osteoclast activity and the formation of 
an acidic resorption lacunae, facilitating the decarboxylation of OCN into its bio-active, 
undercarboxylated form (unOCN) and its release into the circulation. (Modified from 
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with permission from the publisher, Elsevier.) 
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1.3 The discovery of OCN as an endocrine regulator of energy metabolism 
OCN is a highly conserved 11kDa protein that is initially synthesized as pre-pro-OCN, 
which undergoes proteolytic cleavage to form the mature OCN peptide
8
. OCN 
undergoes further posttranslational modification in the lumen of the endoplasmic 
reticulum, whereby a second carboxyl group is added to glutamic acid (Glu) residues 
13, 17 and 20 (mouse) or 17, 21 and 24 (human) to form γ-carboxyglutamyl (Gla) 
residues. This vitamin K (VK)-dependent γ-carboxylation leads to a conformational 
change in OCN that confers a high affinity for calcium and hydroxyapatite, the mineral 
component of the bone extracellular matrix (ECM)
9
. During bone remodelling, the low 
pH present within OC resorption lacunae promotes the decarboxylation of Gla-OCN 
into Glu-OCN (herein referred to as undercarboxylated OCN (unOCN)), which reduces 
its affinity for bone and facilitates its release into the circulation
10
.  
OCN is the most abundant non-collagen bone matrix protein and has been widely used 
as a biochemical serum marker of bone formation
11
. While the precise molecular 
mechanisms remain unclear, OCN has been shown to control bone mineralization and to 
limit bone formation in mice
12
. Intriguingly, in addition to having an increased bone 
mass phenotype, Ocn knockout mice (Ocn
-/-
) have increased levels of visceral fat
12,13
, 
which suggests that OCN may also regulate energy metabolism. In line with this, Ocn
-/-
 
mice exhibit hyperglycaemia, hypoinsulinemia, impaired insulin secretion and 
sensitivity and are glucose intolerant
13
. These defects in glucose homeostasis are 
accompanied by a reduction in pancreatic islet size and number and reduced -cell mass 
and insulin content
13
. In vitro, OCN increases glucose-stimulated insulin secretion in β-
cells, maintained in either low or high glucose
14
 and dose-dependently induces the 
expression of β-cell Ins1, Ins2, Ccnd2 and Cdk4
15
. In vivo, long-term administration of 
OCN to wild-type (WT) mice improves glucose-stimulated insulin secretion and 
glucose tolerance
15
. Taken together, these findings demonstrate that OCN directly acts 
on pancreatic β-cells to promote insulin expression and secretion and β-cell 
proliferation.     
1.3.1 Sensitizing effects of OCN: direct and indirect mechanisms 
Despite increased levels of visceral fat, the insulin-resistant phenotype observed in Ocn
-
/-
 mice is associated with significantly lower serum levels of adiponectin, an adipocyte-
specific insulin-sensitizing hormone
13
. This observation suggests that OCN may also 
regulate insulin sensitivity via adiponectin. Indeed, compound mice harbouring a 
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heterozygous deletion of Ocn and Adipoq exhibit lower adiponectin levels and are 
insulin resistant, despite no detectable changes in insulin secretion, fasting glucose 
levels and serum insulin levels
13
. Furthermore, mice deficient in Esp (encoding 
osteotesticular protein tyrosine phosphatase (OST-PTP)), which regulates OCN 
carboxylation: Esp
-/-
 mice) display improved glucose tolerance and increased insulin 







 mice also have significantly elevated serum unOCN levels and 
increased adiponectin levels
13
. Furthermore, in vitro studies have shown that 
supplementation of adipocyte cultures with unOCN, but not Gla-OCN, results in a dose-
dependent increase in adiponectin expression
13,15
. Uncarboxylated OCN has 
subsequently been shown to induce an accumulation of cAMP in adipocytes that 
activates CREB (cAMP response element binding protein) leading to the upregulation 
of peroxisome proliferator-activated receptor γ (PPARγ) and induction of adiponectin 
gene expression
16
. It should also be noted that addition of adiponectin to OB cultures 
stimulates OCN secretion
17
, and siRNA-mediated knockdown of AdipoR1 in MC3T3-
E1 cells, leads to a decrease in OCN expression
18
. These data suggest that an endocrine 
loop between bone and adipose tissue may exist, where OCN regulates adipose-derived 
adiponectin levels and insulin sensitivity and, in turn, adiponectin acts on bone to 
regulate OCN levels. 
Independent to the insulin-sensitizing effects of adiponectin, OCN can also directly 
regulate glucose metabolism in skeletal muscle. In vitro, unOCN enhances insulin-
stimulated glucose uptake and up-regulates Akt signalling by activation of ERK kinase 
(MEK) in differentiated C2C12 myotubes
19
. In vivo, transient or chronic administration 
of unOCN to 12-week-old mice was found to improve the exercise capacity of WT mice 
without affecting insulin levels
20
. Furthermore, chronic administration of unOCN to 
aged mice (15 months of age) restored their exercise capacity to the same level as 3-
month-old mice and led to increased muscle mass
20,21
. This improvement in exercise 
capacity can be attributed to the OCN-dependent increase in glycogen and fatty acid 
catabolism in muscle fibers
21
. Furthermore, OCN signalling in muscle fibres directly 
stimulates glucose uptake by inducing the translocation of the glucose transporter, 
GLUT4, to the plasma membrane
21
. OCN was identified as a major regulator of 
interleukin-6 (IL-6) expression in muscle, a myokine whose plasma levels increase 
during exercise and enhances exercise capacity. IL-6 promotes glucose uptake and fatty 





Moreover, in vitro, IL-6 stimulates the expression of Rankl and suppresses Opg in OBs, 
factors that favour bone resorption
21
. Thus, in a feedforward loop, OCN stimulates IL-6 
production in muscle which in turn binds to OBs to favour the decarboxylation 
(activation) of OCN by stimulating bone resorption. 
1.3.2 The undercarboxylated form of OCN is responsible for the metabolic functions 
of OCN 
While both Gla-OCN and unOCN are detectable in the peripheral circulation
23,24
, 
several in vivo mouse models have suggested that the endocrine functions of OCN are 
mediated by unOCN, and not Gla-OCN. unOCN administration to WT mice 
significantly improves glucose tolerance and insulin sensitivity
25,26
, and intermittent 
injection of unOCN can protect mice from diet-induced insulin resistance and obesity
25
. 
Moreover, unOCN administration to Ocn
-/-
 mice improves their glucose tolerance and 
insulin secretion
13
. In addition, partial or complete OB-specific inactivation of 
γ-glutamyl carboxylase (Ggcx), results in a 3-fold or >15-fold increase in unOCN 
levels, respectively
27
. This increase in unOCN levels is associated with either 
unchanged or decrease in circulating levels of Gla-OCN in the partial or complete OB-
specific inactivation of Ggcx, respectively, (with total OCN levels remaining 
unchanged), and improved glucose tolerance in mice fed with normal chow
27
. 
Importantly, inactivation of OB-specific Ggcx is sufficient to prevent diet-induced 
glucose intolerance in mice fed with a high fat diet (HFD)
27
. Conversely, while in vivo 
administration of Gla-OCN has not been performed so far, in vitro studies have revealed 
that Gla-OCN fails to induce Adipoq expression in cultured adipocytes and Ins and 
Ccnd1 expression in islet cultures
13
. Taken together, these data demonstrate that the 
endocrine function of OCN is mediated by unOCN, but not Gla-OCN.   
1.4 Insulin signalling, bone remodelling and regulation of OCN 
1.4.1 Insulin signalling in OBs favours bone remodelling to increase OCN bioactivity 
OBs express abundant levels of the insulin receptor (INSR) and respond to insulin by 
upregulating the expression of anabolic bone markers and increasing collagen synthesis, 
alkaline phosphatase production and glucose uptake
28,29
. In addition, localized insulin 
delivery accelerates fracture healing by enhancing bone formation in vivo
30
, whereas 
insulin deficiency, as observed in patients with type 1 diabetes, is associated with low 






Insulin signalling in OBs controls OB development and differentiation. Mice with OB-
specific deletion of INSR (INSR
OB-/-
) display impaired postnatal trabecular bone 
formation and decreased serum levels of bone resorption markers
32
, and the addition of 
insulin to OB cultures increases OB proliferation and differentiation
33
. While OC 
numbers in INSR
OB-/-
 mice are unchanged compared to controls, OC activity is 
significantly reduced
32
. This reduction in OC activity is secondary to increased 
expression of osteoprotegerin (OPG), a soluble decoy receptor for the potent 
osteoclastic factor, receptor activator of nuclear factor kappa B ligand (RANKL). 
Binding of OPG to RANKL prevents the binding of RANKL to the RANK receptor on 
OCs, thereby inhibiting osteoclastogenesis (Figure 1.1).  
Importantly, INSR
OB-/-
 mice have significantly decreased serum levels of total OCN and 
unOCN compared to WT controls. The impaired OC activity and low circulating 
unOCN levels in INSR
OB-/-
 mice suggests that OCs might be responsible for the 
decreased decarboxylation of OCN in these mice. Indeed, Opg
-/-
 mice, which exhibit 
increased OC numbers, have significantly higher serum unOCN levels while OC 
ablation in adult mice results in significantly lower serum unOCN levels
34
.  
As outlined in Figure 1.1, insulin signalling favours bone resorption by increasing the 
expression of CTSK (Cathepsin K),
 
a lysosomal protease, and Tcirg1, a proton pump 
component, in OCs 
32
. The increased expression of Tcirg1 enhances proton transport 
into OC resorption lacunae and increases bone matrix acidification (i.e. lowering pH), 
facilitating the decarboxylation of OCN and its release into the circulation.  These data 






OB-insulin signalling also directly induces OCN expression by attenuating the negative 
actions of the Twist2 transcription factor on RUNX2, an OB-specific transcription 
factor and key activator of Bglap
13,36
. Moreover, OB-insulin signalling indirectly 
regulates OCN expression and activity through its downstream targets, FoxO1 and 
ATF4. In the absence of insulin signalling, FOXO1 induces Esp and Opg expression 
37
 
and physically interacts with RUNX2 preventing it from binding to its cognate binding 
site within the Bglap promoter
38
. ATF4, a negative regulator of insulin signalling and a 
transcription factor required for OB function, has been shown to co-localize with 
FOXO1 to induce the expression of Esp
39
. As a result, OB-specific FoxO1 knockout 
mice (FoxO1
OB-/-
) exhibit increased Ocn expression, decreased Esp expression and 
increased serum unOCN levels
37
, whereas over-expression of ATF4, either in all tissues 











 mice display 
improved glucose disposal and insulin sensitivity due to increased β-cell mass and 
increased serum adiponectin levels, which highlights the synergistic effect of these two 
OB transcription factors in regulating glucose homeostasis
37,39,40
. In addition, 
phosphorylation-mediated destabilization of FOXO1 by insulin signalling in OBs leads 
to nuclear exclusion of FOXO1, thereby reducing its ability to activate the Esp and Opg 
promoters and inhibit Runx2 activity. Thus, in a feed-forward loop, insulin signalling in 
OBs promotes the production of unOCN by OBs, which in turn enhances insulin 
production and release by pancreatic -cells
13,35
.  
1.4.2 Insulin signalling in OBs is required for proper glycaemic control 
Deletion of the INSR in OBs not only affects bone development but also results in 
metabolic abnormalities including hyperglycaemia, hypoinsulinemia, insulin resistance 
and increased peripheral adipose deposits
32,35
. Importantly, OBs express significant 
levels of GLUT4, an insulin-dependent glucose transporter
41
. In vitro ablation of 
GLUT4 in OBs impairs insulin-stimulated glucose uptake while OB-specific GLUT4 
knockout (ΔGlut4) mice exhibit increased peripheral fat deposition, hyperinsulinemia 
and insulin resistance
41
. Analysis of the transcript levels of insulin-sensitive genes in 
white adipose tissue and skeletal muscle of ΔGlut4 mice revealed unchanged or 
increased expression levels, indicating that the development of insulin resistance in 





Further evidence for the importance of bone as a significant site of glucose disposal has 
been revealed in studies utilizing radiolabelled glucose and whole-body bio-distribution 
studies. Using euglycaemic hyperinsulinemic clamping, administration of 2-[U-
14
C] 
deoxyglucose to 12-week-old WT mice revealed that, in the insulin-independent 
manner, bone takes up 20% of the quantity of glucose taken up by skeletal muscle and 
50% of what is taken up by white adipose tissue
42
. In a more-recent study, using 




F]-FDG) uptake in bone (tibia) was shown to be 
significantly higher than classical insulin target and glucose-storing tissues including 
liver, muscle (quadriceps) and adipose tissues (gonadal WAT) (50%, 80% and 90% 
higher in bone respectively)
43
. Furthermore, insulin administration significantly 
increased skeletal accumulation of [
18
F]-FDG while decreased skeletal accumulation of 
[
18




. Importantly, in WT mice fed a HFD to 
induce an insulin-resistant state, the skeletal uptake of [
18
F]-FDG is significantly 
reduced
43
. While the mode of glucose administration, age of the mice and experimental 
design are likely to account for the observed difference in uptake rates observed in these 
studies; taken together, these results highlight the importance of the skeleton as an 
insulin-target tissue and raises important questions as to the role of the skeleton in the 
development and treatment of diet-induced induced insulin resistance. 
1.5 Skeletal insulin resistance disrupts whole-body glucose homeostasis 
While OBs have been shown to contribute to the maintenance of whole-body glucose 
homeostasis, their role in the development of insulin resistance, a major cause of type 2 
diabetes mellitus (T2DM), has only recently been investigated. As previously discussed, 
insulin signalling in OBs is essential for whole-body glucose homeostasis in mice fed 
with normal chow. When challenged with a HFD, mice over-expressing the INSR in 
OBs have smaller fat deposits and lower fasting glucose and insulin levels, metabolic 





 mice fed a HFD have significantly lower serum levels of unOCN 
and develop more severe metabolic abnormalities compared to WT littermates
25
. These 
findings suggest that insulin signalling in bone plays an important role in the 
development of diet-induced insulin resistance. Indeed, WT mice fed a HFD develop 
insulin resistance in OBs, as evidenced by a decrease in insulin-stimulated activation of 
AKT, an important insulin effector protein
44
. This decrease in responsiveness to insulin 
can be partially rescued by over-expressing INSR in OBs. Conversely, reducing the 
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level of INSR in OBs by deleting one allele of INSR (Col1a1-INSR
+/-
) exacerbates 
HFD-induced skeletal insulin resistance
44





mice fed a HFD can be rescued by daily 
administration of unOCN
25,44
. These data demonstrate that insulin resistance in OBs 
leads to a reduction in serum unOCN levels which, at least in part, leads to impaired 
glucose tolerance and insulin resistance in mice. 
1.5.1 mTORC1 negatively regulates insulin signalling – implications for insulin 
resistance 
mTORC1 is a central regulator of growth and metabolism in all eukaryotes and is 
controlled by nutrients, growth factors and cellular energy status (reviewed in 
45
). In 
response to insulin, mTORC1 signalling promotes mRNA translation, ribosome 
biogenesis, protein synthesis and the activation of anabolic cellular processes
46
 (Fig. 
1.2). mTORC1 also negatively regulates insulin signalling by disrupting the interaction 
between INSR and its adaptor protein, IRS1. Several pathways involved this mTORC1-
mediated negatively regulation of insulin signalling include (1) activation of S6K1 
which mediates IRS1 phosphorylation at Ser 270/307/636/1101 and thus induces 
ubiquitin mediated-proteosomal degradation of IRS1
47
, (2) activation and stabilization 
of the receptor tyrosine kinase (RTK) inhibitor growth factor receptor-bound protein 10 
(Grb10), which inhibits IRS1 from binding to activated INSR
48,49
, or (3) direct 
phosphorylation of IRS1 at Ser 636/639, sites that lie in close proximity to the PI3-
kinase activation motif, the phosphorylation of which suppresses IRS1-mediated PI3-
kinase activation
50
. Importantly, dysregulation of mTORC1 signalling has been 
implicated in the development of insulin resistance (reviewed in 
51
). Under conditions of 
nutrient excess, hyperactivation of mTORC1 leads to sustained stimulation of S6K1 and 
S6K1-mediated serine phosphorylation and degradation of IRS1, which eventually 
results in desensitization of insulin signalling
52
. In this insulin-resistant state, glucose 
uptake in muscle and glycogen synthesis in both liver and muscle are impaired, while 
gluconeogenesis in liver increases. Collectively, these conditions exacerbate the 
hyperglycemic condition. Therefore, as a consequence of chronically high nutrient 
levels in the circulation, mTORC1 remains active and maintains the negative feedback 







Figure 1.2 Glucose uptake by osteoblasts integrates bone formation and the 
skeletal regulation of glucose metabolism. In an insulin-independent manner, glucose 
uptake via GLUT1 inhibits the activity of AMPK and promotes the activity of 
mTORC1, resulting in increased protein synthesis. Furthermore, glucose uptake inhibits 
the ability of AMPK to favour RUNX2 proteosomal degradation by phosphorylating 
SMURF1, an E3 ubiquitin protein ligase. The accumulation of RUNX2 leads to 
transcriptional activation of Glut1 and Ocn. OB insulin signalling activates AKT, which 
promotes glucose uptake into the cell by increasing translocation of GLUT4 to the 
plasma membrane. Activation of AKT results in the nuclear exclusion of FOXO1, 
thereby removing its inhibitory effects on RUNX2 transcriptional activity. Akt also 
attenuates the inhibitory effects of the TSC1/TSC2 complex on RHEB leading to 
activation of mTORC1. While not yet confirmed in OBs, the physical association of 
cytoplasmic FOXO1 and TSC2 could result in the degradation of the TSC1/TSC2 
complex, further enhancing activation of mTORC1. In a feed-back loop, mTORC1 
negatively regulates insulin signalling by disrupting the interaction between InsR and 
IRS1 via activation of S6K1. The molecular link between TSC-mTOR and FOXO1 
suggests a role for OB mTORC1 in the regulation of bone formation, OCN production 
and skeletal glucose metabolism. 
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Deletion of the major mTORC1 effector proteins, S6K1, 4E-BP1 or 4E-BP2, in mice 
also causes significant perturbations in glucose metabolism. Whole-body inactivation of 
S6K1 leads to hypoinsulinemia, impaired glucose tolerance and reduced β-cell mass 
associated with reduced insulin secretion in mice fed with a normal diet
54
. These mice 
also maintain normal fasting glucose levels, which is suggestive of insulin 
hypersensitivity
54
, and are also protected against obesity and HFD-induced insulin 
resistance
47
. Conversely, global deletion of 4E-BP1 and 4E-BP2, which are negatively 
regulated by mTORC1, has the opposite metabolic phenotype to that of S6K1
-/-
 mice, 
with increased adiposity and sensitivity to diet-induced obesity which eventually leads 
to insulin resistance
55
. Consistent with these results, overexpression of 4E-BP1 protects 
against HFD-induced obesity and insulin resistance in male mice, whereas the 
overexpression of 4E-BP1 does not provide any beneficial protection to HFD-fed 
female mice
56
. Moreover, mice with ablation of Grb10 (Grb10
-/-
) in peripheral tissues 
(except brain)
57




 have increased body weight 
but reduced adiposity, increased insulin sensitivity and glucose tolerance and enhanced 
insulin signalling in insulin-target tissues such as skeletal muscle and fat. Furthermore, 
conditional deletion of raptor, an essential component of mTORC1, in adipose tissue 
results in lean mice that are protected against diet-induced obesity
59
. In contrast, raptor 
deletion in skeletal muscle leads to glucose intolerance
60
, suggesting that mTORC1 in 
skeletal muscle exerts a positive effect on whole body glucose handling. Collectively, 
these findings suggest that dysregulation of mTORC1 in the skeleton may have a 
significant impact on whole-body energy metabolism.  
1.5.2 mTORC1 in bone – integrating bone development and skeletal regulation of 
glucose metabolism? 
Recent studies have demonstrated that mTORC1 signalling is a crucial regulator of 
bone formation and OB differentiation. Mice in which Raptor, an essential component 
of mTORC1, is deleted in OBs (Rptorob
-/-
) are severely osteopenic and Raptor-null OBs 
fail to undergo mineralization
61,62







. Transcriptomic analyses revealed that raptor-null OBs have an 
immature bone phenotype, suggesting that mTORC1 signalling is crucial for the 
differentiation of pre-OBs into mature OBs
61,62
. Importantly, total OCN levels are 




. While this may be secondary to the stall in 




While the function of mTORC1 in OBs requires further investigation, mTORC1-
dependent regulation of protein synthesis is thought to play a key role. Conditional 
deletion of Raptor in the developing mesenchyme (Prx-1-Cre)
64
 and pre-osteoblasts 
(Osx-Cre)
61
 causes a significant reduction in protein synthesis, which may account for 
the defects in limb length and bone mineralisation observed in these mice. In support of 
this, a significant reduction in mTORC1 activity and protein synthesis was observed in 





These mice displayed a significant delay in OB differentiation which was due, in part, 





that Glut1-depedendent uptake of glucose is an early 
determinant of osteogenesis where glucose acts to block AMPK activity, thereby 
promoting protein synthesis by mTORC1 and suppressing SMURF1-dependent 
degradation of Runx2, a master regulator of osteogenesis
42,65
 (Fig. 1.2).  
Conversely, mice with constitutively active mTORC1 signalling in OBs, via OB-
specific deletion of Tsc1 (∆Tsc1) or Tsc2 (∆Tsc2), negative regulators of mTORC1, 
exhibit increased bone mass and OB number, however OB function is impaired
66,67
. 
Moreover, ∆Tsc2 mice display a 4.5-fold increase in total OCN levels and a 10-fold 
increase in unOCN levels that is associated with hypoglycaemia and hyperinsulinemia 
at one week of age
67
. Interestingly, with age, ∆Tsc2 mice develop metabolic 
abnormalities similar to those of INSR
OB-/-
 mice, including increased peripheral 
adiposity, hyperglycaemia and decreased pancreatic β-cell mass
67
. The metabolic 
abnormalities in these mice appear to arise from chronic exposure to high levels of 
OCN which leads to the down-regulation of its receptor in pancreatic islet cells
67
. The 
dramatic increase in OCN production in these mice appears to be attributable to the 
inhibition of FOXO1 activity, as demonstrated by increased levels of FOXO1 
phosphorylation (inhibitory) in the Tsc2-deficient OBs
67
. In support of this, FOXO1 can 
associate with TSC2, which leads to the degradation of the TSC1-TSC2 complex and 
the activation of mTORC1
68
 (Fig. 1.2). This direct interaction between TSC2 and 
FOXO1 provides a potential molecular link between TSC-mTOR and FOXO1 activities 
and OCN production. Of note, conditional deletion of a single mTOR allele in ∆Tsc2 
mice rescues these metabolic abnormalities and normalizes the perturbations in bone 
formation
67
. Collectively, these findings suggest that bone-specific mTORC1 plays a 
key role in the skeletal regulation of glucose metabolism. Moreover, dysregulation of 
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mTORC1 function in bone may play an important role in the development of diet-
induced insulin resistance. 
1.6 The discovery of the OCN receptor, GPRC6A, and its role in male fertility 
The identification of OCN as a bone-derived regulator of glucose metabolism raised the 
possibility that the skeleton may also be involved in other inter-organ endocrine loops. 
Given that steroid sex hormones are also well-known regulators of bone remodelling, it 
was postulated that the skeleton may also regulate reproductive function
69
. The first 
evidence to support this was the observation that Ocn
-/-
 mice are poor breeders and have 
smaller litter sizes compared to WT mice
70
. This reduced fecundity is associated with 
lower testosterone levels, oligospermia and a reduction in reproductive organ weight, all 
of which can be subsequently reversed by OCN administration
70
. In contrast, Esp
-/-
 mice 




. Moreover, in vitro 
co-culture of Leydig cells with OB-conditioned media significantly increases Leydig 
cell testosterone production, with no change in sex hormone production observed in 
ovarian cell co-cultures
70




 mice are 






Given that the role of OCN in sex hormone production is restricted to males, Oury et al. 
concluded that OCN must act through a testis-specific receptor, and sought to identify 
this receptor by comparing the expression of putative G-protein coupled receptors in the 
testis and ovary. From these studies, GPRC6A was identified as a putative OCN 
receptor
70
. GPRC6A is broadly expressed in many organs including the bone, pancreas, 
muscle, fat, testis, liver and prostate and is activated by a number of unrelated ligands 
such as extracellular cations and amino acids
71,72





have nearly identical metabolic and reproductive phenotypes, including 






























































during fed state 
Hyperglycaemia 
Hypoglycaemia 
at early age. 
Increased 
fasting glucose 
levels with age 
Glucose tolerance ↑ ↓ ↓ ↓ ↓ 
Serum insulin levels ↑ ↓ ↓ ↓ ↓ 
Insulin secretion ↑ ↓ ↓ ↓ ↓ 
Insulin sensitivity ↑ ↓ ↓ ↓ 
↑ at 6 weeks old 
↓ at 12 weeks 
old 
Pancreatic β-cell mass 
and area 
↑ ↓ ↓ - ↓ 
Serum adiponectin 
levels 
↑ ↓ - - - 
Energy expenditure ↑ ↓ ↓ - - 
Serum triglyceride 
levels 
↓ ↑ - - - 
Serum total OCN and 
unOCN levels 
↑ - ↓ - ↑ 
Adipocyte number and  
fat pad mass 
↓ ↑ - ↑ fat mass - 
Male Reproductive Phenotype 
Circulating 
testosterone 
High Low Low Low - 
Sperm count ↑ 30% ↓ 50% ↓ 30% - - 





























-  = Not determined 
↑ = Increased 





The biochemical mechanisms by which OCN-GPRC6A modulates β-cell function have 
since been studied both in vitro and in vivo
74,75
. In two independent in vivo studies, β-




) was found to reduce 
pancreatic weight, islet number and insulin protein content, and lead to abnormal 
glucose tolerance but normal insulin sensitivity
74,76
. Collectively, these studies 
demonstrate that pancreatic GPRC6A directly controls β-cell proliferation and insulin 
production. Furthermore, compound heterozygous knockout mice lacking one copy of 





 mice, demonstrating that OCN and GPRC6A lie in the same 
genetic cascade
76
. Importantly, insulin resistance and hyperglycaemia are only observed 
in mice with global knockout of GPRC6A (Gprc6a
-/-
 mice) but not a β-cell specific 




 mice), suggesting that GPRC6A 
may also control insulin sensitivity in peripheral tissues. 
Additionally, Leydig cell-specific deletion of GPRC6A (Gprc6a
Leydig+/-
) in mice leads to 




. While further studies are 
required to identify the biochemical pathways by which OCN mediates its effects in 
Leydig cells, it has been reported that OCN signalling regulates the expression of genes 
associated with testosterone production in a cAMP response element-binding protein 
(CREB)-dependent manner
70
, and that GPRC6A transduces the non-genomic responses 
of free testosterone in vitro
77
. In vivo studies in Gprc6a-/- mice have also shown that 
GPRC6A is a crucial mediator of testosterone biosynthesis in Leydig cells and is 
necessary for testosterone-mediated stimulation of insulin secretion in the pancreatic 
islets
78
. Taken together, these observations confirm a role for OCN-GPRC6A-
testosterone in regulating energy homeostasis and male fertility.  
Intriguingly, using a computational approach, unOCN has been predicted to have a 
similar structure to that of sex hormone-binding globulin (SHBG), a glycoprotein that is 
bound by testosterone under physiological conditions, and both unOCN and SHBG 
activate GPRC6A via a common binding site
79
. It is therefore possible that testosterone, 
via SHBG-mediated activation of GPRC6A in Leydig cells, may act in an autocrine 
manner to enhance its own production and thereby affect peripheral tissues to regulate 
glucose and fat metabolism. In addition, SHBG may be a negative regulator of the 
OCN-testosterone endocrine loop by competing for the same binding site. 
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As discussed earlier, the ability of OCN to affect glucose metabolism is influenced by 
OC bone resorption, and OB insulin signalling enhances bone resorption
35
. This raises 
the possibility that OB insulin signalling may regulate testosterone biosynthesis in the 
testis in an OCN-dependent manner. In support of this, INSR
OB-/-
 mice have a similar 




 and compound mutant mice lacking one 







. As summarized in Fig. 1.3, these observations point to the existence 
of a pancreas-bone-testis axis where communication between organs is facilitated by 






















Figure 1.3 Osteocalcin-dependent endocrine functions of bone. Insulin signalling in 
bone stimulates the production and decarboxylation of OCN into its bio-active, 
undercarboxylated form (unOCN). unOCN is then released into the circulation where it 
binds to its putative receptor, GPRC6A, expressed by β-cells (pancreas), Leydig cells 
(testis), myofibers (muscle) and adipocytes (adipose tissue). Bone-derived unOCN 
stimulates β-cell insulin secretion, promotes glucose uptake in muscle and adipose 
tissues and promotes testosterone biosynthesis by Leydig cells. Testosterone, in turn, 
favours bone growth, maintenance and maturation. Furthermore, OCN promotes uptake 
and catabolism of glucose and FFA in muscle and the release of interlukin-6, a myokine 
that favours adaptation to exercise and enhances exercise capacity. In a feedforward 
manner, IL-6 then acts on the bone to increase OCN decarboxylation. A growing body 
of evidence suggests that the insulin sensitizing effects of unOCN are due, in part, to an 
increase in adiponectin secretion from adipocytes, which acts on peripheral tissues. 
(Modified from 
80




1.7 Endocrine roles of OCN in humans  
1.7.1 Differences in the regulation of OCN between mice and humans 
In the pioneering studies by Ferron et al, which identified OCN as a bone-derived 
regulator of glucose metabolism, the authors showed that unOCN administration to 
wild-type mice improves insulin sensitivity
25
, and that unOCN administration to HFD-
fed mice leads to reduced weight gain and improved glucose tolerance and insulin 
sensitivity compared to controls
15,25
. However, in more recent studies, unOCN 
administration to male mice fed a HFD or high-sucrose diet was found to induce 
glucose intolerance, insulin resistance and adipocyte hypertrophy while increasing 
circulating testosterone and adiponectin levels
81
. In contrast, unOCN administration to 




While these sex-dependent effects in mice need to be investigated further, the 
potentially positive metabolic effects associated with unOCN administration raises the 
possibility of utilizing unOCN to treat metabolic disorders in humans. However, for a 
number of reasons, the translation of these findings to the human setting has proved 
problematic. Firstly, in humans, Esp is a pseudogene with no functional product. Whilst 
a functional human homologue for murine Esp has not been identified, a protein closely 
related to OST-PTP, protein-tyrosine phosphatase 1B (PTP1B), is expressed in human 
OBs and has been shown to dephosphorylate INSR, suggesting that it may play a 
similar role to Esp
35,83
. Thus, the mechanisms by which OCN is decarboxylated and 
modulates insulin signalling in humans are different to those of mice. Secondly, the 
circadian rhythm of OCN differs between humans and mice. In mice, OCN levels peak 
during the light period and are at their lowest during the dark period whereas in humans, 
OCN levels fall in the early morning, rise in the afternoon and peak at night
84
. While the 
differences in OCN circadian regulation between these two species could, at least in 
part, be explained by the fact that humans are active in the light period whereas mice are 
active in the dark period, it may also be attributed to modulation in glucocorticoid 
levels. In humans, high serum levels of cortisol in the morning are thought to be 
responsible for the daytime nadir in serum OCN levels and the night time peak is due to 
the decline of cortisol levels in the evening
85
. Similarly, in rodents, the levels of 
corticosterone remain constant from early morning to afternoon followed by a 
significant elevation at 20:00 in the evening
86
. Therefore, the time point at which 
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samples are collected should be taken into account when extrapolating findings from 
mouse studies into the human setting. Lastly, while all three Gla residues (i.e. 13, 17, 
and 20) in murine OCN are fully carboxylated, the corresponding residues in human 
OCN are differentially carboxylated with lower frequencies of carboxylation at residue 
17 and 21 and near complete carboxylation of residue 24
87
. As a result, humans have 
various forms of circulating carboxylated OCN and variations in carboxylation status 
are associated with vitamin K intake
88
. 
1.7.2 Clinical observations of OCN in humans 
Since the discovery of metabolic functions of OCN in rodents, a number of cross-
sectional studies have been performed to examine the clinical significance of OCN in 
humans. Whilst the current evidence for using OCN levels as a predictor of metabolic 
disorders or male infertility in humans remains inconclusive, as outlined below, many 
clinical studies have provided supportive associations between OCN levels, glucose 
metabolism and testosterone levels.  
1.7.2.1 OCN levels and metabolism 
Circulating OCN levels have been shown to inversely correlate with body mass index, 
fat mass and plasma glucose levels in adults and elderly men and women
89,90
. Elevated 
levels of total OCN are also associated with lower fasting glucose and acetylated 
haemoglobin (HbA1c) levels, higher insulin secretion and increased serum adiponectin 
levels in both diabetic and non-diabetic patients
91
, and lower levels of unOCN are 
associated with impaired glucose tolerance in children
92
. Interestingly, untreated T2DM 
and pre-diabetic patients exhibit decreased levels of unOCN and total OCN, and 
increased OCN levels are associated with improved β-cell function
93
. A recent Japanese 
study of T2DM patients also found that levels of unOCN positively correlate with the C-
peptide response in glucagon loading and meal tolerance tests, suggesting that unOCN 
could be used for the assessment of insulin secretion in patients with T2DM
94
. 
Correlations between total OCN levels and glucose metabolism also appear to be age- 
and sex-dependent, as elevated levels of total OCN are associated with lower HbA1c 
levels in young men and women (<50 years of age) and only older men (>50 years of 
age)
91
. Furthermore, serum OCN levels are strongly associated with adiponectin levels 
in women and testosterone levels in men
95
 suggesting sex-dependent mechanisms may 
play a role in mediated in the metabolic effects of OCN.  
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1.7.2.2 OCN and testosterone 
In pubescent males, a significant association between serum OCN and testosterone 
levels has been observed
96
. Moreover, in patients with Klinefelter syndrome (a male-
specific genetic disorder in which males are born with an extra copy of the X 
chromosome; KS), reduced testosterone levels are one of the major causes of impaired 
bone density, marked by a significant reduction in bone formation markers including 
OCN levels
97
. Interestingly, a high incidence of metabolic disorders was reported in 70 
KS patients compared to aged-matched controls (50% and 10% respectively)
98
. In 
healthy men aged 25-65 years, low testosterone levels are associated with insulin 
resistance and glucose intolerance and an increased risk of developing T2DM
99,100
. 




The effect of testosterone administration on OCN levels and metabolism remains 
unclear. While increased bone mineral density is normally observed following 
testosterone treatment, OCN levels initially increase during the first 3 months of 
treatment, then plateau before trending towards a reduction after 6 months of 
treatment
102,103
. Systematic analysis of the OCN and GPRC6A loci in a cohort of 
patients with primary testicular failure identified a heterozygous missense variant in the 
transmembrane domain of GPRC6A (F464Y), which prevents localization of the 
receptor to the cell membrane and transduction of the GPRC6A signalling pathway
73
. 
Interestingly, patients harbouring this mutation shared a similar history of glucose 





 mice, suggesting that the OCN/GPRC6A pathway is conserved 
between mice and humans
13,63,70,73
. 
Taken together, these results suggest an important role for OCN in human biology and a 
possible role for OCN in the control of testosterone levels in patients with T2DM. While 
these data raise the possibility of (1) utilizing unOCN as a therapeutic treatment and/or 
marker for the development of metabolic disease and (2) using the GPRC6A loci as a 
primary genetic screen for testicular failure in humans, prospective studies using larger 
and more diverse cohorts of patients are necessary to confirm these observations. In 
addition, further insights into the biochemical pathways that control OCN production 
and its tissue-specific functions are required. 
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1.8 OCN and evidence for other osteokines 
Recent evidence suggests that, in addition to OCN, OBs secrete other factors or 
“osteokines” that regulate insulin sensitivity. This was first demonstrated in mice with 
conditional ablation of OBs
26
. Mice with a 50% reduction in OB numbers are glucose 
intolerant and insulin insensitive; metabolic phenotypes which are consistent with the 
significant reduction in total OCN levels observed in these animals. However, while 
restoration of OCN levels rescued the glucose intolerance and normalized insulin levels, 
OCN only partially restored insulin sensitivity
26
. Furthermore, the ablation of OBs was 
associated with changes in metabolism, including a decrease in gonadal fat mass and 
increased energy expenditure, phenotypes not observed in OCN knockout animals
13
 
suggesting that OCN-independent mechanisms may play a role in the skeletal control of 
glucose metabolism. Further evidence for this is seen in mice with conditional deletion 
of Y1, the receptor for neuropeptide Y (NPY)
104
. Deletion of Y1 in OBs was found to 
enhance bone mass, which was associated with a modest increase in total OCN levels
104
. 
However, these mice are glucose intolerant and hypoinsulinemic as a result of reduced 
islet number and β-cell area. Co-culture of Y1-null OBs with Min6 cells, an OCN-
responsive islet cell line, failed to stimulate Ins1 and Ins2 gene expression relative to 
WT OBs, suggesting that Y1 may regulate the expression and/or secretion of factor(s) 
independent to OCN
104
. More recently, Lipocalin 2 (LCN2) has been identified as an 
additional OB-secreted factor that regulates glucose metabolism
105
. Mice with global or 
bone-specific deletion of Lcn2 are glucose intolerant, insensitive to insulin and 
hypoinsulinemic due to reduced islet number and reduced β-cell mass and 
proliferation
105
. Bone mass and OCN expression were not affected in these mice, 
suggesting that the metabolic phenotype was not secondary to the bone defect or a 
reduction in OCN levels
105
. Furthermore, LCN2 was shown to directly stimulate insulin 
secretion from primary islet cells, suggesting that OB-secreted LCN2 regulates glucose 
metabolism by modulating insulin production
105
. Intriguingly, OB-secreted LCN2 was 
shown to regulate appetite by binding to the melancortin 4 receptor (MC4R) in the 
hypothalamus, which activates the MC4R-dependent appetite suppressing pathway
105
. It 
is also important to note that LCN2 was identified based on the transcriptional profile of 
OBs isolated from Foxo1OB
-/-
 mice, where Lcn2 expression was upregulated 5-fold
105
. 
As noted in Section 1.3.1, FOXO1 is a negative regulator of OCN expression and bio-
activation (carboxylation)
37
 suggesting the expression levels of LCN2 and OCN are 
regulated, at least in part, through a common signalling pathway. While OCN has not 
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been shown to control appetite, the findings that LCN2 can suppress appetite and 
regulate insulin secretion, insulin sensitivity and glucose tolerance, further highlight the 
endocrine functions of bone and the complexity of inter-tissue communications in the 
regulation of whole-body metabolism. 
1.9 Summary and Objectives 
The identification of the skeleton as an important endocrine organ has considerably 
expanded our understanding of skeletal physiology and whole-body energy metabolism. 
The classical view of skeleton as a hormone-responsive tissue should now be replaced 
by one in which the skeleton actively communicates with other organ systems to 
coordinate the balance between its own remodelling process and overall energy status. 
OCN is now recognized as a bone-derived hormone that regulates glucose metabolism 
and male reproductive function by stimulating pancreatic β-cell insulin secretion, 
improving insulin sensitivity in peripheral tissues and enhancing Leydig cell 
testosterone production. Remarkably, insulin signalling in OBs is a positive regulator of 
OCN production and bio-activation, and accumulating evidence from transgenic mouse 
models has confirmed the existence of a pancreas-bone-testis axis mediated by OCN.  
To date, the involvement of the skeleton in the development of insulin resistance and 
the mechanism(s) underlying pathological effects of insulin resistance on the skeleton is 
not fully understood. Modulation of insulin receptor levels in OBs, to emulate a loss of 
responsiveness to insulin, suggests that skeletal insulin resistance has global effects on 
glucose metabolism and insulin sensitivity. At the molecular level, insulin signalling in 
OBs activates mTORC1, a central signalling hub that senses fluctuations in intracellular 
nutrients and extracellular growth factors and integrates these multiple signals to control 
cellular growth and metabolism. At present, the role played by OB-specific mTORC1 in 
the control of systemic glucose metabolism and the regulation of insulin-stimulated 
OCN bio-activation and testosterone production remains to be determined. As aberrant 
activation of mTORC1 signalling leads to the development of insulin resistance, the 
major cause of T2DM, gaining a greater understanding of the function of the mTORC1 
pathway in bone is likely to aid the future development of targeted therapies for the 
treatment of T2DM and associated diseases. 
26 
 
The Aim of this project was to investigate the role of OB-specific mTORC1 in the 
regulation of skeletal glucose metabolism and systemic energy metabolism. To achieve 
this, mice with conditional deletion of Rptor, an essential component of mTORC1, in 
pre-osteoblast were utilised (Rptorob
-/-
 mice). The metabolic phenotype of Rptorob
-/-
 
mice was measured using a complementary suite of metabolic tests (e.g. glucose 
tolerance tests, insulin tolerance tests, indirect calorimetry assessment, serum analyses) 
coupled with detailed assessment of the effect of disrupting mTORC1 function in OBs 
on insulin sensitivity in the major insulin-responsive tissues. Furthermore, given that 
hyper-activation of mTORC1 signalling has been implicated in the development of 
insulin resistance (reviewed in 
51
), the role of OB-specific mTORC1 signalling in the 
development of diet-induced insulin resistance was also explored.  
The central hypothesis of this project was that OB-mTORC1 plays a central role in the 
skeletal regulation of systemic glucose homeostasis, and that inhibition of mTORC1 
signalling in bone will protect against diet-induced insulin resistance. In order to test 
this hypothesis, the studies outlined herein were designed to address the following 
Research Questions: 
1. Does suppression of OB-mTORC1 function influence whole-body energy 
metabolism? 
2. What is the effect of OB-mTORC1 disruption on distal insulin-responsive tissues? 
3. What are the mechanisms by which suppression of OB-mTORC1 function improve 
gluco-regulatory function? 
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CHAPTER 2:  
LOSS OF MTORC1 FUNCTION IN PRE-OSTEOBLASTS 
IS ASSOCIATED WITH SYSTEMIC IMPROVEMENT IN 
GLUCOSE HOMEOSTASIS WHICH OCCURS 
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Recent studies have shown that the skeleton plays a central role in regulating systemic 
glucose metabolism, although the mechanisms by which this occurs remain to be fully 
elucidated. mTORC1 is a crucial mediator of insulin signalling and a primary nutrient 
sensor that coordinates anabolic and catabolic processes and, as such, is likely to be 
critically involved in the skeletal regulation of whole-body energy homeostasis. To 
investigate this, mice in which Rptor, an essential component of mTORC1, was 
specifically deleted in osteoblasts (Rptorob
-/-
) were generated and a comprehensive in 
vivo assessment of the metabolic phenotype was performed.  
Under normal chow conditions, Rptorob
-/-
 mice exhibited enhanced glucose tolerance 
and increased insulin sensitivity. A net negative energy balance in Rptorob
-/- 
mice 
resulted in lean mice and a shift in whole-body fuel utilisation toward fat oxidation, 
which was associated with elevated ketone body levels. Mechanistically, these 
improved metabolic indices occur independently of osteocalcin and instead may be 
attributable to elevated serum adiponectin levels arising from increased bone marrow 
adiposity. These studies also revealed sex-dependent differences in body composition 
and energy metabolism, with a significant decrease in fat mass, white adipocyte size and 
an increase in glucose tolerance observed in male, but not female, Rptorob
-/-
 mice. 
Furthermore, while both sexes show a preference for fat utilisation and elevated serum 
ketone body levels, increased energy expenditure (with unaltered food intake) and lower 
serum triglyceride levels were observed only in male Rptorob
-/-
 mice.  
These results point to an integral role for osteoblasts in the regulation of nutritional 
status and glucose metabolism and extend the current knowledge of how osteoblasts 




The skeleton is a highly metabolic tissue that plays an important role in coordinating 
global energy utilisation via hormonal interactions with other tissues. More recently, the 
skeleton has been identified as an insulin target tissue that plays a central role in 





 mice) resulted in elevated blood glucose levels, 
reduced serum insulin levels and insulin resistance. Consistent with this, mice with OB-




, negative regulators of insulin signalling, 
display the opposite phenotype of INSROB
-/-
 mice with improved glucose disposal and 
-cell mass, and increased serum adiponectin levels. 
To date, OBs and hepatocytes are the only cell types in which disruption of insulin 
signalling hampers glucose metabolism in mice fed a normal diet
1
, which highlights the 
importance of these tissues in regulating glucose homeostasis. 
Mechanistically, studies to date have shown that insulin signalling in OBs regulates 
whole-body glucose metabolism via a feed-forward loop involving the bone-specific 
protein, OCN. Undercarboxylated OCN (unOCN) acts as a hormone to directly improve 
glucose handling by stimulating pancreatic β-cell proliferation
5
 and insulin secretion
6
 
and indirectly through its stimulation of glucagon-like peptide-1 secretion by the gut
7
. 
unOCN also increases insulin sensitivity in liver, muscle and adipose tissue by 
regulating levels of adiponectin
6,8
, an adipokine that modulates glucose homeostasis 
independently of insulin. Consistent with these observations, daily administration of 




mTORC1 is the primary nutrient-sensing pathway in cells that, in response to nutrients, 
hormones, growth factors and the cellular energy status, controls cellular growth and 
metabolism
10
. Activation of mTORC1 by insulin regulates genes that control 
metabolism, protein synthesis and cell growth. In a negative feedback loop, mTORC1 
regulates insulin signalling by disrupting the interaction between the INSR and insulin 
receptor substrate 1 (IRS1), thus allowing tight regulation of insulin signalling. 
Accumulating evidence from gene deletion studies in which Rptor, (encoding 
RAPTOR, an essential component of mTORC1) is selectively deleted in specific 
insulin-responsive tissues has revealed an important role for mTORC1 in the control of 
whole-body glucose metabolism. For example, conditional deletion of Rptor in adipose 
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tissue results in lean mice that are protected against diet-induced obesity
11,12
 while 
deletion of Rptor in skeletal muscle leads to glucose intolerance
13
. These data suggest 
that mTORC1 has tissue-specific effects in regulating whole-body energy metabolism.  
The mTORC1 pathway has been shown to play a crucial role in skeletal development. 
Mice in which Rptor is deleted in OBs have low bone mass (osteopenia) and skeletal 
fragility
14,15
. Moreover, a reduction in mTORC1 activity and protein synthesis is 
observed in mice with OB-specific deletion of Glut1, a glucose transporter
16
. Glucose 
uptake by GLUT1 has been shown to promote bone formation and OB differentiation 
by suppressing AMPK-dependent inhibition of mTORC1 function. Conversely, 
conditional deletion of Tsc2, a negative regulator of mTORC1, in OBs (∆Tsc2 mice) 
results in the accumulation of poorly differentiated OBs
17
. With age, ∆Tsc2 mice 
develop a metabolic phenotype similar to mice lacking the INSR in OBs
17
, which 
suggests a potential role for mTORC1 signalling in integrating bone development and 
glucose metabolism in response to insulin. 
To investigate the role of OB-specific mTORC1 signalling in the regulation of whole-
body glucose metabolism, mice with conditionally deleted Rptor in osteoprogenitor 
cells using Osterix-Cre (Rptorob
-/-
) were generated. These results show that Rptorob
-/-
 
mice display a significant sex-specific improvement in glucose metabolism and a lean 
phenotype which results from increased energy expenditure and a shift in whole-body 
fuel utilisation toward increased fat oxidation. 
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2.3 Materials and Methods 
2.3.1 Transgenic mice. All mice were bred and housed in pathogen-free conditions at 
the SAHMRI Bioresources Facility (SAHMRI, Adelaide, Australia) under a 12 hour 
light–dark cycle (lights on at 06:00) and constant temperature (20-23°C), with ad 
libitum access to food (Teklad global 18% protein diet #2918, Harlan, IN, USA; 
detailed in Supplementary Table 2.1) and water. All studies were performed with 
Institutional Ethics approval (SAHMRI Animal Ethics Committee, #SAM164). 
Conditional knockout mice in which Rptor, a unique and essential component of 














 mice lines were bred separately. The Osx1-GFP:Cre and 
Rptor
fl/fl
 mice lines were bred separately. The Osx1-GFP:Cre line was maintained by 
mating F1 males harboring a single copy of the tTA:Osx1-GFP:cre transgene with 
wildtype C57BL/6J females. For the Rptor
fl/fl
 line, all F2 mice were produced from the 
offspring of F1 breeders. For the Osx1-GFP:Cre x Rptor
fl/fl
 crosses, all F2 mice were 
produced by new crosses between separate F1 male Osx1-GFP:Cre and female Rptor
fl/fl
 
mice. As preliminary studies revealed that serum OCN levels (both total and 
undercarboxylated), fasting glucose levels and glucose metabolism (glucose tolerance 
and insulin sensitivity) were unaltered in Osx1-GFP:Cre mice relative to age/sex 
matched wildtype mice, wildtype Osx1-GFP:Cre-negative; Rptor
fl/fl
 littermates were 
used as the control group (Supplementary Figure 2.1, A-I). It is also important to note 
that no detectable off-target Cre recombinase activity in metabolic tissues including 
spleen, liver, brain and intestine has been observed in Osx1-GFP:Cre mice
5
. 
Furthermore, as Osx1-GFP:Cre line has been reported to develop malocclusion when 
maintain without doxycycline
6
 all Osx1-GFP:Cre-positive animals were closely 
monitored and their teeth were trimmed fortnightly. Animals were weighed twice-
weekly for the duration of the study and at the end of the study, body length and whole-
body lean and fat mass were measured post-mortem using a dedicated mouse dual X-ray 
absorbitometer (DXA) (Lunar Piximus II, GE Medical Systems, Madison WI, USA). 
2.3.2 Metabolic phenotyping. Insulin and glucose tolerance tests (ITTs and GTTs) were 
performed following intraperitoneal injection of 0.75U/kg insulin (Novo Nordisk 
Pharmaceuticals, Australia) or 2g/kg glucose, respectively after a 6-hour (07:00–13:00) 
fast. Blood glucose levels were measured at indicated time points using a handheld 
glucometer (Accu-check, Roche, Australia). At 0- and 30-minute time points of the 
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GTT, ~50 µL of whole blood was collected and serum was immediately frozen at -80
o
C 
for later assessment of glucose-stimulated insulin levels using a commercial insulin 
ELISA kit (EZRMI-13K, Millipore, MA, USA) as per manufacturer’s instructions. 
Blood ketone levels (β-hydroxybutyrate) were measured after a 6-hour fast using a 
handheld ketone meter (FreeStyle, Abbott, Australia). 
2.3.3 Indirect calorimetry and body composition analyses. Indirect calorimetry 
assessments were performed using the Promethion metabolic cage system (Sable 
Systems, NV, USA). Mice were single-housed in Promethion cages for 72-96 hours 
with ad libitum access to food and water. Monitoring was performed for 24–48 hours 
following an initial 24 hour acclimatisation period. RQ was calculated as the ratio of 
VCO2/VO2 with an RQ=0.7 indicative of pure fat oxidation and an RQ=1.0 indicative of 
pure carbohydrate oxidation.  
2.3.4 Faecal lipid assessment. Dried faeces (1 g) were collected from individually-
housed mice. Faeces were pulverised using a mortar and pestle and rehydrated in 5 mL 
of normal saline. A 2:1 chloroform: methanol solution was used to extract the lipids 
from suspension as previously described
22
.  
2.3.5 ELISA. Non-fasted blood samples were collected at the end of the study via 
cardiac puncture into Minicollect tubes (Greiner bio one, Kremsmünster, Austria). Sera 
was isolated by centrifugation at 845 x g for 10 minutes at room temperature and stored 
at -80°C. Commercial ELISA kits were used for the measurement of: triglycerides and 
free fatty acids (ab65336 and ab65341 respectively, Abcam, Cambridge, MA, USA), 
leptin and adiponectin (EZML-82K and EZMADP respectively, Millipore, Burlington, 
MA, USA), OCN (MK129, Takara, Kusatsu, Japan), unOCN (BT-470, Alfa Aesar, 
Lancashire, United Kingdom), lipocalin-2 (RDSMLCN20, R&D Systems, Minneapolis, 
MN, USA) and testosterone  (55TESMS-E01, R-Biopharm, Darmstadt, Germany), as 
per manufacturer’s instructions.  
2.3.6 Male reproductive organ assessment. Male reproductive organs (testes, seminal 
vesicles and epididymides) were dissected and weighed. Caudal epididymides were 
incised to allow sperm extravasation for 60 minutes at 37°C into 1 mL of PBS. Sperm 
counts were performed on a 1:10 dilution of the suspension, and an average of two 
sperm counts was recorded for each mouse.  
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2.3.7 Histology and Immunohistochemistry. Pancreas and adipose tissues (inguinal and 
gonadal) were carefully dissected from surrounding tissues, fixed in 10% formalin, and 
adipose tissue sections. For assessment of adipocyte cell size, Image J 
23
 was used to 
measure cell size and distribution as percentage of total cells in n=5 images per mouse. 
For pancreatic tissues, immunohistochemistry was performed using rabbit anti-insulin 
antibody (ab209483, Abcam, Cambridge, MA, USA, 1:1000). The number and size of 
insulin-positive islet cells was quantified from at least five sections per pancreas (each 
50 µm apart) using a camera attached to a microscope (Leica Microsystems, Wetzlar, 
Germany) and Osteomeasure software (Osteometrics, Decatur, GA, USA). Total 
pancreatic surface was also measured using Image J and used to determine islet cell 
number per mm
2
 and β-cell area (area positive for insulin immunostaining divided by 
the total pancreatic surface).  
2.3.8 Protein isolation and Western blotting. For insulin signalling studies, mice were 
fasted for 6 hours (07:00-13:00) prior to administration of insulin (150mU/g BW, i.p) or 
PBS control. After 20 minutes, mice were euthanized and tissues (liver, and skeletal 
muscle) were harvested, snap-frozen in liquid nitrogen and stored at -80 °C prior to 
further analysis. Tissue samples were lysed in modified RIPA buffer (1% NP40, 20 mM 
Tris pH 7.4, 2 mM EDTA, 150 mM NaCl, 2 mM Na3VO4, 2 mM NaF, 0.1% SDS, 2.5 
mM Na4P2O7.H2O, 10% glycerol, 1 mM β-glycerol phosphate and protease inhibitors 
(cOmplete™, Roche, Basel, Switzerland) and homogenised using a TissueRuptor 
(QIAGEN, Victoria, Australia). Equal amounts of protein (50 µg, unless otherwise 
stated) were resolved by SDS-PAGE and transferred to Immobilon-FL PVDF 
Membrane (MerckMillipore, Darmstadt, Germany). Immunoblotting was performed 
with the following antibodies: phospho-AKT (Ser473), phospho-INSR (Tyr1150/1151), 
total AKT, total INSR (Cell Signaling Technology, Danvers, MA, USA), and β-Actin 
(Sigma, St. Louis, MO, USA). After incubation with fluorescently-tagged secondary 
antibody, membranes were scanned using a Li-Cor Odyssey imaging system (LI-COR 
Biosciences, Lincoln, NE, USA). Quantitative analysis was performed using Image 
Studio software (LI-COR Biosciences). 
For analysis of adiponectin multimers, serum samples were electrophoresed on 3-8% 
CriterionTM XT Tris-Acetate Protein gradient gels (Bio-rad, Hercules, CA, USA) and 
protein complexes transferred to Immobilon-FL PVDF Membrane (Merck, Darmstadt, 





using an adiponectin-specific antibody (Sigma). Bound antibody was detected using a 
fluorescently-tagged secondary antibody and visualised as described above. 
2.3.9 RNA isolation and quantitative RT-PCR. Unless otherwise stated, all RNA 
extractions were carried out using TRIzol reagent (Sigma) according to manufacturer’s 
instructions. Total RNA (1.5 µg) was reverse transcribed into cDNA using Superscript 
IV Reverse Transcriptase (Invitrogen, Carlsbad, CA, USA). Real-time PCR reactions 
were performed using RT
2
 SYBR Green ROX reagent (QIAGEN, Hilden, Germany) in 
a CFX Connect™ Real-Time PCR machine (Bio-Rad). Forward and reverse primer 
pairs, designed to amplify across intron-exon boundaries, are listed in Supplementary 
Table 2.2. The efficiencies of PCR were assessed with visual assessment of geometric 






2.3.10 Statistical analysis. All data are presented as mean ± standard error of the mean 
(SEM). Statistical analyses were performed using a one-way or two-way ANOVA with 
a Tukey test or an unpaired Students t-test using GraphPad Prism (GraphPad Software 
Inc, CA, USA). Significance was accepted at p<0.05, with asterisks denoting p-value 












2.4.1 Loss of mTORC1 function in pre-osteoblasts is associated with altered body 
composition in male but not female mice 
To investigate the role of OB-mTORC1 in the skeletal regulation of metabolism, mice 
with conditional deletion of Rptor in osteoprogenitor cells using the Osx1-GFP::Cre 
mice
18
 were generated as previously described
15
. Owing to previously observed gene 
dosage effects in these mice
15,25
, both heterozygous (Rptorob
-/+
) and homozygous 
(Rptorob
-/-
) knockout animals were analysed in this study. 
During the first 2 months of life, both male and female Rptorob
-/-
 mice weighed 
significantly less the control mice (Fig.2.1A and B), and were approximately 10% 
shorter in length than the controls (Fig. 2.1C). Whilst the lower body weight of male 
Rptorob
-/- 
mice could be attributed, in part, to their shorter length, male Rptorob
-/- 
mice 
were found to have a significantly lower BMI (Fig. 2.1D) suggesting the lower body 





 mice were shorter than the controls, female Rptorob
-/+
 
mice had significantly higher BMI than both control and Rptorob
-/- 
mice, however no 
difference was observed between the control and Rptorob
-/- 
mice (Fig. 2.1D). To 





 mice had significantly lower total fat mass compared to controls 
(Fig. 2.1E). Similar to the males, female Rptorob
-/-
 mice also displayed lower body 
weight and fat mass relative to controls (Fig. 2.1E). Correcting fat mass to account for 
the differences in total body weight (as a percentage of total body weight: Fig. 2.1F) or 
body length (fat mass index, FMI: fat mass/height
2
, Fig. 2.1G) showed that the males 
show a preferential loss of fat mass that is disproportionate to the decreased body mass, 
whereas decreased fat mass in the females is proportionate to their decreased body 
mass.  





quantitative assessment of discrete white adipose tissue (WAT) depots at necropsy 





mice compared to controls, but not females (Fig. 2.1H and Supplementary Fig. 2.2A). In 





 mice of either sex, relative to control mice (Fig. 
2.1H and Supplementary Fig. 2.2A). Further histological examination of gWAT and 
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iWAT depots revealed a marked reduction in adipocyte size in male Rptorob
-/-
 mice, as 
evidenced by an increase in the frequency of smaller adipocytes (Fig. 2.1I-K), but this 
was not observed in female mice (Supplementary Fig. 2.2B).  
The higher proportion of small adipocytes observed in Rptorob
-/-
 iWAT and gWAT 
could either be attributable to (i) enhanced adipogenesis (resulting in an increase in 
small, newly-generated adipocytes), (ii) decreased lipogenesis and/or enhanced lipolysis 
in existing adipocytes, or (iii) a combination of both. To address this question, the 
expression levels of genes involved in adipogenesis, lipogenesis and lipolysis were 
analysed by qRT-PCR. As shown in Fig. 2.1L and M, the expression levels of Cebpα 
and Pparg, master regulators of adipogenesis, and their downstream target gene, 
lipoprotein lipase (Lpl), were significantly increased in iWAT and gWAT collected 
from male Rptorob
-/-
 mice, suggesting that adipogenesis is enhanced in both of these fat 
depots. In contrast, while expression levels of Srebp1c were unaltered in both fat 
depots, levels of fatty acid synthase (Fasn), an important Srebp1c target gene, were 
significantly reduced in Rptorob
-/-
 gWAT and increased in Rptorob
-/-
 iWAT compared to 
the controls, and no significant changes in adipose triglyceride lipase (Atgl), an 
important lipolysis enzyme, were observed (Fig. 2.1L and M). Consistent with the lack 




 mice, no significant 
change in the expression levels of genes involved in adipogenesis, lipogenesis and 





















Fig. 2.1 Loss of OB-mTORC1 function results in altered body composition. (A-B) 
Temporal body weight changes in male and female mice (n≥15/genotype). (C) Body 
length of 9-week old mice, as measured from nose to anus (n=5-6/genotype). (D) Body 
mass index (BMI) (n=5-6/genotype). (E) DXA analysis of fat mass and (F) % fat mass 
normalised to total body weight (n=5-6/genotype). (G) Fat mass index (FMI) (n=5-
6/genotype). (H) Body weight-adjusted gonadal and inguinal white adipose tissue 
(gWAT and iWAT) and interscapular brown adipose tissue (iBAT) mass in male mice 
at 9-weeks of age (n=10/genotype). (I-J) Size distribution of gWAT and iWAT 
adipocytes of male mice calculated from H&E stained sections using Image J (n=5 
sections/mouse, n=3-6/genotype). (K) Representative H&E section of gWAT and 
iWAT from male mice, scale bar = 50µm. (L-M) Relative expression of adipogenesis - , 
lipogenesis - and lipolysis - related genes, normalised to β-actin, in gWAT and iWAT 
from male mice (n=3-5/genotype). All panels except K: data are expressed as mean ± 
SEM. *p<0.05, **p<0.01, ***p<0.001, two-way ANOVA with Tukey’s post-hoc test.  
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2.4.2 Improved glucose metabolism and increased insulin sensitivity in Rptorob
-/-
 mice 
The striking effects of OB-mTORC1 inhibition on body composition suggested that 
metabolism was likely to be significantly altered in Rptorob
-/-
 mice. Indeed, upon further 
examination, Rptorob
-/-
 mice were found to have significantly lower fasting glucose 
levels (Fig. 2.2A: 22.8% and 22.0% lower compared to controls in males and females, 
respectively). Fasting glucose levels were also significantly lower in male, but not the 
female, Rptorob
-/+
 mice compared to controls (Fig. 2.2A). When fasted animals were 
challenged with a bolus of glucose, male mice exhibited enhanced glucose clearance 
compared to controls, whereas no change in glucose tolerance was observed in male 
Rptorob
-/+
 mice or in the female cohort (Fig. 2.2B-D). Strikingly, the hypoglycaemia and 
increased glucose tolerance observed in male Rptorob
-/-
 mice was not attributable to 
hyperinsulinemia, as the fasting insulin levels of both male and female Rptorob
-/-
 mice 
were 50% lower than control levels (Fig. 2.2E). Fasting insulin levels were also 
significantly lower in heterozygous mice of both genders relative to controls (Fig. 2.2E).  
Enumeration of insulin-positive pancreatic islets in male Rptorob
-/-
 mice revealed that 
the hypoinsulinemia was not due to a reduction in the number of islets, although trends 
toward a reduction in β-cell area (p=0.065) and islet size (p=0.077) were observed 
(Supplementary Fig. 2.3A and B). No significant changes in islet morphology were 
observed in female mice (Supplementary Fig. 2.3B). Despite lower circulating insulin 




 mice to 
secrete insulin in response to a glucose bolus (glucose-stimulated insulin secretion tests 
[GSIS]) remained functional as demonstrated by a significant increase in insulin levels 
at 30 minutes post glucose bolus compared to the basal levels (Fig. 2.2F and G). 
Moreover, the relative insulin levels at 30 minutes (i.e. insulin fold induction relative to 
basal levels to account for lower basal insulin levels) in response to glucose bolus were 




 mice relative to controls in both sexes 
(Fig. 2.2H). 
The reduced fasting insulin and glucose levels observed in Rptorob
-/-
 mice, coupled with 
their improved glucose disposal and ability to maintain lower levels of circulating 
insulin after glucose bolus, suggested that these mice were more sensitive to insulin 
compared to their Rptorob
-/+ 
and control littermates. To address this question, insulin 
tolerance tests (ITTs) were performed to assess their peripheral sensitivity to insulin. As 
shown in Fig. 2.2I-K, both male and female Rptorob
-/-
 mice were more insulin sensitive 
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compared to controls, whereas no difference was observed in Rptorob
-/+
 mice of both 
genders.  
To further investigate insulin sensitivity in Rptorob
-/-
 mice, gene expression levels of 
known markers of insulin sensitivity (muscle: Pcg1α and its target genes, Mcad and 
Nrf1; liver: Foxa2) and insulin-targeted genes involved in carbohydrate metabolism in 
primary insulin target tissues were analysed. Somewhat unexpectedly, no significant 
changes in the expression levels of these genes were observed in either tissue 
(Supplementary Fig. 2.4A and B). Furthermore, the levels of insulin-stimulated 
phosphorylation of the INSR at Tyr
1150/1151
 and its downstream effector protein AKT at 
Ser
473














Fig. 2.2 Loss of OB-mTORC1 function leads to improved whole-body glucose 
metabolism. (A) Fasting blood glucose levels in 9-week old male and female mice 
(n=11-15/genotype). (B-C) GTT blood glucose levels in mice at 9-week of age, and (D) 
Incremental area under the curve analysis (n=10-15/genotype). (E) Fasting serum 
insulin levels at 9-week of age (n=7-13/genotype). (F-G) Glucose-stimulated insulin 
levels in male and female mice, and (H) fold change in insulin levels at 30 minutes 
relative to basal levels (n=7-12/genotype). (I-J) ITT blood glucose levels in male and 
female mice at 8-week of age, and (K) Area under the curve analysis (n=8-15/group). 
All panels except B, C, I and J: data are expressed as mean ± SEM. *p<0.05, **p<0.01, 
***p<0.001, two-way ANOVA with Tukey’s post-hoc test. For panel B, C, I and J: 
*p<0.05 between Rptorob
-/-















 mice have increased total energy expenditure and increase fat 
oxidation 
To further examine the underlying mechanisms associated with the altered body 
composition of Rptorob
-/-
 mice, serum metabolite markers, food intake, energy 
expenditure and physical activity were examined. To account for the differences in their 
body size, each of these metabolic parameters were normalised to their lean mass. In 
line with their reduced adiposity (Fig. 2.1E), circulating leptin levels were found to be 
significantly lower in both male and female Rptorob
-/-
 mice (Fig. 2.3A). Importantly, 
whilst absolute food intake was lower in male Rptorob
-/-
 mice (Fig. 2.3B) compared to 
controls, when normalised to lean mass there were no significant differences in food 
intake across the three genotypes (Fig. 2.3C), which indicates that their food 
consumption was proportional to body size. Faecal lipid content was examined to 
determine if food malabsorption may account for the lean phenotype of male Rptorob
-/-
 
mice. However, no difference in faecal lipid content was observed (Fig. 2.3D). In 
contrast, in female Rptorob
-/-
 mice, food intake (both absolute and normalised) was 
significantly lower (Fig. 2.3B and C) and faecal lipid content showed a trend toward a 
reduction (Fig. 2.3D; p=0.066). 
As whole-body adiposity is determined by the balance between food intake and caloric 





 mice in the presence of unaltered proportional caloric 
intake. Total energy expenditure (TEE) normalised to lean mass (kcal/g of lean mass), 
was significantly higher in male Rptorob
-/-
 mice during both the light and dark period 
despite no significant changes in physical activity, both ambulatory (X+Y movements: 
walking) and Z-axis (rearing) (Fig. 2.3E-H). Respiratory quotient (RQ) was also 
significantly lower in male Rptorob
-/-
 mice during both the light and dark periods (Fig. 
2.3I and J), indicating a preference for fat oxidation. Of note, there were no differences 
between male Rptorob
-/+
 and control mice in any of the parameters measured. 
Conversely, physical activity (both ambulatory (X+Y movements: walking) and Z-axis 




 mice while 
TEE was equivalent to that of controls (Fig. 2.3K and L). The lower RQ of female 
Rptorob
-/-
 mice, while only observed during the light period, suggested a preference for 
fat oxidation (Fig. 2.3M and N).  
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To further examine this potential shift in energy utilisation towards fat oxidation in 
Rptorob
-/-
 mice, circulating levels of ketone bodies, free fatty acids (FFA) and 
triglycerides (TG) were measured. Serum levels of β-hydroxybutyrate (βOHB), the 
primary ketone body, were significantly higher in both male and female Rptorob
-/-
 mice 
compared to controls (Fig. 2.3O), whilst circulating TG levels were lower (Fig. 2.3P) 
and FFA levels unchanged (Fig. 2.3Q) in male Rptorob
-/-
 mice compared to the controls. 



























Fig. 2.3 Loss of OB-mTORC1 function shifts whole-body fuel utilisation toward fat 
oxidation. (A) Serum leptin levels in 9-week old male and female mice (n=7-
15/genotype). (B) Food intake per day, measured over 48-h, presented as absolute food 
intake (kcal/day), or (C) normalised to lean mass (kcal/g lean mass/day). (D) Faecal 
lipid content (% lipid/g faeces) (n=7-10/genotype). (E) Ambulatory X+Y axis activity 
per day. (F) Z-axis (rearing) locomotor activity per day. (G) Total energy expenditure, 
normalised to lean mass, per light and dark cycle, and (H) over a 48-h time course in 
male mice. (I) Average respiratory quotient (RQ) per light and dark cycle, or (J) over a 
48-h time course in male mice. (K) Total energy expenditure, normalised to lean mass, 
per light and dark cycle, and (L) over a 48-h time course in female mice. (M) Average 
respiratory quotient (RQ) per light and dark cycle, or (N) over a 48-h time course in 
female mice. (O) Fasting serum ketone body levels (n=4-5/genotype). (P) Serum 
triglyceride levels measured at non-fasted condition (n=6-10/genotype). (Q) Serum free 
fatty acid levels measured at non-fasted condition (n=8-11/genotype). All panels: data 
are expressed as mean ± SEM from n=5-6/group, unless indicated otherwise. *p<0.05, 
**p<0.01, ***p<0.001, two-way ANOVA with Tukey’s post-hoc test. Panels H, J, L, 









2.4.4 Metabolic improvements in Rptorob
 -/-
 mice occur independently of osteocalcin 
Previous pioneering studies by the Karsenty laboratory have attributed the skeletal 
regulation of whole-body glucose metabolism to the actions of OCN
1,6
. OCN binds 
avidly to bone hydroxyapatite and, following decarboxylation to its active form 
(undercarboxylated OCN: unOCN), is released into the circulation
26
. unOCN binds to 
its receptor on pancreatic β-cells to increase insulin secretion and β-cell proliferation
27
 
and on muscle, adipose tissues, and liver to increase insulin sensitivity and glucose 
uptake into these tissues. To investigate whether the metabolic improvements in 
Rptorob
-/-
 mice are attributable to OCN, expression levels of the OCN gene, Bglap, in 
the long bones and circulating serum OCN levels were investigated. Consistent with  
previously-published studies
15
, mRNA and serum levels of both total OCN and unOCN 
were both significantly lower in male and female Rptorob
-/-
 mice (Fig. 2.4A-C).  
In addition to OCN, more-recent studies have shown that the skeleton can regulate 
appetite and glucose homeostasis via lipocalin-2 (LCN2)
28
, an OB-enriched, secreted 
protein. To determine if increased LCN2 levels may be compensating for the decreased 




 mice, serum LCN2 levels were 
measured; however no differences were found across the three genotypes (Fig. 2.4D). 
More recently, osteoglycin (OGN) has been identified as a novel downstream mediator 
of NPY/Y1 signaling in OBs that plays a role in coordinating bone accrual and global 
energy balance
29,30
. Under the conditions of a negative energy balance, an increase in 
NPY signaling in bone leads to an increase in OGN secretion, which then suppresses 
bone formation and increases systemic glucose uptake by enhancing insulin action
30
. In 





, the circulating OGN levels were elevated ~2.6 and 1.7-fold in 
male and female Rptorob
-/-
 mice relative to controls respectively (Fig. 2.4E). Taken 
together, these findings suggest that the improvements in glucose and energy 
metabolism observed in Rptorob
-/-
 mice may result from an increase in OGN secretion 
and OGN-dependent regulation of insulin sensitivity.  
2.4.5 Loss of mTORC1 function in pre-OBs is associated with reproductive defects in 
males  
While the reduced levels of serum OCN and unOCN observed in the Rptorob
-/-
 mice 
suggested that OCN was not responsible for the improvement in glucose metabolism, it 
prompted a question as to whether the low levels of OCN were associated with any 
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other physiological outcomes. Previous studies have shown that OCN is important for 
male fertility by acting on Leydig cells in the testes to promote testosterone production 
and spermatogenesis
31




 mice have 
significantly smaller testes and seminal vesicles compared to controls, while epididymal 
weights were unchanged across all genotypes (Fig. 2.4F). Circulating testosterone levels 




 mice compared to the 




 mice having 
lower testosterone levels, only Rptorob
-/-
 mice have a lower sperm count compared to 
controls (Fig. 2.4H). Gene expression analyses also confirmed a significantly lower 
expression of genes involved in testosterone biosynthesis, such as StAR, Cyp17 and 
Cyp11α, whilst genes involved in estradiol production (i.e. Cyp19a and Hsd17b3) were 
unchanged in Rptorob
-/-
 mice (Fig. 2.4H). Consistent with the lower circulating 
testosterone levels in Rptorob
-/+
 mice, StAR expression was found to be significantly 

















Fig. 2.4 Improvements in glucose metabolism observed in Rptorob
-/-
 mice occur 
independently of osteocalcin. (A) Bglap gene expression in flushed long bones 
(femur/tibia, n=3-4/genotype) from 9-week old male and female mice. (B) Serum OCN 
(total) levels (n=6-13/genotype). (C) Serum unOCN levels (n=5-13/genotype). (D) 
Serum lipocalin-2 levels (n=7-10/genotype). (E) Serum osteoglycin levels (n=7-
10/genotype). (F) Male reproductive organ weights (testis, seminal vesicles (SV), 
Epididymides (Epi.), n=8-13/genotype). (G) Serum testosterone levels (n=6-
15/genotype). (H) Sperm counts (n=8-13/genotype). (I) Relative expression of genes 
involved in testosterone biosynthesis (StAR, Cyp17, Cyp11α) and estradiol production 
(Cyp19a, Hsd17b3), normalised to β-actin, in testicle samples from male mice 
(n=3/genotype). All panels: data are expressed as mean ± SEM. *p<0.05, **p<0.01, 
***p<0.001, two-way ANOVA with Tukey’s post-hoc test.  
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2.4.6 The improved metabolic profile of Rptorob
 -/-
 mice is associated with elevated 
serum adiponectin levels  
The low total body fat in Rptorob
-/-
 mice raised a question as to whether changes in 
serum adipokine levels could be playing a role in their metabolic phenotype. 
Adiponectin has been shown to play an important role in sensitising tissues to insulin 
and elevated adiponectin levels are associated with improved insulin sensitivity
32
. In 
particular, levels of the high molecular weight (HMW) form of adiponectin, the most 
bio-active form, correlate negatively with insulin resistance
33
. Indeed, adiponectin 
mRNA expression and circulating adiponectin protein levels are significantly lower 
under conditions of excess adiposity (i.e. obesity) and diabetes in both mice and 
humans
34
, while its levels are markedly higher under conditions of extreme leanness 
such as dietary restriction (DR) and anorexia nervosa (AN)
35
. Consistent with the 
improvement in insulin sensitivity observed in male and female Rptorob
-/-
 mice (Fig. 
2.2G), serum adiponectin levels were significantly higher (~1.5-fold in both sexes) 
relative to controls (Fig. 2.5A). For the heterozygous knockout
 
mice, adiponectin levels 
remained unchanged in both males and females (Fig. 2.5A) which is consistent with the 
lack of improvement in their insulin sensitivity (Fig. 2.2I-J). Western blot analysis of 
the adiponectin complexes revealed a 2-fold increase in the HMW complex in both 
male and female Rptorob
-/-
 mice (Fig. 2.5B-E). 
While WAT has long been considered as the major source of adiponectin, recent studies 
have shown that bone marrow adipose tissue (BMAT) is also a significant source of 
adiponectin under the condition of restricted dietary
36
. Consequently, expression levels 
of adiponectin transcripts and protein in both WAT and whole bone were examined. As 
shown in Fig. 5F and G, levels of Adipoq mRNA expression were unchanged in both 




 male mice relative to controls, 





 mice. Strikingly, however, levels of Adipoq mRNA expression 
were ~2.3-fold higher in the BMAT-containing long bones (combined Tibia/femur: 
Tib/fem) of Rptorob
-/-
 mice (Fig. 2.5F-G). At the protein level, adiponectin levels were 
~4-fold and ~1.5-fold higher in lysates from male and female Rptorob
-/-
 long bones 
(tibia/femur), respectively, compared to controls (Fig. 2.5H-K). No genotypic 
differences in adiponectin levels were observed in both iWAT and gWAT depots. 
Although the physiological role of BMAT remains largely unknown, its expansion has 





 and AN in humans
35
, high-fat diet feeding
38
 and leptin deficiency
39
. Of 





and herein we have shown that BMAT expansion in Rptorob
-/-
 mice is associated with 
hypoleptinemia (Fig. 2.3A). More recently, BMAT expansion, in response to DR, has 
been associated with increased serum levels of glucocorticoids
40
. Consistent with this 
finding, the circulating levels of corticosterone were significantly increased in Rptorob
-/-
 





























Fig. 2.5 Bone marrow adipose-derived adiponectin levels are increased in Rptorob
-/-
 
mice. (A) Serum adiponectin levels in 9-week old male and female mice (n=8-
13/genotype). (B-E) Western blot analysis of high molecular weight (HMW), low 
molecular weight (LMW) and total adiponectin levels in sera from male and female 
mice (n=4/genotype). (F-G) Adipoq gene expression, normalised to β-actin, in gWAT, 
iWAT and whole long bone (tibia/femur) samples (n=3-5/genotype). (H) Levels of total 
adiponectin protein expression in gWAT, iWAT and whole long bone (tibia/femur) 
samples in male mice (n=3-4/genotype) and (I) Quantitative analysis of adiponectin 
protein levels, relative to β-actin, from (H). (J) Levels of total adiponectin protein 
expression in gWAT, iWAT and whole long bone (tibia/femur) samples in females mice 
(n=3/genotype) and (K) Quantitative analysis of adiponectin protein levels, relative to 
β-actin, from (J). (L) Serum corticosterone levels in 9-week old male and female mice 
(n=5-11/genotype). All panels except B, C, H, I: data are expressed as mean ± SEM. 











Fig. 2.6 Schematic summary. Inactivation of mTORC1 via deletion of Rptor in early 
osteoprogenitor cells leads to a decrease in bone formation and subsequent lower 
circulating osteocalcin levels. While these reduced osteocalcin levels lead to the reduced 
testosterone levels in the male mice and may contribute to lower circulating insulin 
levels in both sexes, the increase in serum osteoglycin and the elevated levels of bone 
marrow adipose tissue (BMAT)-derived adiponectin results in an overall improvement 
in metabolic health, including an increase in insulin sensitivity and glucose tolerance. 
The expansion of BMAT is associated with low leptin and increased corticosterone 
levels in the Rptorob
-/-
 mice. Furthermore, at least in the male mice, the increase in 
energy expenditure with unaltered food intake results in a lean phenotype and a shift in 





Recent advances in skeletal research have revealed previously unimagined functions for 
the skeleton, with OBs, the bone-forming cells of the skeleton, now known to play an 
important role in the regulation of systemic glucose metabolism. The results presented 
herein further support the concept that OBs play a critical role in gluco-regulation and 
energy homeostasis. Importantly, these results suggest an integral role for OBs in the 
regulation of nutritional status and glucose metabolism and extend the knowledge of 
how OBs contribute to the whole-body homeostatic balances (Fig. 2.6). 
2.5.1 Skeletal mTORC1, insulin signalling and glucose uptake  
Previous studies have demonstrated that mTORC1 plays an important role in bone 
formation and OB differentiation as mice with inactivated mTORC1 in OBs are 
severely osteopenic
14,15,41
. In this current study, it was revealed that Rptorob
-/-
 mice also 
display a marked whole-body metabolic phenotype characterised by low glycaemic 
levels, enhanced glucose tolerance, increased insulin sensitivity and increased insulin 





 mice are very similar
2
. However, unexpectedly, the metabolic 
phenotype of Rptorob
-/-
 mice is the complete opposite to INSROB
-/-
 mice, which exhibit 
hyperglycaemia, decreased insulin sensitivity and increased peripheral adiposity
1
.  
The disparity in the metabolic phenotypes might be a consequence of removing the 





 and indirectly via S6K1
43
, phosphorylates IRS-1, promoting 
its ubiquitination and degradation. mTORC1 also phosphorylates and stabilises receptor 
tyrosine kinase (RTK) inhibitor growth factor receptor-bound protein 10 (Grb10)
44
, 
leading to feedback inhibition of the phosphatidylinositol 3-kinase (PI3K) pathways. 
The removal of these mTORC1-regulated negative controls could potentiate insulin 
signalling, leading to insulin hypersensitivity in the OBs of the Rptorob
-/-
 mice. 
Consistent with this view, the metabolic phenotypes of the Rptorob
-/-
 mice are similar to 
those of mice with OB-specific deletion of either FoxO1 or Atf4, negative regulators of 
insulin signalling
4,45
. Furthermore, it is possible that this potentiated insulin signalling 
could also explain the hypoglycaemia in the Rptorob
-/-
 mice, whereby hyper-activation 
of insulin signalling in OBs activates AKT, which promotes translocation of glucose 
transport 4 (GLUT4) to the plasma membrane and thus increases GLUT4-mediated 
glucose uptake into the OBs
46
. In support of this, significantly higher levels of Glut4 
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mRNA (Supplementary Fig. S2.5A) and genes involving in glycolysis (Supplementary 
Fig. 2.5B) were observed in the bones of male Rptorob
-/-
 mice. However, further 
investigations are required to verify if there is an increase in translocation of GLUT4 to 
the plasma membrane and glucose uptake in OBs in the Rptorob
-/-
 mice.  
Given that bone constitutes approximately 15% of body mass, increased glucose uptake 
into the bone could lower overall glucose levels. While this mechanism has not yet been 
confirmed in the bones of Rptorob
-/-
 mice, hyper-activation of PKB/AKT as a result of 
mTOR deficiency in muscle (mTOR
-/-
) has been reported to increase basal glucose 
uptake
47
. Moreover, the hyper-activation of PKB/AKT was also reported in mice with 
muscle-specific Rptor deletion (RAmKO)
13
, indicating that mTORC1 disruption is 





RAmKO are glucose intolerant, suggesting that mTORC1 in skeletal muscle exerts a 
positive effect on whole-body glucose handling
13
. In contrast, conditional deletion of 
Rptor in adipose tissue (raptor
ad−/−
), results in lean mice that are resistant to diet-
induced obesity
11
. These contradicting findings suggest that mTORC1 has tissue-
specific functions that affect different aspects of whole-body energy metabolism. 
Collectively, the data described herein indicate that dysregulation of mTORC1 in the 
skeleton has a significant impact on whole-body glucose metabolism and thus highlights 
the importance of skeletal contribution to the regulation of glucose homeostasis.  
2.5.2 Metabolic phenotypes independent of OCN 
Previous studies have demonstrated that unOCN, a bone-derived secretagogue, acts in a 
feed-forward loop to enhance pancreatic β-cell insulin secretion and improve insulin 
sensitivity in peripheral tissues
6
. Moreover, in both animal and human studies
6,48
, 
circulating OCN levels are generally inversely correlated with plasma glucose levels, fat 
mass and the degree of impaired glucose metabolism. Based on these data, it was 
initially hypothesised that the improved metabolic characteristics of Rptorob
-/-
 mice were 
attributable to the actions of OCN. However, the unexpectedly lower levels of both total 
and unOCN in the Rptorob
-/-
 mice were incongruent with a role of OCN in mediating 
systemic metabolic phenotypes in Rptorob
-/-
 mice. Moreover, Ocn-deficient mice (Ocn
-/-
) 
are phenotypically opposite to Rptorob
-/-
 mice, in that Ocn
-/-
 mice exhibit higher 
adiposity, hyperglycaemia, hypoinsulinemia, impaired insulin secretion and sensitivity 
and are glucose intolerant
6
. These defects in glucose homeostasis are accompanied by 
impairment in pancreatic β-cell proliferation and insulin secretion and development of 
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insulin resistance in other insulin-targeted tissues
6
. While low serum levels of unOCN 
could possibly lead to the hypoinsulinemia in Rptorob
-/-
 mice, no impairment in other 
OCN-mediated effects on the bone-pancreas axis were observed (i.e. both pancreatic 
histology and insulin secretion were normal in Rptorob
-/-
 mice). Furthermore, there was 
no reduction in markers of insulin sensitivity nor altered activation of the insulin 
signalling pathway observed in peripheral tissues of Rptorob
-/-
 mice.  
The low serum levels of OCN observed in the Rptorob
-/-
 mice are likely secondary to the 
stall in osteogenesis in response to reduced mTORC1 activity in pre-OBs. In support of 





 has previously been reported to dramatically reduced OCN 
expression and serum levels of total OCN in mice. Conversely, hyper-activation of 
mTORC1 in OBs, by deleting Tsc2 (ΔTsc2 mice), leads to an increase in bone mass and 
markedly elevated circulating OCN levels
17
. The chronic exposure to high levels of 
OCN, however, has been shown to lead to the desensitisation of OCN targeted tissues, 
including pancreatic β-cells, thus resulting in development of metabolic abnormalities 




. While there is the possibility that metabolic 
improvement observed in Rptorob
-/-
 mice is due to low levels of OCN priming its 
targeted tissue to be highly sensitive to OCN, this is unlikely, as serum unOCN levels 




 mice, but only Rptorob
-/-
 mice showed 
improvement in the metabolic phenotypes. 
2.5.3 Sex-dimorphism and energy imbalance in Rptorob
-/-
 mice 
Given that an improvement in glucose tolerance was restricted to the male Rptorob
-/-
 
mice, this could arise from the sex-dependent action of OCN and the effects of sex 
steroid hormones. In support of this concept, long-term intermittent or daily oral 
administration of unOCN has been shown to improve glucose tolerance and increase 
fasting insulin and pancreatic β-cells area (without affecting insulin sensitivity) in 
female wildtype mice fed either chow or high-fat, high-sucrose diet
7
. Conversely, in 
male mice, administration of unOCN leads to an increase in circulating testosterone 
levels, glucose intolerance and resistance to insulin under high-fat, high-sucrose diet
50
. 
Importantly, orchiectomy of male mice fed such a diet resulted in similar beneficial 
phenotypes of unOCN administration to female mice, while these effects were reversed 
in orchiectomised male mice or intact female mice supplemented with testosterone. 
Furthermore, ovariectomy in females or orchiectomised males supplemented with 
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estradiol did not negate the beneficial effects of unOCN, indicating that the 
advantageous effects of unOCN was independent of female sex hormones while the 
deleterious effects of unOCN is mediated by the increase in testosterone. Low unOCN 
in the male Rptorob
-/-
 mice could contribute to the lower testosterone levels (GPRC6A, a 
putative OCN receptor, is expressed only in testicular Leydig cells) protecting them 
from high testosterone-induced glucose intolerance and resistance to insulin. Moreover, 
there is a possibility that the reduction in circulating testosterone could result in higher 
estrogen levels in male Rptorob
-/-
 mice. While serum estrogen levels were not measured 
in this study, low testosterone with high estrogen levels have been reported in the 
GPRC6A knockout mice
51
. Notwithstanding, gene expression levels of Cyp19a, an 
aromatase responsible for conversion of testosterone to estrogen, was normal in male 
Rptorob
-/-
 mice (Fig. 2.4H).  
The altered body composition (i.e. reduced %fat) observed in the male Rptorob
-/-
 mice 
did not occur in the female Rptorob
-/-
 mice, which could be attributable to sex 
asymmetry (and thus sex hormones) in metabolism (reviewed in 
52
). Females resist the 
loss of energy stores better than males, which may also have contributed to this sex-
specific phenotype. Indeed, sex-specific differences in the ability to resist loss of fat 
storage are known to occur in other stains of mice
53,54
. In the female Rptorob
-/-
 mice, 
unaltered energy expenditure with lower food intake (either absolute or adjusted to their 
body size) suggest that they are in caloric deficiency. Recent evidence suggests 
skeletally derived LCN2 can suppress food intake
28
, however no changes in circulating 
LCN2 levels were observed in female Rptorob
-/-
 mice. In contrast, significantly lower 
circulating leptin levels were observed in the female Rptorob
-/-
 mice despite lower food 
intake. It is suspected that the hypoleptinemia in Rptorob
-/-
 mice is a consequence of low 
adiposity and negative energy balance as a result of restricted dietary intake in these 
mice and that this hypoleptinemia may account for the hypercorticosteronaemia in these 
mice. Further investigation is required to determine if other appetite-regulating 
hormones (i.e. ghrelin, neuropeptide Y, etc.) could play a role. 
2.5.4 OCN-independent mechanisms and a possible link between local nutrient-
sensing in bone and whole-body energy homeostasis 
Apart from OCN, OGN, also known as mimecan, is a proteoglycan that has recently 
been shown to coordinate the control of bone production and whole-body energy status. 
Levels of circulating OGN inversely correlate with energy balance and bone formation. 
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In wild-type mice fed a HFD (i.e. a positive energy balance), OGN levels are decreased 
whereas in human gastric bypass patients (i.e. a negative energy balance), serum OGN 
levels correlate with body weight lost and lower glycemic levels
30
. In line with the 
imbalance of increased energy expenditure with unaltered food intake and low bone 
mass phenotype of male Rptorob
-/-
 mice, circulating levels of OGN were significantly 
increased in these mice. Collectively, this study supports the notion that the skeleton 
actively communicates with other organ systems to coordinate the balance between its 
own remodeling process and overall energy status. 
In male Rptorob
-/-
 mice, the failure to build up the energy store (as evident by a marked 
reduction in body fat and accumulation of small adipocytes in the fat depots) is likely 
due to the increased energy expenditure with unaltered caloric intake state. This 
lipoatrophy could represent an adaptive response to the concurrent low insulin and 
glucose levels, which together increase the production of ketone bodies by increased 
mobilisation of fatty acid from the fat storage to the liver, as alternative energy sources, 
in order to prevent hypoglycaemic death. In support of this, recent studies have shown 
that during short-term starvation in lean rats, both hypoleptinemia and insulinopenia are 
necessary to maintain euglycaemia and thus promote survival
55
. Hypoleptinemia 
stimulates secretion of corticosterone which, in the presence of hypoinsulinemia, leads 
to WAT lipolysis and the shift from whole-body carbohydrate to fat/ketone oxidation
55
. 
Furthermore, the changes in body composition with significant reduction in total body 
weight and fat mass while paradoxically increased bone-marrow adipose tissues 
(BMAT) are observed under starvation both in dietary restricted mouse models
37
 and in 
human AN patients
35
. A growing number of studies now attribute the beneficial effects 
of BMAT expansion to adiponectin production under restricted caloric conditions
36,37,40
 
and as such, elevated serum adiponectin levels could contribute to the improved 
metabolic phenotype of Rptorob
-/-
 mice. Concordance in the phenotypes of starved rats, 
calorie-restricted mice and Rptorob
-/-
 mice (i.e. hypoleptinemia, hypoinsulinemia, high 
corticosterone and an increase in ketone bodies) suggests that loss of mTORC1 function 
in OBs mimics a starvation response. Furthermore, a reduction in bone mass and an 
expansion of BMAT in the male Rptorob
-/-
 mice previously reported in
15
, combined with 
elevated BMAT-derived adiponectin levels as evident in this study, suggest that 
suppression of mTORC1 function in OBs triggers a ‘starvation response’ in the bone 




In summary, these results suggest that the mTORC1 complex in OB plays an important 
role in the regulation of both skeletal development and skeletal regulation of whole-
body energy homeostasis. The improvement in glucose metabolism in normal chow-fed 
Rptorob
-/-
 mice also raises the possibility that these mice could be protected from 
deleterious consequences induced by a high-fat diet. Finally, these findings further 
highlight the important contribution of skeleton to whole-body glucose homeostasis. 
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Supplementary Fig. 2.1 Osx:Cre and floxed wild type mice display equivalent 
metabolic phenotypes. (A) Serum OCN (total) levels in 9-week old male and female 
mice (n=12/genotype). (B) Serum unOCN levels (n=12-13/genotype). (C) Fasting 
glucose levels (n=11-15/genotype). (D-E) ITT blood glucose levels in male and female 
mice at 8-week of age, and (F) Area under the curve analysis (n=11-15/group). (G-H) 
GTT blood glucose levels in male and female mice at 9-week of age, and (I) area under 








Supplementary Fig. 2.2 Female Rptorob
-/-
 mice display normal fat mass and 
adipocyte morphology. (A) Body weight-adjusted inguinal white adipose tissue 
(iWAT) and interscapular brown adipose tissue (iBAT) mass in 9-week-old female mice 
(n=6-10/genotype). (B) Size distribution of iWAT adipocytes of female mice calculated 
from H&E stained sections using Image J (n=5 sections/mouse, n=4-6/genotype). (C) 
Representative H&E-stained iWAT section from female mice, scale bar = 50µm. (D) 
Relative expression of adipogenesis, lipogenesis and lipolysis genes, normalised to β-
actin, in female iWAT samples (n=3-5/genotype). All panels: data are expressed as 






Supplementary Fig. 2.3: Rptorob
-/-
 mice display normal pancreatic morphology. (A) 
Representative images of insulin immunostaining in pancreas samples from 9-week-old 
male mice. Boxes in 4X panels indicate the area depicted in the corresponding 20X 
panels. Scale bars: upper panels (4X) = 500µm; lower panels (20X) = 50µm. (B) 
Histomorphometric analysis of β-cell area, islet number and islet size (n=3/genotype). 
In Panel B, data are expressed as mean ± SEM, and p-values, t-test: Rptorob
-/-





















Supplementary Fig. 2.4 Increased insulin sensitivity in Rptorob
-/-
 mice is not due to 
changes in insulin signalling in the muscle or liver. (A)  Relative expression of genes 
involved in insulin sensitivity, normalised to β-actin, in liver samples from 9-week old 
male (left) and female (right) mice (n=3/genotype). (B) Relative expression of genes 
-actin, in skeletal muscle samples from 
9-week old male (left) and female (right) mice (n=3/genotype). (C) Western 
immunoblot analysis of indicated proteins in liver (left) and muscle (right) samples 
harvested under basal (fasted + 20 minutes PBS) and insulin-stimulated (fasted + 20 
minutes insulin) conditions in male mice (n=4-5/genotype). (D) Western immunoblot 
analysis of indicated proteins in liver (left) and muscle (right) samples harvested under 
basal (fasted + 20 minutes PBS) and insulin-stimulated (fasted + 20 minutes insulin) 
conditions in female mice (n=4-5/genotype). (E-F) Quantitative analysis of indicated 










Supplementary Fig. 2.5 Increased expression levels of genes involved in cellular 
glucose transportation and glycolysis in Rptorob
-/-
 mice. Gene expression analysis of 
(A) glucose transporters and (B) glycolysis in the flushed femur/tibia from 9-week old 
male mice (n=3-5/genotype). All panels: data are expressed as mean ± SEM. **p<0.01, 
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mTORC1 is the primary cellular nutrient-sensing hub that coordinates anabolic and 
catabolic processes to control cellular growth and metabolism. Importantly, mTORC1 is 
a critical mediator of insulin signalling and negatively regulates insulin signalling, via a 
negative feedback loop, to control insulin activity. Under states of nutrient overload, 
mTORC1 becomes hyper-activated, which leads to downregulation of insulin signalling 
and the development of insulin resistance. The skeleton has emerged as a critical insulin 
target tissue and recent studies have shown that modulating insulin signalling in OBs 
has a profound effect on systemic glucose metabolism. These findings suggest that 
dysregulation of insulin signalling in OBs, by hyperactivation of mTORC1 under states 
of nutrient overload, may contribute to the development of metabolic dysfunction. To 




The studies outlined herein show that Rptorob
-/- 
mice are resistant to high-fat diet (HFD)-
induced weight gain and display a significant reduction in fat mass and adipocyte 
hypertrophy in the gonadal and inguinal white adipose tissue (WAT). Metabolically, 
HFD-fed Rptorob
-/-
 mice have significantly lower fasting glucose and insulin levels and 
exhibit increased glucose tolerance and insulin sensitivity compared to control mice. 
The obesity-resistant phenotype of Rptorob
-/-
 mice is not attributable to changes in food 
intake, physical activity or lipid absorption. Instead, Rptorob
-/-
 mice maintain the ability 
to switch between fuel sources of fat and carbohydrate and exhibit browning of WAT, 
as evidenced by increased UCP1 expression at both mRNA and protein levels. The 
browning of WAT is associated with elevated energy expenditure in the male, but not 
female, Rptorob
-/-
 mice. Furthermore, RNA-sequencing and gene set enrichment analysis 
performed on RNA isolated from tibia revealed positively enriched gene sets for 
glucose uptake and metabolism and insulin signalling pathways as a result of OB-
mTORC1 inhibition, suggesting potentiation of insulin signalling. This was confirmed 
by Western blotting both in vivo and using Rptor-null OBs in vitro. Notably, a profound 
increase in both basal and insulin-stimulated glucose uptake was also observed in 
Rptor-null OBs, suggesting that the low glycaemia and enhanced glucose tolerance in 
Rptorob
-/-
 mice, were partially due to increased skeletal glucose uptake in these mice. 
Collectively, these data suggest that whole-body protection against diet-induced insulin 
resistance in response to OB-specific deletion of the Raptor/mTOR pathway is, at least 
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in part, attributable to a localised increase in responsiveness to insulin signalling leading 

























Dysregulated insulin signalling and the development of insulin insensitivity are 
common features of many chronic disorders including obesity, diabetes and heart 
disease
1
. Furthermore over-nutrition, or excessive nutrient consumption, is a major 
contributing factor to the increasing prevalence of these metabolic diseases
2
. At the 
centre of nutritional challenges is mTORC1, the primary-nutrient-sensing hub involved 
in responding to changes in environmental nutrient availability to control cellular 
growth and metabolism. Binding of insulin to the insulin receptor (INSR) activates 
mTORC1, which in turn promotes mRNA translation, ribosome biogenesis and protein 
synthesis
3
. mTORC1 negatively regulates insulin signalling by disrupting the 
interaction between INSR and its adaptor protein, IRS1, via (i) activation of S6K1, 
which mediates IRS1 phosphorylation at Ser
270/307/1101 
and thus induces ubiquitin 
mediated-proteasomal degradation of IRS1
4,5,6
; (ii) activation and stabilisation of the 
receptor tyrosine kinase (RTK) inhibitor growth factor receptor-bound protein 10 
(Grb10), which inhibits IRS1 from binding to activated INSR
7,8
; or (iii) direct 
phosphorylation of IRS1 at Ser
636/639
, sites that lie in close proximity to the PI3-kinase 




In addition to insulin, multiple nutrient signals independently stimulate the mTORC1 
pathway (reviewed in 
10
). These include amino acids, in particular branched chain 
amino acids (BCAAs) via RAG GTPase-dependent signalling
11
. mTORC1 activity is 
also stimulated by glucose and fatty acids through cellular energy status, whereby high 
cellular energy levels (low AMP/ATP ratio) inactivates AMP-dependent kinase 
(AMPK), leading to suppression of the TSC1/2 complex, a negative regulator of 
mTORC1
12,13
. Consequently, in states of nutrient overload, mTORC1 is chronically 
activated, leading to sustained stimulation of S6K1 and S6K1-mediated phosphorylation 
and degradation of IRS1
14
. This eventually desensitises cellular insulin signalling and 
impairs the PI3K/AKT signalling pathway, thus rendering cells resistant to insulin
15
. In 
this insulin-resistant state, glucose uptake in muscle and glycogen synthesis in both liver 
and muscle are impaired, while gluconeogenesis in the liver is increased. Collectively, 
these conditions exacerbate the hyperglycaemic condition. Thus, as a consequence of 
chronically high nutrient levels in the circulation, mTORC1 remains active and 
maintains the negative feedback loop to the INSR, independently of insulin signalling, 





Inhibition of mTORC1 or elements of the mTORC1 signalling pathway, either 
genetically or pharmacologically, is associated with an improved metabolic profile. 
Whole-body inactivation of S6K1 in mice protects against diet-induced insulin 
resistance and obesity due to elevated lipolysis and metabolic rate
17
, while 
pharmacological inhibition of S6K1 with PF-4708671 improves glucose tolerance in 
mice fed a HFD
18
. In these mice, the increased insulin sensitivity is associated with an 
enhanced insulin-induced AKT phosphorylation at Ser
473
 and loss of the negative 





. Conversely, combined disruption of 4E-BP1 and 4E-BP2, 
which are negatively regulated by mTORC1, has the opposite effect, with these mice 
displaying increased adiposity and sensitivity to both HFD-induced obesity and the 
development of insulin resistance
19
. An increased in insulin resistance in these mice was 
associated with increased S6K activity and impairment of AKT phosphorylation in 
muscle, liver and adipose tissues
19
.  
The skeleton has recently emerged as a critical insulin target tissue. Importantly, insulin 
signalling in OBs, the bone-forming cells of skeleton, is necessary for whole-body 
glucose homeostasis, whereby OB-specific deletion of INSR (INSR
OB-/-
 mice) causes 
elevated blood glucose, increased insulin resistance and increased peripheral fat mass in 
animals fed a normal diet
20,21
. Furthermore, in response to an obesogenic HFD, mice 
lacking one allele of INSR in OBs (Col1a1-INSR
+/-
) have higher fasting glucose and 
insulin levels and develop exacerbated metabolic responses associated with severely 
impaired glucose and insulin tolerances
22
. Conversely, mice over-expressing the INSR 
in OBs (Col1a1-INSR
Tg
) have smaller fat deposits, lower fasting glucose and insulin 
levels and are protected from HFD-induced glucose intolerance and insulin resistance
22
. 
Remarkably, bones isolated from HFD-fed wildtype mice exhibit features of insulin 
resistance such as reduced insulin-stimulated phosphorylation of AKT at Ser
473
 and 
down-regulation of the INSR
22
. This reduction in insulin signalling in OBs was similar 
to that observed in other primary insulin target tissues such as liver, skeletal muscle and 
adipose tissues
22
. Collectively, these findings demonstrate that the skeleton plays an 
important role in the metabolic dysfunction associated with diet-induced insulin 
resistance and that restoration of insulin signalling in bone has systemic effects on 
insulin sensitivity. As aberrant activation of mTORC1 signalling leads to the 
development of insulin resistance, suppression of skeletal mTORC1 signalling may 
abrogate HFD-induced dysregulation of insulin signalling in the skeleton.  
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To investigate this question, mice with conditional deletion of Rptor, an essential 
component of mTORC1, in pre-OBs were utilised (Rptorob
-/-
 mice). As shown in this 
Chapter, detailed metabolic analyses of these mice revealed that inactivation of OB-
mTORC1 results in lean mice that are resistant to weight gain and are protected against 
the negative metabolic effects of HFD-induced obesity. Mechanistically, the protective 
phenotypes of Rptorob
-/-
 mice are, at least in part, attributable to enhanced insulin 
signalling and thereby increased glucose uptake and glycolysis in the OBs of these 


















3.3 Materials and Methods 
For all other techniques previously outlined in Chapter 2, please refer to Section 2.2 for 
the detailed Materials and Methods 
3.3.1 High-fat diet studies. All mice were bred and housed in pathogen-free conditions 
at the SAHMRI Bioresources Facility (SAHMRI, Adelaide, Australia), with ad libitum 
access to food (High fat diet: Specialty Feeds #SF16-096: 19.4% protein, 23% fat, WA, 
Australia; detailed in Supplementary Table 3.1) and water.  
3.3.2 Calculation of Food Quotient. The food quotient (FQ), defined as an ideal diet-
specific ratio of VCO2/VO2, was calculated using the following equation
23
: (0.835 × 
%protein) + (1.0 × %carbohydrate) + (0.71 × %fat). The HFD contained 39.3% energy 
from protein, 43.4% energy from fat and 17.3% energy from carbohydrate resulting in a 
calculated FQ of 0.8093. Alternative FQ was estimated from linear regression analysis 
of change in body mass during the measurement period (∆Mb: x-axis) and 24-hour RQ 
(y-axis) as previously described 
24
 (Supplementary Fig. 3.1).  
3.3.3 Histology and Immunohistochemistry. Immunohistochemistry was performed on 
interscapular brown adipose tissue using rabbit anti-UCP1 (ab209483, Abcam, 
Cambridge, MA, USA, 1:5000). For Oil red O staining, liver samples were mounted in 
Tissue-Tek Optimum Cutting Temperature compound (Sakura Finetek, The 
performed as previously described
25
.  
3.3.4 Protein isolation and Western blotting. Additional details of sources and 
concentrations of antibodies used in the immunoblotting are listed in Supplementary 
Table 3.2.  
3.3.5 RNA isolation and quantitative RT-PCR. Additional details of forward and 
reverse primer pairs, designed to amplify across intron-exon boundaries, are listed in 
Supplementary Table 3.3.  
3.3.6 RNA high-throughput sequencing and gene expression analysis. RNA isolated 
from marrow-flushed combined femora/tibiae was processed and sequenced through the 
low-input RNA-seq pipeline at The David Gunn Genomics Facility, SAHMRI (Illumina 
Nextseq, San Diego, CA, USA) using a 75 cycle v2 High Output sequencing kit. 
Analyses were then conducted by the SAHMRI Bioinformatics Facility. Initial raw read 
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processing was performed using an in-house pipeline developed at SAHMRI. Raw 75bp 
single-end FASTQ reads were assessed for quality using FastQC and results aggregated 
using R/Bioconductor package ngsReports
26
. Reads were then trimmed for sequence 
adapters using AdapterRemoval
27
 and aligned to the GRCh38/mm10 version of the 
mouse genome using the RNA-seq alignment algorithm STAR
28
. After alignment, 
mapped sequence reads were summarised to the mm10 gene intervals using 
featureCounts
29
, and count table transferred to the R statistical programming 
environment for expression analysis. 
Gene counts were filtered for low expression counts by removing genes with less than 1 
count per million (cpm) in more than four samples and then normalised by the method 
of trimmed mean of M-values
30
. Differential gene expression was carried out on log-





. Gene Set Enrichment Analysis (GSEA) was performed using the Molecular 
Signature Database (MSigDB) and other gene-sets were generated using the limma 
package 
34


















 mice are protected against high-fat diet-induced obesity  
As outlined in Chapter 2, loss of mTORC1 function in pre-OBs is associated with 
improved glucose disposal and insulin sensitivity in mice fed a normal chow diet. These 
results suggest that mTORC1 signalling in OBs plays an important role in the regulation 
of glucose homeostasis. Furthermore, given that nutrient-overload leads to hyper-
activation of mTORC1 signalling and the development of insulin resistance
9
, this led to 
the hypothesis that suppression of OBs-mTORC1 could protect animals from 





 and littermate controls were placed on HFD (40% calories from fat) from 4-
weeks of age and weight gain was monitored twice-weekly. Both male and female 
Rptorob
-/-
 mice weighed significantly less the control mice (Fig.3.1A and B). As shown 
in Figure 3.1C and D, Rptorob
-/-
 mice initially gained weight on the HFD at a similar rate 
to control and Rptorob
-/+ 
mice, and in the case of female mice, gained weight more 
rapidly. However, unlike the control and Rptorob
-/+ 
mice, which continued to gain 
weight in response to the obesogenic diet, weight gain in the Rptorob
-/-
 mice plateaued 
after approximately 6 weeks and they gained only a small amount of additional weight 
thereafter (i.e. from 6-13 weeks on HFD, control mice gained 9.3g and 7.2g in male and 
female respectively, whereas Rptorob
-/-
 mice gained only 1.7g; Fig. 3.1C-D).  
The lower body weight of Rptorob
-/- 
mice was independent of difference in their body 
length but rather due to the changes in the body composition as suggested by a 
significant lower BMI in the Rptorob
-/- 
mice (Supplementary Fig. 3.2A-B). Further 
examination of body composition in these HFD-fed mice revealed that the difference in 
their body weight was largely attributable to a significant reduction in fat mass in 
Rptorob
-/-
 mice (Fig. 3.1E), with a modest reduction in lean mass also observed 
(Supplementary Fig. 3.2C-D). When expressed as a percentage of total body mass, fat 
mass in male or female Rptorob
-/-
 mice was 50% lower than that of the control mice (Fig. 
3.1F). The total fat mass and % fat mass of HFD-fed Rptorob
-/+ 
mice was also found to 
be significantly lower than the controls in the male, but not female cohorts (Fig. 3.1E 
and F). Furthermore, the difference in fat mass in HFD-fed Rptorob
-/-
 mice was clearly 
evident upon dissection and analysis of individual fat pad weights (Fig. 3.1G and H), 
whereas no such differences in lean organ weights (i.e. liver, heart, kidney, brain, 
85 
 
spleen; Supplementary Fig. 3.2E and F) were observed in Rptorob
-/-
 mice compared to 
controls.  




 mice using Promethion cages 
revealed that the resistance of Rptorob
-/-
 mice to HFD-induced weight gain and fat 
accumulation occurred independently of alterations in food intake, faecal lipid content 
and levels of physical activity (Supplementary Fig. 3.2G-K). Total energy expenditure 
(normalised to grams of lean mass, to account for the disproportionate HFD weight 
gaining between the genotypes) was similar between the genotypes during the light 
period, but was significantly higher in male Rptorob
-/-
 mice during the dark cycle than 
the controls (Fig. 3.1I). Conversely, energy expenditure was equivalent across all 
genotypes during both light and dark cycles in the female cohort (Fig. 3.1J). 
Interestingly, while 24-h (daily) RQ values were similar across all three genotypes in 
both male and female cohorts, RQ patterns were noticeably different (Fig. 3.1K and L). 
To interrogate the hourly RQ patterns further, the food quotient (FQ), where FQ is the 
theoretical RQ produced by the diet, were calculated
10
 and 24-h RQ≈FQ indicates a 
state of energy and macronutrient balance
11
. As detailed in Supplementary Fig 3.1A-C, 
the FQ of the HFD used in this study was calculated to be 0.7976, and is represented in 




 mice exhibited RQ>FQ 
during the dark cycle, relative to controls, whereas only in Rptorob
-/-
 mice was RQ<FQ 
during the light cycle, culminating in a 24-h RQ close to the FQ. This suggests that 
Rptorob
-/-
 mice maintain their constant weight and energy balance through greater 
substrate flexibility, with greater utilization of fat storage during the light cycle which 
provide a glycerol substrate for increased gluconeogenesis, thus resulting in higher 
carbohydrate oxidation in the dark cycle (Fig. 3.1K and L). Conversely, in Rptorob
+/-
 
mice, higher carbohydrate oxidation and lipid synthesis in the dark cycle was not offset 
by greater utilization of fat storage during the light cycle. Thus, even with greater 
substrate flexibility, as is evident in Rptorob
-/-
 mice, higher energy storage during the 
dark cycle surpassed fat oxidation during the light cycle, resulting in overall continuous 
weight gain. In contrast, the average phasic RQ values of the control mice remained 
approximately constant, which is indicative of fewer shifts in their fat storage and 














Fig. 3.1 HFD-fed Rptorob
-/-
 mice are protected against diet-induced obesity and 
exhibit greater substrate flexibility. (A-B) Temporal body weight changes in male 
and female mice (n≥15/genotype). (C-D) Body weight gained in response to high fat 
diet (HFD) in male and female mice (n≥15/group). Dotted lines indicate the point at 
which Rptorob
-/-
 mice became resistant to further weight gain. (E-F) DXA analysis of 
total fat mass and % fat mass normalised to total body weight in 18-week old HFD-fed 
mice (n=4-5/genotype). (G-H) gWAT and iWAT fat pad mass, normalised to body 
weight, in male and female mice at 18-week of age (n=4-9/genotype). (I-J) Total energy 
expenditure, normalised to lean mass, over a 48-h time course (left) and per light/dark 
cycle (right) in male and female HFD-fed mice (n=5-7/genotype). (K-L) Average 
respiratory quotient (RQ) over a 48-h time course (left) and per light and dark cycle 
(right) in male and female mice (n=5-7/genotype). All panels: data are expressed as 
mean ± SEM. *p<0.05, **p<0.01, ***p<0.001, two-way ANOVA with Tukey’s post-





 mice are resistant to liver steatosis and adipocyte hypertrophy and 
exhibit increased browning of white adipose tissue 
On a systemic level, maintaining metabolic homeostasis during feeding or fasting relies 
on multi-organ coordinated control of available fuel. Fasting lowers the insulin-to-
glucagon ratio, which stimulates hydrolysis of adipose tissue triacylglycerol (TG) (i.e. 
lipolysis) and thereby increases circulating levels of free fatty acids (FFAs) and their 
delivery to the periphery. Conversely, during postprandial states, high insulin levels 
favour glucose uptake, glycolysis, and pyruvate oxidation in liver and skeletal muscle 
while stimulating adipose de novo lipogenesis (DNL) from lipids and glucose. 
Furthermore, fatty acids derived from a meal also trigger adipose tissue to reduce FFA 
release and prompt hepatocytes to reduce endogenous TG release, which together 
stimulates the clearance of circulating TG
38,39,40,41
. The increased ability to switch 
metabolism between carbohydrate and fat oxidation in Rptorob
-/-
 mice was associated 
with lower circulating TG levels in the male, but not the female mice, while FFA levels 
were higher in male Rptorob
+/-
 mice relative to control and Rptorob
-/-
 mice (Fig. 3.2A and 
B). Of note, significantly higher serum levels of β-hydroxybutyrate, the most abundant 
ketone
42
, which are typically produced under prolonged fasting, were observed in both 
HFD-fed male and female Rptorob
-/-
 mice compared to controls (Supplementary Fig. 
3.3A). 
Both histological examination and quantification of lipid content in the liver revealed 
significantly less hepatic steatosis and lower levels of accumulated TG and FFA in the 
liver of HFD-fed Rptorob
-/-
 mice compared to the controls (Fig. 3.3C-E) while 
expression analyses of genes involved in glucose or fatty acid metabolism failed to 
detect any changes in mRNA levels (Supplementary Fig. 3.3B and C). Analysis of 
adipocyte size and distribution revealed a significantly higher proportion of small 
adipocytes and a lower number of large adipocytes in both male Rptorob
-/- 
gWAT and 
iWAT depots in response to the obesogenic diet (Fig. 3.2C, F and G). This reduction in 
adipocyte hypertrophy in Rptorob
-/-
 mice was accompanied by an upregulation in the 
expression of adipogenic genes (Cebpα, Pparγ and Lpl) (Fig. 3.2H and I). An increase 
in adipose de novo lipogenesis, which promotes conversion of excessive carbohydrates 
to fatty acids for storage, has been reported to be beneficial to the body by sequestering 
excess TG thereby preventing lipotoxicity in other tissues (reviewed in 
43
). Expression 
levels of DNL genes (Fasn, Acc and Acyl) were significantly upregulated in both fat 
depots of Rptorob
-/-





 mice could contribute to the lower levels of circulating and hepatic TG 
observed in these mice. 
Strikingly, increased multilocularity of lipid droplets, a characteristic of brown 
adipocytes, was observed in iWAT of male HFD-fed Rptorob
-/- 
mice suggesting 
“browning” of adipocytes (Fig. 3.2K). Consistent with these morphological 
observations, a strong upregulation in Ucp1 mRNA and other genes associated with 
adipogenisis (e.g. Pcg1a, Cidea and Cox7a) was observed in Rptorob
-/-
 iWAT samples 
compared to controls (Fig. 3.2J). Immunohistochemistry on the iWAT section and 
Western blotting of protein lysates made from iWAT confirmed the significant increase 
in protein levels of UCP1 in HFD-fed Rptorob
-/-
 mice compared to the controls (Fig. 3.2J 
and L). In light of the observed browning of iWAT in HFD-fed Rptorob
-/-
 mice, other 
adipose depots were also examined to determine whether they also displayed this effect. 
As shown in Supplementary Figure 3.3D-H, upregulation of Ucp1 and Pcg1a 
expression was observed in the gWAT of Rptorob
-/-
 mice at the mRNA level, but not at 
the protein level, whereas no changes in morphology, nor Ucp1 expression, were 
observed in Rptorob
-/-
 BAT. Similar data were obtained for the female mice 














Fig. 3.2 HFD-fed male Rptorob
-/-
 mice exhibit browning of white adipose tissue. (A) 
Serum triglyceride levels in HFD-fed mice at 18-week of age (n=6-9/genotype). (B) 
Serum free fatty acid levels (n=6-11/genotype). (C) Representative images of H&E and 
Oil red O-stained sections of liver and H&E section of gWAT and iWAT from HFD-fed 
male mice, scale bar = 100 µm. (D) Hepatic triglyceride levels and (E) hepatic free fatty 
acid levels in 18-week old mice (n=3-4/genotype). (F-G) Size distribution of male 
gWAT and iWAT adipocytes calculated from H&E stained sections using Image J (n=5 
sections/mouse, n=5-6/genotype). (H-I) Gene expression levels of adipogenesis and de 
novo lipogenesis markers in HFD-fed male gWAT and iWAT tissues, normalised to β-
actin (n=3-5/genotype). (J) Representative images of H&E (top) and UCP1 immuno-
staining section (bottom) of iWAT from male mice, scale bar = 100µm. (K) Gene 
expression levels of brown adipose tissue markers in HFD-fed male iWAT tissue, 
normalised to β-actin (n=3-5/genotype). (L) Levels of UCP1 protein expression in 
HFD-fed male iWAT tissue (left) and quantitative analysis of protein levels relative to 
β-actin (right) (n=4/genotype). All panels except C and K: data are expressed as mean ± 







The upregulation of protein levels of UCP1 only in the iWAT, but not the gWAT, 
suggested that browning of WAT in Rptorob
-/-
 mice occurred in a depot-specific manner. 
Furthermore, even though proximal tibia regions (which are juxtaposed to trabecular 
bone) of BMAT have been reported to express markers of brown fat
44,45
, Ucp1 levels 
were undetectable in the bone of Rptorob
-/-
 mice (data not shown). Collectively these 
findings suggest that the mechanism(s) underlying this increase browning of white fat in 
Rptorob
-/-
 mice may occur in an endocrine, not paracrine, manner. Recent studies have 
reported that skeletal muscle-secreted irisin
46
 and fibroblast growth factor 21 (FGF21)
47
 
increase beige adipogenesis, raising the possibility that factors secreted from bone cells 
could alter the secretion of these factors. As shown in Fig. 3.3A and B, levels of Fgf21 
mRNA expression in the liver (the primary source of FGF21) were unchanged, and 
levels of skeletal muscle Fndc5 expression (which encodes for Irisin) were significantly 
lower in both male and female Rptorob
-/-
 mice. More recently, bone morphogenetic 
protein 7 (BMP7)
48
 and the Wnt-signalling inhibitor, sclerostin
49
 have been identified as 
additional regulators of WAT browning. As shown in Fig. 3.3C and D, mRNA 
expression levels of both Bmp7 and Sost were significantly higher in flushed tibia/femur 
samples from male, but not female, Rptorob
-/-
 mice. Consistent with the observed 
increase in Sost mRNA expression, sclerostin protein levels were also significantly 
elevated in the long bones of HFD-fed Rptorob
-/-
 mice (Fig. 3.3E); however when 
expression levels of Axin2, a canonical Wnt signalling target gene, or total β-catenin 
levels were examined in the iWAT, there was no evidence of any inhibition of the Wnt 
signalling pathway (Fig. 3.3F and G). Given that browning of iWAT occurs in both 
sexes, this data suggests that increased Bmp7 or Sost are not required for the beiging 









Fig. 3.3 Browning of iWAT in HFD-fed Rptorob
-/-
 mice occurs independent of 
known browning inducers. (A) Fgf21 gene expression, normalised to β-actin in liver 
(n=3-5/genotype). (B) Fndc5 gene expression, normalised to β-actin in muscle (n=3-
5/genotype). (C) Bmp7 and (D) Sost gene expression, normalised to β-actin in bone 
samples (n=3-5/genotype). (E) Levels of Sclerostin protein expression in HFD-fed male 
bone tissue (top) and quantitative analysis of protein levels relative to β-actin (bottom)  
(n=4-5/genotype). (F) Axin2 gene expression, normalised to β-actin in iWAT samples 
(n=3-5/genotype). (G) Levels of total β-catenin protein expression in HFD-fed male 
iWAT tissue (top) and quantitative analysis of protein levels relative to β-actin (bottom)  
(n=3-4/genotype). All panels: data are expressed as mean ± SEM. *p<0.05, **p<0.01, 





 mice are resistant to diet-induced insulin resistance 
In addition to their role as an energy storage depot, adipose tissues play a crucial role in 
controlling energy metabolism via the actions of adipokines such as leptin and 
adiponectin
50
. Consistent with the lower fat mass observed in Rptorob
-/-
 mice (Fig. 
3.1D), serum leptin levels were greatly reduced in Rptorob
-/-
 mice compared to both 
Rptorob
-/+ 
and control mice (Fig. 3.4A). Conversely, serum adiponectin levels were 
significantly higher in the Rptorob
-/-
 mice compared to controls (Fig. 3.4B). Furthermore, 
analysis of adiponectin multimers showed a higher level of high molecular weight 
(HMW), the most bioactive, form of adiponectin in the serum of both male and female 
Rptorob
-/-
 mice suggesting a greater sensitivity to insulin in Rptorob
-/-
 mice (Fig. 3.4C 
and D).  
 
 
Fig. 3.4 OB-specific deletion of Rptor affects serum adipokine levels. (A) Serum 
leptin levels in HFD-fed mice at 18-week of age (n=11-14/genotype). (B) Serum 
adiponectin levels (n=10-15/genotype). (C-D) Western immunoblot analysis of high 
molecular weight (HMW), low molecular weight (LMW) and total adiponectin levels in 
sera from 18-week old HFD-fed male and female mice (top, n=4/genotype), and 
quantitative analysis of protein levels relative to β-actin (bottom). All panels: data are 
expressed as mean ± SEM. *p<0.05, **p<0.01, ***p<0.001, two-way ANOVA with 





 mice showed a trend toward decreasing fasting glucose levels over the 
time course of HFD. Specifically, in 16-week old male Rptorob
-/-
 mice, the fasting 
glucose levels were significantly lower than Rptorob
-/+ 
and control mice (Fig. 3.5A) 
while the fasting glucose levels of female Rptorob
-/-
 mice were persistently lower than 
the control mice (Fig. 3.5B). The lower levels of fasting glucose in the Rptorob
-/-
 mice 
were accompanied by a significant lower fasting insulin levels (Fig. 3.5C). As a result, 
calculation of homeostatic model assessment of insulin resistance (HOMA-IR) identify 
them as being more insulin-sensitive that both the Rptorob
-/+ 




 suggest that in cases of significant difference in the fasting glucose levels, 
assessing glucose levels as a percentage of basal glucose for an ITT, can lead to 
erroneous interpretation of the results and thus all the ITT results were presented as 
absolute glucose levels. At 16 weeks of age, both male and female Rptorob
-/-
 mice 
recapitulated all the key features of the metabolic profiles that were evident in the 
normal chow-fed studies, including the maintenance of higher glucose tolerance (Fig. 
3.5E-G) as evidenced by with consistently lower glucose levels and significantly lower 
incremental area under the curve (iAUC) and higher responsiveness to insulin (Fig. 
3.5H- J) compared to the controls. The improvements in glucose disposal in both male 
and female Rptorob
-/-
 mice were associated with a higher fold change of insulin levels at 
30 minutes post glucose injection, as measured by glucose-stimulated insulin secretion 
tests (Fig. 3.5K-N). Moreover, smaller β-cell islet hypertrophy was observed in male 
Rptorob
-/-


















Fig. 3.5 HFD-fed Rptorob
-/-
 mice are protected against diet-induced insulin 
resistance. (A-B) Fasting glucose levels over 8-17 weeks old male (A) and female (B) 
mice (n=5-15/genotype). (C) Fasting insulin levels (n=8-10/genotype). (D) HOMA-IR 
calculations of HFD-fed female mice (n=3-8/genotype). (E-F) Glucose tolerance tests 
(GTTs) in 17-week old male (E) and female (F) mice (n=6-15/genotype). (G) 
Incremental area under the curve analysis from (E-F). (H-I) Insulin tolerance tests 
(ITTs) in 16-week old male (H) and female (I) mice (n=6-15/genotype). (J) Area under 
the curve analysis from (H-I). (K-N) Insulin levels during a glucose-stimulated insulin 
secretion tests (GSIS) in male (K) and female (M) and Fold change in insulin levels at 
30 minutes post glucose injection relative to basal levels (L and N) (n=8-10/genotypes). 
(O) Mean pancreatic islet area (n=5/genotype) and representative image of insulin 
immunostaining of pancreas at 18-week of age, scale bar=50μm. All panels except E, F, 
H and I: data are expressed as mean ± SEM. *p<0.05, **p<0.01, ***p<0.001, two-way 
ANOVA with Tukey’s post-hoc test. For panel E, F, H and I: *p<0.05 between Rptorob
-
/-

















To further investigate the higher whole-body insulin sensitivity observed in HFD-fed 
Rptorob
-/-
 mice, the insulin-induced phosphorylation of INSR at Tyr
1150/1151 
and AKT at 
Ser
473
 in the main insulin-target tissues: liver, skeletal muscle and adipose (iWAT and 
gWAT), was examined. Somewhat surprisingly, no significant difference in INSR or 
AKT phosphorylation was observed in either sex, with only a modest increase in AKT 
phosphorylation observed in skeletal muscle and INSR phosphorylation in iWAT from 
female HFD-fed Rptorob
-/-
 mice (Fig. 3.7A-B). Of note, the levels of INSR 
phosphorylation in the male Rptorob
-/-
 liver samples trended towards a decrease, 
compared to controls (Fig. 3.6A-D). 
mTORC1 negatively regulates insulin signalling via a feedback loop where mTORC1 
directly, and indirectly via S6K1 activation, leads to phosphorylation of IRS-1 and its 
subsequent ubiquitin-mediated degradation
17,52
. HFD feeding and obesity are associated 
with hyperactivation of the mTOR pathway, with increased S6K activity
53
 and reduced 
IRS-1 protein levels
35,54
 observed in the liver and skeletal muscle. To further interrogate 
the activation of the mTOR pathway in HFD-fed Rptorob
-/-
 mice, the phosphorylation of 
rpS6 at Ser
240/244
, a substrate of S6K1, and total IRS-1 levels in the liver, skeletal muscle 
and adipose tissues was examined. Consistent with previously published studies
53
, basal 
phosphorylation of rpS6 was consistently detected in liver samples from all three 
genotypes, however basal phosphorylation of rpS6 at Ser
240/244





 mice, but not in the controls (Fig. 3.6A and B and 
3.7A and B). Despite this, the levels of insulin-stimulated rpS6 phosphorylation in 
muscle and liver were similar across all three genotypes (Fig. 3.6A and B and 3.7A and 
B). While no significant difference was observed in basal S6 phosphorylation in the 
both fat depots, a significant induction in rpS6 phosphorylation was observed in 
response to insulin stimulation in gWAT of both male and female Rptorob
-/-
 mice (Fig. 
3.6A and B and 3.7A and B). In iWAT, rpS6 phosphorylation was significantly higher 
in male (Fig. 3.6A and B) and a trend toward significant (p=0.06) in the female Rptorob
-
/-
 mice (Fig. 3.7A and B), indicative of increased insulin-stimulated mTOR signalling. 
Increased IRS-1 protein levels were also observed in fat depots of Rptorob
-/-
 mice under 
both basal conditions and in response to insulin stimulation (Fig. 3.6A and B and 3.7A 
and B). These results suggest that enhanced insulin signalling in the fat depots of 
Rptorob
-/-
 mice may account for the higher peripheral sensitivity to insulin demonstrated 
by ITTs in the Rptorob
-/-
 mice (as indicated by ITT data, Fig. 3.3F-H) and is attributable 













Fig. 3.6 Insulin signalling in peripheral tissues in HFD-fed male mice. (A) Western 
immunoblot analysis of indicated protein levels in skeletal muscle (top left), liver (top 
right), iWAT (bottom left), and gWAT (bottom right) tissues from 18-week old HFD-
fed male mice collected after a 6 hour fast, under either basal (6 hr fast + PBS; 
n=2/genotype) or insulin-stimulated (6 hr fast + insulin stimulation; n=2-3/genotype) 
conditions. (B) Quantitative analysis of indicated protein levels from (A). Panels B: data 

















Fig. 3.7 Insulin signalling in peripheral tissues in HFD-fed female mice. (A) 
Western immunoblot analysis of indicated protein levels in skeletal muscle (top left), 
liver (top right), iWAT (bottom left), and gWAT (bottom right) tissues from 18-week 
old HFD-fed female mice collected after a 6 hour fast, under either basal (6 hr fast + 
PBS; n=2/genotype) or insulin-stimulated (6 hr fast + insulin stimulation; n=2-
3/genotype) conditions. (B) Quantitative analysis of indicated protein levels from (A). 




3.4.6 Transcriptional changes associated with OB-specific Rptor deletion in male 
HFD-fed mice. 
To investigate how impaired mTORC1 function in pre-OBs contributes to systemic 
changes in metabolism, RNA-sequencing was used to identify transcriptional networks 
that are modulated in the bones of male Rptorob
-/-
 mice. mTORC1 regulates transcription 
either directly, by controlling the nuclear import of transcription factors
55,56
, or 
indirectly through the translation of transcription factors
57
. To identify genes that are 
differentially regulated by mTORC1, RNA-seq analysis was performed to compare the 
transcriptomes of flushed long bone (tibia/femur) samples from control and Rptorob
-/-
 
mice. Gene set enrichment analysis (GSEA) of the whole transcriptome in the bone of 
Rptorob
-/-
 mice identified an upregulation in gene sets associated with glucose uptake 
and oxidation, lipid oxidation pathways and insulin signalling (Fig. 3.8A). Furthermore, 





, pathways involved in B-cell development were down-
regulated in the Rptorob
-/-
 mice (Supplementary Fig. 3.6). A complete list of upregulated 
and downregulated pathways is detailed in Appendix I and II. 
After data processing and filtering, 986 genes were found to be differentially expressed 
with 868 genes being significantly up-regulated and 118 genes significantly down-
regulated in Rptorob
-/-
 bones. These differentially-expressed genes (DEGs) were then 
mapped to the KEGG pathway enrichment analysis. Consistent with GSEA, DEGs were 
highly clustered towards glucose metabolism and response to insulin signalling 
including insulin signalling pathway (15/140 genes; enrichment FDR= 7.95E-04), 
Glycolysis / Gluconeogenesis pathway (9/67 genes; enrichment FDR= 1.87E-03), PI3K-
Akt signalling pathway (25/357 genes; enrichment FDR= 8.65E-03), Starch and sucrose 
metabolism (5/33 genes; enrichment FDR=1.16E-02) and FoxO signalling pathway 
(11/131 genes; enrichment FDR= 2.23E-02).  
Consistent with the enrichment of glycolysis pathway from GSEA (Fig. 3.8B) and 
KEGG pathway analysis, gene expression analyses revealed significantly higher 
expression levels of genes involved in glucose oxidation – e.g. hexokinase 2 (HkII), 
phosphoglycerate kinase 1 (Pgk1), lactate dehydrogenase A (Ldha), phosphoinositide-
dependent kinase-1 (Pdk1) and 6-phosphofructokinase (Pfkm1) (Fig. 3.8C). OBs are 
known to express three glucose transporters (Glut1, 3 and 4)
59,60,61
. Glut1, 
predominantly expressed in undifferentiated OBs, is crucial for insulin-independent 
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glucose uptake for differentiation and proliferation
62
 while Glut4 mediates insulin-
stimulated glucose uptake by mature OBs
63
. As shown in Figure 3.8C, levels of Glut4 
mRNA expression were 2-fold higher in the long bones of Rptorob
-/-
 mice compared to 
the controls, whereas no change in Glut1 expression was observed. The higher 
expression of Glut4, an insulin-dependent glucose transporter, together with 
upregulation of glycolysis and insulin signalling pathways suggests a potential increase 


















Fig. 3.8 Increased glycolysis and insulin signalling pathways in the bone of HFD-
fed male Rptorob
-/-
 mice. (A) Gene set enrichment analysis (GSEA) of positively-
enriched pathways (upregulated) of RNA isolated from combined flushed femur and 
tibia (n=5; controls versus Rptorob
-/-
). (B) Enrichment plots of glycolysis (left) and 
insulin-like growth factor receptor signalling pathways (right). (C) Gene expressions of 
glycolysis (HkII, Pgk1, Ldha, Pdk1 and Pfkm1) and glucose transporters (Glut1 and 
Glut4) in the flushed femur/tibia from HFD-fed mice (n=3-5/genotype). Panel C: data 
are expressed as mean ± SEM. *p<0.05, **p<0.01, ***p<0.001, two-way ANOVA with 
Tukey’s post-hoc test. Panels A: orange bar indicates pathways relating to glucose 
metabolism or insulin signalling, green bar indicates pathways relating to lipid 
metabolism, and black bar indicates pathways relating to bone development. Grey bar 




3.4.5 Increased insulin signalling and glycolysis in bone of Rptorob
-/-
 mice 
In light of the RNA-seq data, we next interrogated if the systemic changes in glucose 
metabolism in Rptorob
-/-
 mice, under HFD, was associated with an increase in insulin 
sensitivity in bone. Previous studies have shown that insulin resistance develops in the 
skeleton of HFD-fed mice and genetically increasing or decreasing insulin signalling in 
OBs protected or worsened whole-body glucose homeostasis in HFD-fed mice, which is 
partly due to the effects of insulin signalling on OCN activity
22
. Gene expression 
analysis of Bglap mRNA expression in the long bones of Rptorob
-/-
 mice revealed a 
significant upregulation of Bglap expression in male, but not female, Rptorob
-/-
 mice, 
compared to controls (Fig. 3.9A). However, at the protein level, circulating levels of 
both total and undercarboxylated OCN were found to be unchanged in both male and 
female Rptorob
-/-
 mice compared to controls (Fig. 3.9B-C). Furthermore, the circulating 
levels of other reported osteokines, lipocalin 2 (LCN2)
64
 and osteoglycin (OGN)
65
, were 
also unchanged between all three genotypes (Fig. 3.9D-E). An assessment of bone 
mineral density (BMD) using DEXA in HFD-fed Rptorob
-/-
 mice revealed a significant 








Fig. 3.9 Improvements in glucose metabolism observed in HFD-fed Rptorob
-/-
 mice 
occur independent of osteocalcin and other osteokines. (A) Gene expression of 
Bglap -actin (n=3-4/genotype). (B) Serum 
levels of total osteocalcin, (C) undercarboxylated osteocalcin, (D) lipocalin-2 and (E) 
osteoglycin in HFD-fed mice at 18-weeks of age (n=7-15/genotype). All panels: data 
are expressed as mean ± SEM. *p<0.05, **p<0.01, ***p<0.001, two-way ANOVA with 
Tukey’s post-hoc test.  
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Insulin responsiveness in bone (calvaria) of Rptorob
-/-
 mice was assessed biochemically 
following insulin stimulation. Initially, Rptor deletion was confirmed in calvaria by 
qRT-PCR, using primers specific to floxed exon 6. A significant reduction in Rptor 
gene expression was observed in Rptorob
-/-
 mice consistent with Cre-mediated excision 
(Fig. 3.10A).Intracellular signalling events triggered by insulin, such as phosphorylation 
of insulin receptor at Tyr
1150/1151
, were significantly higher in the bone of Rptorob
-/-
 mice 
(Fig. 3.10B). In contrast, insulin-stimulated phosphorylation of rpS6, a major effector 
protein downstream of mTOR1, at Ser
240/244 
was blunted in the Rptorob
-/-
 mice compared 
to controls, consistent with reduced mTORC1 activity. Importantly, both basal and 




) were significantly increased in 
Rptorob
-/-
 mice (Fig. 3.10B). Concomitant with the increased activation of AKT, in both 
the basal and insulin-stimulated states, the phosphorylation levels of AKT substrates 
including glycogen synthases 3β (GSK3β) at Ser
9
 and AS160 at Thr
642
, a substrate of 
AKT that regulates insulin-stimulated Glut4 trafficking, at Thr
642
 were increased (Fig. 
3.10B). This data, in combination with the RNA-seq data, suggests that loss of 
mTORC1 function in OBs increases basal and insulin-dependent glucose uptake in 
Rptorob
-/-
 mice.  
To address this question, calvarial cells were isolated from newborn Rptor
fl/fl 
mice and a 
tamoxifen-inducible Cre lentivirus was used to generate Rptor knockout OBs (Rptor
KO
) 
and wildtype control cells (Rptor
WT
). Deletion of Rptor in calvariae-derived OBs in 
vitro caused a reduction in basal and insulin-stimulated phosphorylation of the key 
mTORC1 substrates p70S6K and 4E-BP1 and ribosomal protein S6, a p70S6K 
substrate, findings consistent with reduced mTORC1 activity (Fig. 3.10C). Deletion of 
Rptor was also associated with an increase in basal and insulin-stimulated AKT 
activation and phosphorylation of GSK3β at Ser
9
 (Fig. 3.10C), consistent with the in 
vivo insulin pulse experiments (Fig. 3.10B). Furthermore, qRT-PCR analysis revealed 
an increase in the expression of glycolytic genes in Rptor
KO
 cells relative to wildtype 
control cells, mirroring the in vivo findings (Fig. 3.10D). Finally, using the 
accumulation of 2-deoxyglucose as a surrogate measure of glucose uptake, loss of 
mTORC1 function in OBs increased both basal and insulin-stimulated glucose uptake 
into OBs (Fig. 3.10E). Taken together, these findings support a central role for the 
mTORC1 complex in OBs in the control of systemic glucose metabolism and highlight 







Fig. 3.10 In vivo and in vitro loss of OB-mTORC1 lead to potentiation of OB insulin 
signalling. (A) Gene expression of Rptor in the calvarial bone tissue, normalized to β-
actin (n=3-4/genotype). Data are expressed as mean ± SEM. *p<0.05, unpaired 
Student’s t-test. (B) Western immunoblot analysis of indicated protein levels in 
calvarial bone tissue from 18-week old HFD-fed mice collected after a 6 hour fast under 
either basal (6-hr fast + PBS; n=2-3/genotype) or insulin-stimulated (6-hr fast + insulin 
stimulation; n=2/genotype) conditions. (C) Western immunoblot analysis of indicated 
protein levels in wildtype (WT) and Rptor knockout (KO) cultured primary osteoblasts 
collected under normal growth and a 4-h serum starved conditions before or after 
stimulation with 100nM insulin. (D) Gene expression analysis of glycolysis and glucose 
transporters in WT or Rptor KO OBs (n=3). Data are expressed as mean ± SD. *p<0.05, 
***p<0.001, unpaired Student’s t-test. (E) 2-Deoxy-D-glucose uptake (measured as 
units of luminescence) of WT or Rptor KO OBs under either basal or insulin-stimulated 






The data presented in this study provide further mechanistic insight into how insulin 
signalling in the bone contributes to overall systemic glucose homeostasis. Under 
excessive nutrient conditions, suppression of skeletal mTORC1 signalling protects mice 
from developing diet-induced obesity and insulin resistance, which is associated with an 
enhancement in responsiveness to insulin and insulin-dependent glucose uptake in the 
OB of these mice.  
3.5.1 Increased OB insulin signalling  
Previous studies have shown that modulation of insulin signalling in OBs, by 
genetically decreasing or increasing the levels of insulin receptor expression, either 
worsens or enhances glucose tolerance and insulin resistance in HFD-fed animals, 
respectively
22
. Furthermore, mice with OB-specific deletion of FoxO1 (FoxO1
OB-/-
), a 
negative regulator of insulin signalling, are protected from HFD-induced obesity
66
. 
Consistent with these data, suppression of skeletal mTORC1 activity, a downstream 
mediator and negative regulator of insulin signalling, protects mice from diet-induced 
obesity. Of note, the lower fasting glucose levels, enhanced glucose tolerance and 
increased insulin sensitivity displayed by Rptorob
-/-
 mice mimics the metabolic 





. At the molecular level, enhanced insulin signalling, or markers for 
insulin sensitivity, in the peripheral insulin target tissues (muscle, WAT and liver) was 
not observed in the Rptorob
-/-
 mice. As a side note, the dosage of insulin used for this 
intracellular signalling analysis of Rptorob
-/-
 mice was found to be significantly higher 
that other studies (150mU/g body weight vs 0.5mU/g body weight in 
22
 or 0.05mU/g 
body weight
67
) which could potentially lead to saturation of the insulin signalling in 
peripheral tissues
68,69
. Despite this, insulin signalling was found to be significantly 
enhanced in the bone of Rptorob
-/-
 mice. This response is similar to previously published 
studies in Col1a1-INSR
Tg
 mice, which reported enhanced insulin signalling in the bone 
(and not other tissues) under both normal chow and HFD conditions. Moreover, insulin-
dependent activation of both INSR and AKT, in HFD-fed mice, was similar to normal 
chow-fed mice, suggesting insulin sensitivity is maintained in the bones of these mice 
under a HFD
22
. However, it is important to note that in this current study, the normal 
chow-fed (Chapter 2: 8-week old) and HFD-fed (16-week old) mice were not 
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age-matched, which prevents comparisons across diets with respect to insulin-
sensitivity.  
Mechanistically, the protective metabolic phenotype of Col1a1-INSR
Tg
 mice was 
attributed to an insulin-mediated increase in bone resorption, leading to an increase in 
OCN activity and its circulating levels (despite no difference in Ocn mRNA expression 
being observed)
22
. In contrast, both RNA-seq and qRT-PCR analysis of bone samples 
from Rptorob
-/-
 mice revealed a downregulation of genes involved in bone resorption and 
osteoclast differentiation pathways, and an upregulation of genes associated with bone 
formation and OB differentiation. Despite detection of significantly higher Ocn mRNA 
expression levels in male Rptorob
-/-
 mice, circulating levels of both total OCN and 
unOCN, for both male and female Rptorob
-/-
 mice, were equivalent to those of the 
controls. This finding is in contrast to the normal chow study described in Chapter 2, 
where serum OCN levels were significantly reduced in Rptorob
-/-
 mice. At this stage, the 
mechanisms underlying this disparity remain to be determined. OCN is expressed 
exclusively from mature OBs and low serum levels are used as a marker of reduced OB 
activity and bone mass
70
. Low serum OCN levels correlated with the low bone mass 




 whereas no difference in bone mineral 
content (BMC) was observed in HFD-fed Rptorob
-/-
 mice of either sex relative to 
controls. It is important to note that the interpretation of these findings is unclear given 
an inability to directly compare bone mass with age-matched normal chow-fed control 
and Rptorob
-/-
 mice, which would allow us to take into account the skeletal effects of a 
HFD. Previous studies have shown that HFD-fed WT mice have reduced total and 
unOCN levels
22
, suggesting that the apparent “normalisation” of OCN levels in HFD-
fed Rptorob
-/-
 mice may simply reflect this reduction. A full assessment of the skeletal 
phenotype of HFD-fed Rptorob
-/-
 mice, using high-resolution micro Computed 
Tomography, would provide valuable insight into this question.  
3.5.2 Osteoblast glucose uptake and utilisation  
Several lines of evidence point to the potentiation of insulin signalling as being an 
important mechanism in the metabolic phenotype of Rptorob
-/-
 mice. Firstly, using bones 
isolated from HFD-fed mice, RNAseq and GSEA identified an increase in genes 
encoding proteins involved in glycolysis and carbohydrate metabolism. This gene 
expression pattern was also observed in the long bones of normal chow-fed Rptorob
-/-
 
mice (Supplementary Fig. 2.5B) and Rptor KO calvarial cells in vitro. Secondly, basal 
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and insulin-stimulated levels of AKT and AS160 (AKT-dependent phosphorylation of 
AS160 at Thr
642
 is essential for GLUT4 translocation to the plasma membrane) were 
observed in calvarial cells of HFD-fed Rptorob
-/-





 was also observed in vitro in Rptor KO OBs, in both basal and 
insulin-stimulated states. Thirdly, glucose uptake was significantly increased in Rptor 
KO cells in vitro in both basal and insulin-stimulated states, suggesting that constitutive 
activation of AKT leads to an increase in glucose transport in the absence of mTORC1 
activity. Several studies have now recognised bone as a significant site of glucose 
uptake whereby at steady state, the skeleton accounts for almost 15% of glucose uptake 
from the circulation and the magnitude of glucose uptake by bone cells is sufficient to 
impact systemic glucose disposal in mice
61,63,72
. The higher basal phosphorylation levels 
of AKT and AS160 in vivo suggests that an increase in basal skeletal uptake of glucose 
could explain their low glycaemic phenotype. 
3.5.3 Whole-body metabolic flexibility  
In recent years, the effects of mTORC1 perturbation have been examined in a number 
of different metabolic tissues including WAT, skeletal muscle and liver, with each 
revealing a distinctive role for mTORC1 signalling in the tissue itself and in global 
metabolism as a whole. For example, hepatic knockdown of S6K1/2 in mice fed with 
HFD leads to improved systemic insulin sensitivity and glucose tolerance, and 
protection against hepatic steatosis
73
. In contrast, whilst deletion of raptor in WAT also 
protects against diet-induced obesity (via increased energy expenditure), these mice 
suffer from severe hepatic steatosis
74,75
. Similarly, inactivation of mTORC1 in the 
muscle causes resistance to HFD-induced metabolic dysfunction and improved glucose 
tolerance, but has no effect on insulin sensitivity
76
. Furthermore, systemic inhibition of 
mTORC1 signalling by deletion of S6K1
17
 or rapamycin administration
77
 results in 
mice that are resistant to weight gain due to elevated lipolysis and metabolic rate. 
Interestingly, despite the reported mechanistic differences in each of these models, one 
phenotype that is shared amongst these systemic and tissue-specific mTORC1 KO 
models is that they are resistant to HFD-induced weight gain. In this study, suppression 
of mTORC1 in OBs was also met with a resistance to HFD-induced weight gain, 
consistent with previous mTORC1 KO models.  
Based on the data generated herein, the mechanisms underlying the obesity-resistance 
phenotype of Rptorob
-/-
 mice likely include (i) their ability to switch substrate oxidation 
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during the light and dark period, and (ii) their ability to increase browning of iWAT via 
upregulation of Ucp1 expression. The mechanism(s) underlying the browning of iWAT 
in Rptorob
-/-
 mice remains unclear and appears to be independent of previously reported 
browning agents including FGF21 and irisin, as no changes in the expression levels of 





, respectively). It is interesting to note that upregulation 
of two bone-secreted factors, BMP7 and sclerostin
48,49
 was observed in Rptorob
-/-
 mice 
using RNA-seq. However, immunoblotting analysis of signalling pathways that are 
modulated in response to these factors (STAT1/3 for BMP7 and Wnt/β-catenin for 
sclerostin) in iWAT failed to detect any changes. With respect to sclerostin, the increase 
in Sost gene expression correlated with an increase in sclerostin protein levels in the 
long bones of Rptorob
-/-
 mice, suggesting that mTORC1 plays a role in the regulation of 
Sost. Indeed, a recent study has shown that mTORC1 negatively regulates SOST in 
osteocytes via activation of SIRT1, a negative regulator of Sost gene expression
78
 
linking mTORC1 function in OBs/osteocytes with maintaining systemic energy 
balance. 
While overfeeding promotes weight gain through fat storage shifting the 24-h RQ value 
above the FQ value (i.e. positive energy balance), underfeeding results in weight loss 
through lipid oxidation and a shift in 24-h RQ value below the FQ value (i.e. negative 
energy balance)
37
. In animals with balanced intake and expenditure, fat mass is constant 
and the 24-h RQ and FQ values are equal
79
. The energy intake in Rptorob
-/-
 mice, which 
accounts for their smaller body size, suggests that they are slightly hyperphagic. 
However, they appear to offset their energy intake and maintain constant body weight 
through greater substrate flexibility; their excess energy is efficiently stored during the 
dark period (RQ>FQ), and stored fat readily oxidized during the light period (RQ<FQ). 
Conversely, the 24-h RQ>FQ in Rptorob
+/-
 mice suggests that they are in positive energy 
balance and thus even with their greater substrate flexibility, overfeeding and energy 
storage during the dark cycle surpasses fat oxidation during the light cycle and thus 
results in continued weight gain. Even though the control animals appear to be in an 
energy balanced state, they have lost the ability to switch substrate between fat and 
carbohydrate oxidation. In other words, maximal HFD-induced fat oxidation during the 
light period (where animals are less active) is reduced and predictably, they continue to 
gain significant fat.  
109 
 
Of note, while metabolic flexibility is typically defined as an increase in RQ between 
fasting and postprandial states, the fact that Rptorob
-/-
 mice exhibit greater plasticity in 
switching between fatty acid and carbohydrate oxidation during light and dark periods 
under ad libitum feeding suggests that they are capable of maintaining metabolic 
flexibility. Consistent with this, clinical studies in humans have reported lower fat 
oxidation and higher RQ in the subjects with family history of diabetes
80
 and in 
particular, a lesser decrease in RQ during the sleeping period in these subjects
81
. 
Furthermore, impairment in metabolic flexibility has been associated with metabolic 
syndromes including obesity, insulin resistance and diabetes (reviewed in 
82
). These 
results, combined with the impaired glucose metabolism observed in the control mice, 
indicate a correlation between metabolic inflexibility and abnormality in glucose 
homeostasis. As such, the flexibility in substrate switching in Rptorob
-/-
 mice could 
produce the systemic metabolic protection phenotype observed in these mice. 
In summary, inactivation of bone-specific mTORC1 in mice protects against diet-
induced obesity and insulin resistance. These phenotypes are associated with locally 
enhanced responsiveness to insulin and skeletal insulin-dependent glucose uptake, and a 
systemic increase in substrate flexibility and browning of white fat. These studies 
highlight the beneficial systemic consequences of reducing mTORC1 function in OBs 
under nutrient excess revealing skeletal mTORC1 as a potential target for anti-obesity 
and diabetes drugs.  
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3.7 Supplementary data 
3.7.1 Supplementary Figures 
 
Supplementary Fig. 3.1 Alternative food quotient (theoretical FQ) calculation. 
Linear regression analysis of change in body mass during the 48-h measurement period 
(∆Mb: x-axis) and 24-hour RQ (y-axis) were used to estimate alternative FQ whereby 
the y-intercepts were the 24-h RQ when ∆Mb equalled zero or theoretical FQ in (A) 

























Supplementary Fig. 3.2 Daily food intake, physical activities and % of fecal lipid 
are normal in HFD-fed Rptorob
-/-
 mice. (A) Body length of 18-week old mice, as 
measured from nose to anus (n=4-5/genotype). (D) Body mass index (BMI) (n=4-
5/genotype). (B-D) DXA analysis of total lean mass and % lean mass in male and 
female HFD-fed mice (n=4-5/genotype). (E-F) Lean organ weights, normalised to total 
body weight, in 18-week-old HFD-fed male and female mice (n=4-9/genotype). (G) 
%lipid content of 1g faeces collected from male and female HFD-fed mice (n=9-
10/genotype). (E-F) Food intake normalised to lean mass (kcal/g lean mass), measured 
over a 48-h period (left) and per 12-h light/dark cycle (right) in HFD-fed male and 
female mice (n=5-7/genotype). (H-I) Total activity (distance of movement) measured 
over a 48-h period (left) and per 12-h light/dark cycle (right) in HFD-fed male and 
female mice (n=5-7/genotype). All panels: data are expressed as mean ± SEM. *p<0.05, 















Supplementary Fig. 3.3 Serum ketone bodies, hepatic gene expression and UCP1 
gene expression and UCP1 protein levels in other fat depots of HFD-fed Rptorob
-/-
 
mice. (A) Serum ketone bodies levels in HFD-fed mice at 18 weeks of age (n=5-
10/genotype). (B-C) Gene expression levels of ketogenesis, fatty acid oxidation, 
gluconeogenesis and glycolysis genes in HFD-fed male (B) and female (C) liver tissue 
samples, normalised to β-actin (n=3-5/genotype). (D-E) Gene expression levels of 
brown adipose tissue markers in HFD-fed male gWAT and interscapular BAT (iBAT) 
samples, normalised to β-actin (n=3-5/genotype). (F) Levels of UCP1 protein 
expression in HFD-fed male gWAT (top) and quantitative analysis of protein levels 
relative to β-actin (bottom) (n=4/genotype). (G) Representative images of H&E of 
iBAT from male mice, scale bar = 100µm. (H) Levels of UCP1 protein expression in 
HFD-fed male gWAT (top) and quantitative analysis of protein levels relative to β-actin 
(bottom) (n=4/genotype). All panels except G: data are expressed as mean ± SEM. 












Supplementary Fig. 3.4 Adipocyte hypotrophy and browning of iWAT are also 
observed in HFD-fed female Rptorob
-/-
 mice. 
(A) Representative images of H&E section of gWAT and iWAT from HFD-fed female 
mice. Boxes in middle panels indicate the area depicted in the corresponding bottom 
panels. Scale bars: top and bottom panels = 50µm; middle panels = 100µm. (B-C) Size 
distribution of gWAT (B) and iWAT (C) adipocytes from HFD-fed female mice was 
calculated using H&E stained sections using Image J (n=5 sections/mouse, n=5-
6/genotype). (D-E) Gene expression levels of adipogenesis and de novo lipogenesis 
markers in HFD-fed male gWAT and iWAT tissues, normalised to β-actin (n=3-
5/genotype). (F) Brown adipose tissue markers gene expression in iWAT (n=3-
5/genotype). (G) Levels of UCP1 protein in iWAT and quantitative analysis assessed by 
Western blot analysis female mice (n=3-5/genotype). All panels except A: data are 
expressed as mean ± SEM. *p<0.05, **p<0.01, ***p<0.001, one-way ANOVA with 







Supplementary Fig. 3.5 Down regulation of pathways involved in B-cell 
developments in Rptorob
-/-
 mice. Gene set enrichment analysis (GSEA) of negatively 
enriched pathways (down-regulated) of RNA isolated from combined flushed femur and 
tibia (n=5; only controls and Rptorob
-/-
). Blue bar indicates pathways relating to B-cell 
development and/or interleukin 7 signalling and black bar indicates pathways relating to 
bone development. Grey bar (ns) = not significant.  
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Supplementary Table 3.2 Antibodies used for immunoblotting 
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4.1 General Discussion  
Diabetes is a chronic disease that occurs when the pancreas cannot produce sufficient 
insulin or when the body cannot respond to insulin effectively. Type 2 diabetes (T2DM) 
is by far the most prevalent form of diabetes and arises from genetic and environmental 
factors such as obesity and physical inactivity. Over the past three decades, the number 
of people with T2DM has doubled globally, making it one of the most important public 
health challenges currently facing healthcare systems
1
. Loss of postprandial glycaemic 
control, followed by fasting hyperglycaemia, is the hallmark of T2DM
2
. Thus, much 
attention has been directed towards gaining an understanding of the underlying 
mechanisms responsible for T2DM and identifying how insulin-responsive tissues 
interact to control glucose homeostasis. 
Under normal physiological conditions, insulin regulates glucose utilisation by binding 
to the insulin receptor (INSR). The INSR is expressed by several tissues, including the 
heart, liver, skeletal muscle and adipose tissue; INSR activation in these tissues leads to 
an increase in glucose uptake or conversion of glucose to glycogen in the liver. Under 
obesogenic conditions, excessive caloric intake increases serum glucose levels, which 
leads to an increase in insulin production from the pancreas, and chronic exposure of 
insulin-responsive tissues to insulin results in them becoming insulin resistant
3
.  
More-recent studies have shown, somewhat surprisingly, that the skeleton also plays a 
central role in regulating glucose levels in the body. Specifically, studies have identified 
the OB- -cell 
proliferation and insulin secretion and promotes insulin sensitivity in peripheral tissues 
such as muscle, liver and adipose tissues
4,5
. Notably, deletion of the INSR in skeletal 
OBs results in elevated blood glucose and reduced serum insulin levels in normal-chow 
fed mice
6
 while overexpression or downregulation of INSR in OBs results in profound 
changes in systemic glucose metabolism in response to an obesogenic diet
7
. These 
results suggest that dysregulated insulin signalling in bone could play an important role 
in the development of systemic insulin resistance and that restoration of insulin 
signalling in the bone alone could potentially protect against the negative systemic 
metabolic effects arising from an obesogenic diet. 
Mechanistically, binding of insulin to its receptor activates the PI3K pathway. This  
eventually leads to activation of mTORC1 pathways, which results in cell growth and 
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proliferation by promoting protein synthesis, lipid biogenesis and metabolism
8
. 
Additionally, mTORC1 directly, and indirectly via activation of S6K1, negatively 
regulates insulin signalling by disrupting the interaction between INSR and its adaptor 
protein, IRS1. In response to excessive nutrients, mTORC1 becomes hyper-activated 
and turns off insulin signalling inappropriately, rendering cells unresponsive to insulin. 
Based on several lines of evidence, it was hypothesised that mTORC1 function in OBs 
plays an important role in skeletal regulation of systemic glucose homeostasis and that 
inhibition of OB-mTORC1 could protect against the development of systemic HFD-
induced insulin resistance. To investigate this hypothesis, a loss-of-function mouse 
model was generated in which Rptor, which encodes RAPTOR, a defining and essential 
component of mTORC1, was specifically deleted in pre-OBs (Rptorob
-/-
). Using an array 
of metabolic tests, and detailed assessment of insulin and mTORC1 signalling pathways 
in insulin-target tissues, the studies outlined in this thesis have characterised the 
metabolic consequences of OB-mTORC1 impairment in mice fed either normal chow or 
obesogenic HFD. 
In Chapter 2, OB-specific deletion of Rptor was shown to have a profound effect on 
body composition, whole-body glucose metabolism, and the male reproductive system 
in mice fed a normal diet. While both sexes of Rptorob
-/-
 mice were markedly lean and 
showed a preference for fat utilisation and elevated ketone body levels, sex-dependent 
differences in body composition and energy metabolism were observed. Specifically, a 
significant decrease in fat mass and white adipocyte size and a significant increase in 
glucose tolerance were observed in male, but not female, Rptorob
-/- 
mice compared to 
controls. Notwithstanding these differences, both male and female Rptorob
-/- 
mice 
exhibited higher sensitivity to insulin and lower levels of fasting glucose and insulin. 
Inactivation of OB-specific nutrient sensing mTORC1 results in DR-like phenotypes 
Interestingly, while the low glucose levels and increased insulin sensitivity in Rptorob
-/-
 
mice could not be explained by increased levels of OCN, nor increased insulin 
production, they were associated with a dramatic elevation in circulating adiponectin 
levels. Notably, data presented in this thesis suggest that the increased adiponectin 
levels in Rptorob
-/-
 mice arises from the newly-characterised bone marrow adipocytes 
(BMAds, which are dramatically increased in these mice
9
) rather than the classical 
WAT depots. Although the physiological role of BMAT remains largely unknown, its 
expansion has been reported in response to changes in nutrient availability including 
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starvation (reviewed in 
10
),  under dietary restriction (DR) in mice
11





 and leptin deficiency
14
. Furthermore, a growing 
body of literature suggests that BMAT expansion under restricted dietary conditions 
increases production of adiponectin to promote systemic improvements in glucose 
metabolism
12,15,16
. In this regard, the expansion of BMAT, the elevation of BMAT-
derived adiponectin production, and hypoleptinemia observed in Rptorob
-/-
 mice, suggest 
that suppression of mTORC1 in OBs could lead to DR-induced BMAT expansion and 
subsequent systemic adaptation to DR via increased secretion of BMAT-derived 
adiponectin.   
DR has been shown to extend lifespan in a wide spectrum of organisms spanning from 
yeast to vertebrates
17
. Moreover, it has been shown to reduce or delay the development 
of age-related diseases such as cardiovascular disease, cancer, metabolic diseases and 
muscle atrophy
18,19,20
. During DR, low nutrient and high AMP/ATP ratios activate 
AMP-activated protein kinase (AMPK), which inhibits mTORC1 by stimulating 
TSC2
21
, a negative regulator of mTORC1, and/or by phosphorylating RAPTOR
22
. 
Consistent with this view, pharmaceutical inhibition of TOR signalling (via rapamycin 
treatment) extends lifespan
23,24,25
 and genetic ablation of S6K1 in mice (S6K1
-/-
) leads 
to a gene expression profile similar to that of DR mice. Of note, female S6K1
-/-
 are 
long-lived and have reduced incidence of age-related diseases
26
. In this context, it is 
interesting to note that the Rptorob
-/-
 mice share a number of metabolic phenotypes with 
DR mice (i.e. low basal glucose levels, low insulin levels, high adiponectin levels, low 
leptin levels, increased insulin sensitivity and BMAT expansion), which suggests that 
suppression of mTORC1 activity in the skeleton could play an important role in the 
physiological response to DR.  
Roles of OCN beyond regulation of glucose metabolism and sex dimorphism 
In keeping with this, low circulating leptin and testosterone levels observed in Rptorob
-/- 
mice could be part of their metabolic adaptation in response to DR. Under DR 
conditions, leptin can exert a strong effect on the reproductive axis
27
. Low leptin 
directly reduces gonadotropin-releasing hormone (GnRH) secretion from the 
hypothalamus, which itself reduces secretion of luteinizing hormone (LH) from the 
pituitary and a subsequent decreased release of gonadal sex steroid hormones (GH: 
testosterone and estradiol)
28,29
. Thus, the impaired reproductive function of male 
Rptorob
-/-
 mice could be due to the combined effects of low leptin and OCN levels. 
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Given that the effect of OCN on reproductive function is limited to male mice (the 
putative OCN receptor, GRPC6A, is only expressed in testicular Leydig cells and not in 
the ovary
30
) while DR affects reproductive function in both genders, further 
investigation of female reproductive function is required to determine if altered 
reproductive function in Rptorob
-/-
 mice is the consequence of an mTORC1-mediated 
response to DR. 
OCN has also shown to regulate brain development and function, whereby Ocn
-/-
 mice 
were found to be more passive and suffer from increased anxiety and decreased memory 
compared to their control littermates
31
. While both male and female Rptorob
-/-
 mice 
exhibit low circulating OCN levels, only female Rptorob
-/-
 mice were more passive than 
the controls. It is noteworthy that given ad libitum access to food, the food intake (either 
with or without normalisation) is still reduced in female Rptorob
-/-
 mice, suggesting a 
“self-imposed” DR or possibly equivalent to ‘anorexic’ phenotype in these mice. 
Depression and anxiety are the common comorbidities of anorexia
32
 and drastic change 
in feeding and activity behaviours are the early signs of depression-like phenotypes in 
mice
33
. It would be interesting to investigate further if female Rptorob
-/-
 mice display 
other anorexic and/or depression-like behaviours or their passivity is a secondary effect 
of low circulating OCN levels.   
In light of the advantageous metabolic phenotypes of Rptorob
-/-
 mice, including 
improved glucose disposal and insulin sensitivity under normal chow diet feeding (as 
outlined in Chapter 2) and previous data demonstrating that nutrient-overload leads to 
hyper-activation of mTORC1 signalling and the development of insulin resistance
34
, 
this led to the investigation of metabolic responses of Rptorob
-/-
 mice to an obesogenic 
HFD diet (which is well-established to induce insulin resistance in mice) as detailed in 
Chapter 3. Consistent with other studies
35,36,37
, HFD-feeding resulted in significant 
weight gain in the control mice, with more pronounced weight gain observed in males. 
Notably, both male and female Rptorob
-/-
 mice were resistant to HFD-induced weight 
gain and maintained a constant body weight after 6 weeks of HFD, despite consuming 
similar amounts of food to the controls. Body composition analyses confirmed a 
significant reduction in %fat mass and adipocyte hypertrophy in both gonadal and 
inguinal WAT depots. Remarkably, Rptorob
-/-
 mice were able to maintain the favourable 
metabolic phenotypes observed with chow diet feeding (Chapter 2) and were thus 
protected against the negative effects of HFD-feeding on glycaemia (e.g. lower fasting 
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glucose and insulin levels, increased glucose tolerance and enhanced insulin 
sensitivity).  
It is important to note that, while the severe hypoglycaemia observed in the female 
Rptorob
-/-
 mice during the ITTs suggests that they are hypersensitive to exogenous 
insulin administration, it is also possible that they have difficulty in recovering from 
insulin-induced hypoglycaemia. This could arise from a defect in the counter-regulatory 
responses which, in mice, are activated when blood glucose levels fall below ∼80 
mg/dL (~4.4mM)
38
. Further assessment of these glucose counter-regulatory mechanisms 
by hypoglycaemic clamp studies and measurement of hormones such as glucagon, 
corticosterone and epinephrine in these mice could provide further clarification
39,40
.  
Metabolic phenotypes independent of OCN 
Notably, protection from HFD-induced glucose intolerance and insulin resistance has 
been observed in other mouse models in which an increase in OB insulin signalling is 





, a negative regulator of insulin signalling, and mice in which there is an 




. These phenotypes are 
consistent with the data for Rptorob
-/-
 mice reported in Chapter 3. The protected 




 mice were, however, attributed to an 
insulin-mediated increase in bone resorption leading to an increase in OCN activity and 
serum levels (although no difference in Bglap2 mRNA expression was observed)
7
. In 
contrast, both RNA-seq and qRT-PCR analysis of bone samples from HFD-fed Rptorob
-
/-
 mice revealed a downregulation of genes involved in bone resorption and osteoclast 
differentiation pathways, and upregulation of genes associated with  bone formation and 
OB differentiation. Intriguingly, despite detection of significantly higher Ocn mRNA 
expression levels in male HFD-fed Rptorob
-/-
 mice, circulating levels of both total and 
unOCN protein were equivalent to those of the controls. Furthermore, the significantly 
lower levels of total and undercarboxylated forms of OCN have been observed in the 
normal-chow-diet-fed Rptorob
-/-
 mice compared to the control mice, despite their 
improved metabolic phenotype. Of note, the normal chow studies (8-week old mice: 
Chapter 2) and HFD studies (16-week old mice: Chapter 3) were performed at different 
ages, which precludes any direct inter-diet comparison. It is possible that the 






 mice is 





, whereas in Rptorob
-/-
 mice, OCN levels were already-low and their HFD-
resistant phenotype prevented any further fall in the OCN levels. Another possibility is 
that OB-mTORC1 is a negative regulator of Bglap2 (which encodes OCN) gene 
expression and possibly required for Bglap2 translation.  
Notwithstanding this, an important finding of this present study is the observation that 
the beneficial metabolic effects associated with OB-mTORC1 inhibition occur 
independently of OCN. Several studies have implicated OCN-independent mechanisms 
in the bone-metabolism interplay. For example, genetic ablation of OBs, or conditional 
OB-specific inactivation of glycogen synthase kinase (GSK)–3β, β-catenin or Vhl, a 
regulator of Hypoxia-inducible factors (HIFs), leads to systemic metabolic alterations 
that cannot be fully rescued or explained by congruent changes in serum OCN
43,44,45,46
. 
These studies suggest the existence of additional, as yet unidentified, bone 
secretagogues, amongst other factors, that influence global glucose homeostasis and 
energy metabolism. 
Potential molecular mechanism underlying suppression of OB-mTORC1 
Both in vitro and in vivo data suggest that suppression of OB-mTORC1 activity results 
in relaxation of mTORC1-dependent negative feedback controls, which leads to 
potentiation of insulin signalling in OBs. These are evident by (i) in vivo insulin-
stimulated phosphorylation levels of INSR, AKT and subsequent phosphorylation of its 
substrate, AS160 at Thr
642
 and GSK3β at Ser
9
, are significantly higher in calvarial cells 
of HFD-fed Rptorob
-/-
 mice compared to the controls; (ii) at the basal levels, 




and its two substrates is observed in 
calvarial cells of HFD-fed Rptorob
-/-
 mice, but not in the controls; and (iii) hyper-




 is observed in vitro in Rptor KO OBs, in 
both basal and insulin-stimulated states. AKT-mediated phosphorylation of AS160 at 
Thr
642
 has been reported to attenuate its inhibitory effects (i.e. AKT-mediated phospho-
AS160 inhibits its GAP (GTPase-activating protein) activity leading to elevation of the 
‘active’ GTP-bound form of RAB required for GLUT4 translocation: Fig. 4.1) on RAB, 
leading to GLUT4 membrane translocation and thus cellular glucose uptake
47,48
. The 
hyperphosphorylation of AKT observed both in vivo and in vitro, hyperphosphorylation 
of AS160 observed in vivo, and significantly increased glucose uptake in Rptor KO cell 
in vitro in both basal and insulin-stimulated states point to the mechanism in which 
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enhanced and prolonged insulin signalling leads to an increase in glucose transport in 







Figure 4.1 Schematic summary. 
Suppression of mTORC1 activity in pre-OBs results in relaxation of mTORC1-
dependent negative feedback controls (both directly and indirectly via activation of 
p70S6K) on insulin signalling by disrupting the interaction between IRS1 and INSR. 
This leads to enhanced and prolonged insulin signalling as indicated by hyperactivation 




 in both basal and insulin-stimulated states. AKT 
hyperactivation attenuates the inhibitory effects of AS160 on RAB, leading to GLUT4 
membrane translocation. These molecular changes are associated with increased cellular 
glucose uptake in Rptor-deficient OBs and upregulation of the insulin-dependent 
glucose transporter 4 (Glut4) and glycolysis-promoting enzymes in the skeleton of 
Rptorob
-/-
 mice. Systemically, Rptorob
-/-
 mice show persistently low fasting glucose 
levels and significantly increased tolerance to glucose; metabolic phenotypes that are, at 
least in part, attributable to an enhanced responsiveness to insulin and insulin-dependent 
glucose uptake in OBs.  
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Skeletal glucose uptake and utilisation as determinants of whole-body glucose 
metabolism  
Glucose is a primary source of energy for osteogenic cells, with osteogenic cells being 
highly glycolytic in both aerobic and anaerobic environments
49,50
. OB cells express 
three high-affinity glucose transporters: Glut1, Glut3, and Glut4
51,52,53
, which are 
expressed at different stages of OB differentiation. GLUT4 mediates insulin-dependent 
glucose uptake in mature osteoblasts and its expression rises in parallel with the 
increased insulin-stimulated glucose oxidation
54
. Glut4 ablation in OBs in vitro 
abolishes insulin-stimulated glucose uptake, while mice with OB-specific Glut4 
deletion (ΔGlut4) are insulin-resistant with no delectable skeletal changes as measured 
using high resolution micro-computed tomography (microCT)
54
.  
GLUT1, on the other hand, is a major glucose transporter in primary OBs. It mediates 
glucose uptake in an insulin-independent manner and favours OB differentiation and 
bone formation by suppressing AMPK-dependent proteasomal degradation of 
RUNX2
55
. Importantly, accumulation of RUNX2 leads to transcriptional activation of 
Glut1, thereby forming a feed-forward regulation between GLUT1-mediated glucose 
uptake and RUNX2-coordinated OB differentiation and bone formation
55
.  
Expression of Glut1 is also regulated by other transcription factors e.g. hypoxia-




 and un-controlled 
KRAS
59
 in cancer cells. In this context, the bone is a particularly hypoxic tissue with 
pressure of oxygen levels below 1% in hypoxic regions and up to 6% in sinusoidal 
cavities
60
. Consequently, HIF-1α has been shown to play a crucial role in the promotion 
of angiogenesis and coupling between osteogenic and angiogenic processes (reviewed 
in 
61,62
). Under normoxic condition, HIF prolyl hydroxylases hydroxylate specific 
residues in the HIF-α protein, rendering it a substrate for the E3 ubiquitin ligase von 
Hippel–Lindau (VHL) and thus a target for proteasomal degradation
63
. Conversely, 
under hypoxic condition, HIF-1α serves as a molecular switch diverting energy 
production from oxidative to glycolytic metabolism by up-regulating HIF target genes 
such as Vegf, Glut1 and Epo.  
In regard to mTORC1, activation of HIF upregulates REDD1 (also known as 
DDIT4/RTP801/Dig1), which induces mTORC1 inhibition via activation of the TSC1/2 
complex
64,65
. Consistent with this, stabilisation of HIF via deletion of Vhl in OBs (Vhl 
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cKO) results in mice with low glycaemia and increased glucose tolerance and high bone 
mass; this metabolic phenotype resembles Rptorob
-/-
 mice while the bone phenotypes 
that are similar to mice overexpressing GLUT1 in OBs
46,55
. Furthermore, both Vhl cKO 
mice and mice harbouring Vhl-deficient OBs display an approximately 20% and 40% 
increase in glucose uptake, respectively, and a significant upregulation of glycolysis 
genes compared to the controls. Of note, basal glucose uptake is increased both in vivo 
and in vitro in these Vhl-deficient OBs. This increased basal glucose uptake was also 
associated with elevated expression of Glut1 and increase extracellular acidification 
rates (ECARs: reflect lactic acid production and thus glycolysis) while basal oxygen 
consumption rates (OCRs: generation of ATP by mitochondrial therefore oxidative 
phosphorylation) were decreased. These findings suggest increased glycolysis but not 
glucose oxidation; a phenomenon akin to the Warburg effect
46,66
. Furthermore, 
expression levels of RUNX2 in the Vhl cKO mice were 3-fold higher than in the control 
mice, suggesting that the mechanism underlying their high bone mass may be due to the 
feed-forward relationship of Glut1-Runx2 as previously described by Wei et al
55
.  
Consistent with the similarities in their metabolic phenotypes in vivo, Rptor-null OBs 
also exhibited an increase in basal glucose uptake and an upregulation of glycolytic 
genes (as indicated by RNA-seq and GSEA and confirmed with qRT-PCR), with a 
moderate increase in Glut1 expression. On the other hand, the increased basal and 
insulin-stimulated glucose uptake in the Rptor KO OBs was associated with a 
significant upregulation of Glut4 mRNA and the metabolic phenotype of Rptorob
-/-
 mice 
was indeed the opposite to that observed in the ΔGlut4 mice. Furthermore, the 
upregulation of Glut4 is also observed in vivo in the bones of Rptorob
-/-
 mice irrespective 
of diet feeding, suggesting that glucose uptake could be increased in the OBs of Rptorob
-
/-
 mice and this increase in glucose uptake is, at least in part, attributable to their 
enhanced systemic glucose tolerance. 
OBs Bioenergetics and whole-body energy metabolism 
While the bioenergetics of the Rptor-null OBs would require further investigation, 
GSEA showed an upregulation of other intermediary metabolic pathways in addition to 
glycolysis, including conversion of pyruvate from acetyl-coA, tricarboxylic acid (TCA), 
oxidative phosphorylation and respiratory electron transport chain, which argues against 
the Warburg effect in these cells.  
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Apart from glucose, fatty acids and amino acids represent the additional fuel substrates 
that can be processed and oxidised through the TCA cycle. In this regard, GSEA has 
identified upregulation of gene sets involved in fatty acid oxidation and transportation, 
cellular amino acid transport and cellular amino acid catabolism. In the bone, amino 
acids not only provide energy but also serve as substrates for synthesis of collagen and 
other matrix proteins (reviewed in 
67
). Mechanistically, phosphorylation of ATF4 by 
RSK2, a kinase inactivated in Coffin-Lowry Syndrome, promotes its transcriptional 
activity, leading to synthesis of type 1 collagen by favouring amino acid import
68
. 
Moreover, a high protein diet could rescue the skeletal defects in the Coffin-Lowry mice 
lacking RSK2, which are characterised by decreased ATF function
69
. A growing 
number of studies have identified fatty acids as being important fuel substrates for OBs. 
For example, deletion of a fatty acid transporter, CD36, or CPT2, an obligate enzyme 
for fatty acid oxidation, in OBs results in mice with low bone mass and reduced OBs 
number and activity
70,71
. Furthermore, mice with OB-specific deletion of Lrp5, a Wnt 
co-receptor, exhibited a reduction in bone mass while peripheral fat mass and serum TG 
and FFA were significantly increased when fed a normal chow diet
72,73
. Collectively, 
these studies highlight a significant contribution of the skeleton, and in particular the 
choice of fuel substrate by OBs, in the regulation of whole-body energy metabolism. 
Inhibition of mTORC1 as a novel therapeutic approach to treat T2DM 
The studies presented in this thesis are the first to characterise the effects of skeletal 
mTORC1 inactivation on the whole-body energy and glucose metabolism. Since the 
consequences of mTORC1 perturbation have also been described in other metabolic 
tissues such as muscle, adipose or liver, it is evident that mTORC1 has tissue-specific 
effects on whole-body metabolism. For example, inactivation of Rptor in skeletal 
muscle (RAmKO mice) results in resistance to weight-gain and enhanced tolerance to 
glucose compared to controls, but no improvement in insulin sensitivity
74
. These 
phenotypes are associated with increased muscle glycogen levels due to AKT-mediated 
activation of glycogen synthesis and a down-regulation of genes involved in glucose 
transport and glycolysis
74,75
. Conversely, liver-specific Rptor ablation (Raptor
Δhep
 mice) 
results in severe liver damage with augmented inflammation and fibrosis, with 
improved glucose tolerance observed in low fat–fed Raptor
Δhep





. In the context of adipose tissue, mice lacking adipose Rptor using 
Ap2-Cre (raptor
ad−/−
) were found to be lean and resistant to HFD-induced metabolic 
dysfunction, due to the abolition of HFD-induced hyperphosphorylation of S6K1 and 
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restoration of AKT activation in response to insulin
77
. However, recent data has 
indicated that the Ap2-Cre line has a mosaic expression of Cre in adipose tissue and is 
not specific to adipocytes, with extra-adipose Cre activity observed in other cell types 
including endothelial cells in the heart and skeletal muscle
78,79,80
. A more-specific and 
efficient Adiponectin-Cre, which targets mature adipocytes, found that loss of Rptor in 
adipose tissue leads to lipodystrophy and insulin resistance, and a significant increase in 
liver mass and ectopic lipid accumulation
81
.  
These tissue-specific functions and responses to mTORC1 inhibition are further 
highlighted in studies where administration of rapamycin has been shown to have both 
beneficial and detrimental effects on metabolism. For example, in vitro acute rapamycin 
treatment improves muscle insulin sensitivity
82
 while 16-week treatment with 
rapamycin protects against HFD-induced obesity in C57BL/6J mice
83
. Conversely, 
rapamycin has been shown to impair glucose tolerance and insulin sensitivity in both 
inbred and genetically heterogeneous mice
84
, to exacerbate glucose intolerance in HFD-
fed KK/HIJ mice
85
, decrease hepatic insulin sensitivity
86
 and promote insulin resistance 
and hyperlipidemia in rats
87
. These contradictory effects of rapamycin could possibly be 
explained by the duration of the treatment, the off-target inhibition of closely-related 
mTORC2
86,88
, or the tissue-specific responses to rapamycin
89
. Together, this suggests 
that sustained systemic suppression of mTORC1 function has significant limitations. As 
previously discussed, even though ablation of Rptor in these insulin-targeted tissues 
protects these mice from diet-induced obesity, they suffer from other adverse effects 
(i.e. liver damage, increase hepatic steatosis or insulin resistance). Conversely, deletion 
of Rptor in OBs results in enhanced glucose tolerance and increased insulin sensitivity 
irrespective of diet (phenotypes of Rptorob
-/-
 mice are summarised in Table 4.1).  
The unique phenotypes of Rptorob
-/-
 mice have revealed OB-mTORC1 as a target for the 
development of antidiabetic drugs, whereby localised inhibition of skeletal mTORC1 
could have favourable metabolic outcomes in patients with T2DM. However, it is 
important to note that Rptorob
-/-
 mice are a developmental model were the Osx-Cre 
driver is expressed from E14.5
90
.  Further investigations, in a more clinically relevant 
setting (i.e. inhibition of OB-mTORC1 postnatally or pharmaceutically using a bone-
specific mTORC1 inhibitor), are therefore required to confirm the therapeutic potential 
of the current findings. There are several ways that this could be achieved. Firstly, the 
tetracycline-repressible nature of the tTA:Osx:Cre driver in these mice
90
 could be 
exploited by administering tetracycline to dams to suppress Cre expression during 
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development (via  chow and drinking water)
91
. Once the doxycycline is removed, Osx-
1- driven Cre expression will resume and temporal and spatial deletion of Rptor will 
occur in OBs (as the Osx-1 promoter is active throughout post-natal skeletal 
development in mice)
92
. Following postnatal OB-specific deletion of Rptor, animals 
could then be challenged with an obesogenic HFD to assess whether they are protected 
against developing T2DM.  
A pharmaceutical approach, using a bone-specific mTORC1-specific inhibitor, could 
also be developed. NR1, is a newly-identified small molecule that binds to the switch II 
domain of the small G-protein, RHEB and potently inhibits mTORC1 activity without 
affecting mTORC2
93
. Localised drug delivery to bone is readily attainable using a bone-
targeting bisphosphonate
94
 (alendronate, ALN), which binds avidly to hydroxyapatite 
and has been used very successfully as a vehicle to deliver agents to bone
95
. Therefore, 
conjugation of an mTORC1 inhibitor such as NR1 with the ALN could represent a 
novel therapeutic approach to treat T2DM. 
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Table 4.1 Summary of normal chow and high fat diet-fed male and female Rptorob
-/-
 





4.2 Future directions 
The studies outlined in this thesis have identified an important role for the mTORC1 
pathway in the skeletal regulation of glucose metabolism, and provide strong evidence 
to support the concept that dysregulated insulin signalling and changes in glucose 
uptake in OBs have systemic effects on gluco-regulation and energy homeostasis. In 
particular, as described in Chapter 3, the bone-specific inactivation of mTORC1 
protected the mice against diet-induced insulin resistance which, at least in part, may be 
attributable to changes in skeletal glucose uptake. As outlined below, these findings 
have generated several new avenues of research that remain to be fully interrogated in 
order to fully understand this complex metabolic phenotype.  
Is the improvement in glucose disposal and insulin sensitivity in Rptorob
-/-
 mice due to 
elevated adiponectin levels? 
Both chow-fed and HFD-fed Rptorob
-/-
 mice have significantly higher serum levels of 
adiponectin, which may account for their increased insulin sensitivity. In particular, 
levels of the most bio-active HMW form of adiponectin are significantly higher in these 
mice and BMAT appears to be the major source of adiponectin in these mice. Genetic 
manipulation in mice has been extensively used to interrogate molecular mechanisms 
and cellular pathways in the biomedical research. For example, compound mice with 
heterozygous deletions of Ocn and Adipoq were used to provide the genetic evidence 
that OCN regulates insulin sensitivity, partially, via adiponectin
4
. To determine whether 
adiponectin is responsible for insulin-sensitizing effects of Raptor deletion in OBs, 












  and control mice. This will provide the genetic evidence to 
determine if the increased insulin sensitivity in the Rptorob
-/-
 mice occurs, at least in 
part, through adiponectin.  
Does the phenotype observed in Rptorob
-/-
 mice mimic a DR-type response and is OB-
mTORC1-inhibition a DR mimetic? 
The phenotypes observed in Rptorob
-/-
 mice are similar to physiological changes 
associated with DR (e.g. change in body composition resulting in total body weight and 
fat mass reduction but paradoxically elevated BMAT and circulating adiponectin levels, 
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reduced leptin levels and improved glucose metabolism). Furthermore, the reproductive 
phenotypes observed in the male Rptorob
-/-
 mice (e.g. low circulating testosterone levels 
and lower sperm counts) are similar to those observed in mice subject to DR
28
 
suggesting that impaired mTORC1 function in bone mimics a dietary restriction 
phenotype. DR has been shown to disturb the hypothalamic-pituitary-gonadal axis in 
which disturbed GnRH, a high ratio of FSH/LH and low growth hormone are observed. 
Furthermore, female rats subjected to DR exhibit decreased reproductive organ weight, 
abnormal reproductive cycle and aberrant hormonal levels
96
. To characterise the ‘DR-
like’ phenotypes of Rptorob
-/-
 mice, pair-feeding and dietary-restricted control animals 
coupled with their body composition and metabolic analyses could be performed. 
Moreover, determinants of female reproductive functions (hormone measurements, 
reproductive organ weights, ovarian morphology and follicle classification, and gene 
expression analysis for genes related to ovarian follicle growth and degradation (i.e. 
Sfrp4, Sgk, Lhcgr, and Cyp11a1) might offer further support the hypothesis that 
mTORC1 in OBs plays an important role in the DR response. 




As discussed in Chapter 3, the mechanism(s) underlying the browning of iWAT in 
Rptorob
-/-









. These findings suggest the 
existence of other mechanisms or unknown factors which could serve as browning 
inducers.   
- Lactate as by-product of increased skeletal glycolysis? 
Previous studies by Carriere et al. have shown that lactate, an important intermediary 
metabolite, strongly induces thermogenic gene expression in mouse and human WAT 
cells via intracellular redox modifications. Furthermore, β-hydroxybutyrate, a primary 
ketone body that has a similar impact on redox state, is also capable of inducing the 
browning of mouse primary white adipocytes
101
. Serum β-hydroxybutyrate levels are 
higher in the Rptorob
-/-
 mice irrespective of diet. From this, it is speculated that an 
increase in glycolysis in the Rptorob
-/-
 mice, with a concomitant upregulation of lactate 
dehydrogenase (which catalyses the inter-conversion of pyruvate and lactate, the last 
step of anaerobic glycolysis) could lead to a higher output of lactate from the bone into 
the circulation. In support of this, in vitro studies have shown that bone consumes a 
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large amount of glucose, and that >80% of the glucose consumed is converted to 
lactate
49,102
. Measurement of circulating lactate levels in Rptorob
-/-
 mice and ECARs of 
Rptor KO OBs could be used to examine this further. 
- Are there any other novel ‘osteokines’? 
It is also interesting to note that the upregulation of UCP1 in Rptorob
-/-
 mice appears to 
be depot-specific, with marked induction observed only in the iWAT, while 
upregulation of Ucp1 mRNA, but not at the protein levels, was observed in the gWAT. 
Furthermore, even though proximal tibial regions (which are juxtaposed to trabecular 
bone) of BMAT have been reported to express markers of brown fat
103,104
, undetectable 
levels of Ucp1 were observed in the bone of Rptorob
-/-
 mice. Collectively, these results 
suggest that the mechanism(s) underlying this increased browning of white fat in 
Rptorob
-/-
 mice is likely to occur in an endocrine, not paracrine, manner. Further studies 
integrating RNAseq data to identify translated genes that encode secreted proteins and 
non-targeted metabolomic profiling of serum
105
, involving the use of nuclear magnetic 
resonance mass spectrometry or complementary technologies, would be helpful to 
identify novel factor(s) underlying the metabolic phenotypes of Rptorob
-/-
 mice. 
Does potentiated insulin signalling in the bone of Rptorob
-/-
 mice protect them from 
deterioration in bone quality that would otherwise occur under HFD feeding? 
Several lines of evidence demonstrate that increased marrow adiposity is associated 
with lower BMD and increased skeletal fragility
106
 in HFD-fed rodents
13
 and obese or 
diabetic human patients
107,108
. Importantly,  a decrease in number and differentiation of 
OBs and diminished quantities of osteoid lead to a poorly organised bone structure and 
decreased bone quality and increased fracture risk – a phenotype often observed in 
T2DM patients
109,110,111
. It is interesting to note that mice with OB-specific deletion of 
TSC2 (and hence hyperactivation of mTORC1) have high bone mass that is associated 
with the accumulation of poorly differentiated OBs that are insulin-resistant
112
. This 
phenotype is completely opposite to that of Rptorob
-/-
 mice which, on normal chow, are 
osteopenic
9
 and insulin-sensitive as shown in this study. Collectively, these results 
suggest that excess caloric intake, as often occur in T2DM, activates mTORC1-
dependent anabolic processes and that hyper-activation of mTORC1 drives insulin 
resistance in the OBs, leading to formation of poorly formed bone. At the mRNA level, 
RNA-seq and qRT-PCR analyses of bones from HFD-fed Rptorob
-/-
 mice showed strong 
upregulation of the expression of markers of bone formation and OB differentiation (i.e. 
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Sp7, Ocn, Sparc, Col1a1) and a concomitant downregulation of osteoclast markers (i.e. 
Ctsk, Rank, Trap). To characterise the bone phenotype of HFD-fed Rptorob
-/-
 mice, 
micro-CT could be used to analyse bone microarchitecture and structure. Furthermore, 
histomorphometry could be used to assess the effects of potentiation of local insulin 
signalling, as a result of mTORC1 inhibition, on bone modelling and remodelling or 
bone microenvironment, including marrow adiposity, mesenchymal stromal cell fate 
and local inflammation. 
What  other potential mechanisms are revealed by the RNA-seq data?  
RNA-sequencing and GSEA have identified critical pathways that are involved in 
mTORC1-dependent skeletal regulation of glucose homeostasis, including upregulation 
of glycolysis and glucose oxidation pathways in the bone of Rptorob
-/-
 mice. Somewhat 
surprisingly, muscle-related pathways (Supplementary Table 3.4) were found to be 
significantly enriched (i.e. upregulated) in the long bones of Rptorob
-/-
 mice, despite all 
the muscle having been stripped from the tibia/femur during dissection such that no 
muscle was present when RNA was isolated from the flushed cortical and trabecular 
bone. Upon examination of the literature, at least two studies have reported expressions 
of muscle-related genes in the bone cell population. In the first study, the authors 
utilised a dual GFP reporter to selectively isolate mature OBs and osteocytes and,  using 
RNA-seq, identified muscle-related genes as being highly expressed in pre-osteocytes 
and osteocytes compared to osteoblasts
113
. In another study, an examination of gene 
expression patterns in the rat ulnae, following mechanical loading, revealed a 
downregulation of muscle-related genes, together with TGF-β and Wnt/β-catenin 




 mice, RNA-seq 
and GSEA have identified the coincident upregulation of bone formation and muscle-
related genes, which appears to contradict previous reports
114
. As the involvement of 
muscle-related genes in bone biology is still unclear, this disparity could be due to the 
condition of the animals (subjected to mechanical loading) or heterogeneity of the bone 
cell populations whereby the RNA of Rptorob
-/-
 mice could contain a higher proportion 
of osteocytes.  
Another interesting positively enriched pathway identified in the long bones of Rptorob
-/-
 
mice were calcium signalling pathways, in particular, Sarco/Endo-plasmic reticulum 
(SR/ER) Ca
2+
-ATPase (SERCA) which transfers Ca
2+
 from the sarcoplasm into the 





. It is possible that the upregulation of this pathway in the bone of Rptorob
-/-
 
mice could provide an additional mechanism underlying their resistance to obesity in 
addition to the increase browning of their white adipose depots.  
While there are three distinct genes that encode SERCA isoforms and the physiological 
function of each isoform remains unclear, SERCA1 gene is expressed exclusively in 
fast skeletal muscle and is essential for non-shivering thermogenesis. In contrast, 
SERCA3 and SERCA2b genes are expressed in blood platelets and lymphoid 
tissues
116,117,118
. A recent study has reported a role for SERCA2b, in beige adipocytes, in 
the elevation of energy expenditure and glucose oxidation in an UCP1-independent 
manner
119
. RNA-seq analysis revealed significant upregulation of the Atp2a1 gene, 
which encods for SERCA1, while GSEA identifies positive enrichment of pathways 
involved in SR-Ca
2+
 transport, release of Ca
2+
 and cardiac muscle contraction in the 
bone of Rptorob
-/-
 mice. In regard to mTORC1, rapamycin-mediated inhibition of 





 and attenuated ER-stressed induced apoptosis in IRE1-JNK 
signalling manner
121,122
. Furthermore, activation of the SERCA pump has been reported 
in response to ER stress
123,124
 and is involved in the initial phase of autophagy
125
 
suggesting the potential molecular connection between mTORC1 and SERCAs. The 
expression and specific function of SERCA1 in bone cells is currently unknown. 
Western blot could be used to confirm the increase of SERCA1 at the protein levels in 
the bone of Rptorob
-/-
 mice while in vitro confirmation of Atp2a1 expression and its 
cellular location (by qRT-PCR and immunocytochemistry) could be performed on 
Rptor KO OBs. Depletion of SERCA1 in primary OBs culture by lentivirus shRNA or 
CRISPR/Cas9 genome editing, followed by functional assays including oxygen 
consumption assays, intracellular Ca
2+
 flux assays, and glucose uptake and oxidation 
assays could be performed to gain further understanding of the role of SERCA1 in OB 







Over-nutrition causes hyper-activation of mTORC1-dependent negative feedback loops 
leading to down-regulation of insulin signalling and development of insulin resistance. 
In OBs, insulin signalling plays a crucial role in the control of systemic glucose 
homeostasis. To investigate a role of OB-mTORC1 in the regulation of glucose 
metabolism, mice with an OB-specific deletion of Rptor (Rptorob
-/-
) were generated. 
Compared to the controls, Rptorob
-/-
 mice had substantially less fat mass and exhibited 
adipocyte hyperplasia. Remarkably, they were also protected from diet-induced obesity 
and exhibited improved glucose metabolism with lower fasting glucose and insulin 
levels, increased glucose tolerance and insulin sensitivity. This leanness and resistance 
to weight gain was not attributable to changes in food intake, physical activity or lipid 
absorption but instead was due to increased energy expenditure and greater whole-body 
substrate flexibility. RNA-seq revealed an increase in glycolysis and skeletal insulin 
signalling pathways, which correlated with potentiation of insulin signalling and 
increased insulin-dependent glucose uptake in Rptor-knockout osteoblasts. Collectively, 
these findings point to a critical role for the mTORC1 complex in the skeletal regulation 
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APPENDIX III: DETAILS OF AMENDMENTS MADE TO THE THESIS 
Page 
amended 
Amended text or correction 
Page 39 The Osx1-GFP:Cre and Rptor
fl/fl
 mice lines were bred separately. The 
Osx1-GFP:Cre line was maintained by mating F1 males harboring a 
single copy of the tTA:Osx1-GFP:cre transgene with wildtype 
C57BL/6J females. For the Rptor
fl/fl
 line, all F2 mice were produced 
from the offspring of F1 breeders. For the Osx1-GFP:Cre x Rptor
fl/fl
 
crosses, all F2 mice were produced by new crosses between separate F1 
male Osx1-GFP:Cre and female Rptor
fl/fl
 mice. As preliminary studies 
revealed that serum OCN levels (both total and undercarboxylated), 
fasting glucose levels and glucose metabolism (glucose tolerance and 
insulin sensitivity) were unaltered in Osx1-GFP:Cre mice relative to 
age/sex matched wildtype mice, wildtype Osx1-GFP:Cre-negative; 
Rptor
fl/fl
 littermates were used as the control group (Supplementary 
Figure 2.1, A-I). It is also important to note that no detectable off-target 
Cre recombinase activity in metabolic tissues including spleen, liver, 
brain and intestine has been observed in Osx1-GFP:Cre mice
5
. 
Furthermore, as Osx1-GFP:Cre line has been reported to develop 
malocclusion when maintain without doxycycline
6
 all Osx1-GFP:Cre-
positive animals were closely monitored and their teeth were trimmed 
fortnightly. Animals were weighed twice-weekly for the duration of the 
study and at the end of the study, body length and whole-body lean and 
fat mass were measured post-mortem using a dedicated mouse dual X-
ray absorbitometer (DXA) (Lunar Piximus II, GE Medical Systems, 
Madison WI, USA). 
Page 42 2.3.9 RNA isolation and quantitative RT-PCR. Unless otherwise stated, 
all RNA extractions were carried out using TRIzol reagent (Sigma) 
according to manufacturer’s instructions. Total RNA (1.5 µg) was 
reverse transcribed into cDNA using Superscript IV Reverse 
Transcriptase (Invitrogen, Carlsbad, CA, USA). Real-time PCR 
reactions were performed using RT
2
 SYBR Green ROX reagent 
(QIAGEN, Hilden, Germany) in a CFX Connect™ Real-Time PCR 
machine (Bio-Rad). Forward and reverse primer pairs, designed to 
amplify across intron-exon boundaries, are listed in Supplementary 
Table 2.2. The efficiencies of PCR were assessed with visual 
assessment of geometric amplification slopes and relative mRNA 





2.3.10 Statistical analysis. All data are presented as mean ± standard 
error of the mean (SEM). Statistical analyses were performed using a 
one-way or two-way ANOVA with a Tukey test or an unpaired 
Students t-test using GraphPad Prism (GraphPad Software Inc, CA, 
USA). Significance was accepted at p<0.05, with asterisks denoting p-
value levels: *p < 0.05; **p< 0.01; ***p < 0.001. 
Page 45 Figure 2.1K was amended with correct representative images. The 
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figure legend describing Figure 2.1 has been amended to replace on-
way ANOVA with two-way ANOVA. 
Page 48 Figure 2.2I and J were amended to present the absolute glucose levels. 
The figure legend describing Figure 2.2 has been amended to replace 
on-way ANOVA with two-way ANOVA. 
Page 51  Figure 2.3B and C were amended to present food intake as kcal or kcal 
normalised to gram of lean mass, respectively and the legend have been 
updated as follows: 
Fig. 2.3 Loss of OB-mTORC1 function shifts whole-body fuel 
utilisation toward fat oxidation. (A) Serum leptin levels in 9-week 
old male and female mice (n=7-15/genotype). (B) Food intake per day, 
measured over 48-h, presented as absolute food intake (kcal/day), or 
(C) normalised to lean mass (kcal/g lean mass/day). (D) Faecal lipid 
content (% lipid/g faeces) (n=7-10/genotype). (E) Ambulatory X+Y 
axis activity per day. (F) Z-axis (rearing) locomotor activity per day. 
(G) Total energy expenditure, normalised to lean mass, per light and 
dark cycle, and (H) over a 48-h time course in male mice. (I) Average 
respiratory quotient (RQ) per light and dark cycle, or (J) over a 48-h 
time course in male mice. (K) Total energy expenditure, normalised to 
lean mass, per light and dark cycle, and (L) over a 48-h time course in 
female mice. (M) Average respiratory quotient (RQ) per light and dark 
cycle, or (N) over a 48-h time course in female mice. (O) Fasting serum 
ketone body levels (n=4-5/genotype). (P) Serum triglyceride levels 
measured at non-fasted condition (n=6-10/genotype). (Q) Serum free 
fatty acid levels measured at non-fasted condition (n=8-11/genotype). 
All panels: data are expressed as mean ± SEM from n=5-6/group, 
unless indicated otherwise. *p<0.05, **p<0.01, ***p<0.001, two-way 
ANOVA with Tukey’s post-hoc test. Panels H, J, L, N: shaded regions 
represent dark cycle. 
Page 84 Both male and female Rptorob
-/-
 mice weighed significantly less the 
control mice (Fig.3.1A and B). As shown in Figure 3.1C and D, 
Rptorob
-/-
 mice initially gained weight on the HFD at a similar rate to 
control and Rptorob
-/+ 
mice, and in the case of female mice, gained 
weight more rapidly. However, unlike the control and Rptorob
-/+ 
mice, 
which continued to gain weight in response to the obesogenic diet, 
weight gain in the Rptorob
-/-
 mice plateaued after approximately 6 
weeks and they gained only a small amount of additional weight 
thereafter (i.e. from 6-13 weeks on HFD, control mice gained 9.3g and 
7.2g in male and female respectively, whereas Rptorob
-/-
 mice gained 
only 1.7g; Fig. 3.1C-D).  
The lower body weight of Rptorob
-/- 
mice was independent of difference 
in their body length but rather due to the changes in the body 
composition as suggested by a significant lower BMI in the Rptorob
-/- 
mice (Supplementary Fig. 3.2A-B). Further examination of body 
composition in these HFD-fed mice revealed that the difference in their 
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body weight was largely attributable to a significant reduction in fat 
mass in Rptorob
-/-
 mice (Fig. 3.1E), with a modest reduction in lean 
mass also observed (Supplementary Fig. 3.2C-D). When expressed as a 
percentage of total body mass, fat mass in male or female Rptorob
-/-
 
mice was 50% lower than that of the control mice (Fig. 3.1F). The total 
fat mass and % fat mass of HFD-fed Rptorob
-/+ 
mice was also found to 
be significantly lower than the controls in the male, but not female 
cohorts (Fig. 3.1E and F). Furthermore, the difference in fat mass in 
HFD-fed Rptorob
-/-
 mice was clearly evident upon dissection and 
analysis of individual fat pad weights (Fig. 3.1G and H), whereas no 
such differences in lean organ weights (i.e. liver, heart, kidney, brain, 
spleen; Supplementary Fig. 3.2E and F) were observed in Rptorob
-/-
 
mice compared to controls.  
Page 85 This suggests that Rptorob
-/-
 mice maintain their constant weight and 
energy balance through greater substrate flexibility, with greater 
utilization of fat storage during the light cycle which provide a glycerol 
substrate for increased gluconeogenesis, thus resulting in higher 
carbohydrate oxidation in the dark cycle (Fig. 3.1K and L). Conversely, 
in Rptorob
+/-
 mice, higher carbohydrate oxidation and lipid synthesis in 
the dark cycle was not offset by greater utilization of fat storage during 
the light cycle. Thus, even with greater substrate flexibility, as is 
evident in Rptorob
-/-
 mice, higher energy storage during the dark cycle 
surpassed fat oxidation during the light cycle, resulting in overall 
continuous weight gain. In contrast, the average phasic RQ values of 
the control mice remained approximately constant, which is indicative 
of fewer shifts in their fat storage and oxidation and a more constant 
accumulation of adipose tissue mass. 
Page 86 Figure 3.1 was amended to include total body weight over the time-
course of high fat diet feeding (panel A and B) and the legend have 
been updated as follows: 
Fig. 3.1 HFD-fed Rptorob
-/-
 mice are protected against diet-induced 
obesity and exhibit greater substrate flexibility. (A-B) Temporal 
body weight changes in male and female mice (n≥15/genotype). (C-D) 
Body weight gained in response to high fat diet (HFD) in male and 
female mice (n≥15/group). Dotted lines indicate the point at which 
Rptorob
-/-
 mice became resistant to further weight gain. (E-F) DXA 
analysis of total fat mass and % fat mass normalised to total body 
weight in 18-week old HFD-fed mice (n=4-5/genotype). (G-H) gWAT 
and iWAT fat pad mass, normalised to body weight, in male and 
female mice at 18-week of age (n=4-9/genotype). (I-J) Total energy 
expenditure, normalised to lean mass, over a 48-h time course (left) and 
per light/dark cycle (right) in male and female HFD-fed mice (n=5-
7/genotype). (K-L) Average respiratory quotient (RQ) over a 48-h time 
course (left) and per light and dark cycle (right) in male and female 
mice (n=5-7/genotype). All panels: data are expressed as mean ± SEM. 
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*p<0.05, **p<0.01, ***p<0.001, two-way ANOVA with Tukey’s post-
hoc test. Panels H-K: shaded regions represent dark cycle. 
Page 93 Male Rptorob
-/-
 mice showed a trend toward decreasing fasting glucose 
levels over the time course of HFD. Specifically, in 16-week old male 
Rptorob
-/-
 mice, the fasting glucose levels were significantly lower than 
Rptorob
-/+ 
and control mice (Fig. 3.5A) while the fasting glucose levels 
of female Rptorob
-/-
 mice were persistently lower than the control mice 
(Fig. 3.5B). The lower levels of fasting glucose in the Rptorob
-/-
 mice 
were accompanied by a significant lower fasting insulin levels (Fig. 
3.5C). As a result, calculation of homeostatic model assessment of 
insulin resistance (HOMA-IR) identify them as being more insulin-
sensitive that both the Rptorob
-/+ 
and control mice (Fig. 3.3D).  
Studies
12
 suggest that in cases of significant difference in the fasting 
glucose levels, assessing glucose levels as a percentage of basal glucose 
for an ITT, can lead to erroneous interpretation of the results and thus 
all the ITT results were presented as absolute glucose levels. At 16 
weeks of age, both male and female Rptorob
-/-
 mice recapitulated all the 
key features of the metabolic profiles that were evident in the normal 
chow-fed studies, including the maintenance of higher glucose 
tolerance (Fig. 3.5E-G) as evidenced by with consistently lower 
glucose levels and significantly lower incremental area under the curve 
(iAUC) and higher responsiveness to insulin (Fig. 3.5H- J) compared to 
the controls. The improvements in glucose disposal in both male and 
female Rptorob
-/-
 mice were associated with a higher fold change of 
insulin levels at 30 minutes post glucose injection, as measured by 
glucose-stimulated insulin secretion tests (Fig. 3.5K-N). Moreover, 
smaller β-cell islet hypertrophy was observed in male Rptorob
-/-
 mice 
(Fig. 3.5N) which may have been a secondary effect of persistently low 
glucose levels. 
Page 94 Figure 3.5 and the legend have been updated as follows: 
Fig. 3.5 HFD-fed Rptorob
-/-
 mice are protected against diet-induced 
insulin resistance. (A-B) Fasting glucose levels over 8-17 weeks old 
male (A) and female (B) mice (n=5-15/genotype). (C) Fasting insulin 
levels (n=8-10/genotype). (D) HOMA-IR calculations of HFD-fed 
female mice (n=3-8/genotype). (E-F) Glucose tolerance tests (GTTs) in 
17-week old male (E) and female (F) mice (n=6-15/genotype). (G) 
Incremental area under the curve analysis from (E-F). (H-I) Insulin 
tolerance tests (ITTs) in 16-week old male (H) and female (I) mice 
(n=6-15/genotype). (J) Area under the curve analysis from (H-I). (K-
N) Insulin levels during a glucose-stimulated insulin secretion tests 
(GSIS) in male (K) and female (M) and Fold change in insulin levels at 
30 minutes post glucose injection relative to basal levels (L and N) 
(n=8-10/genotypes). (O) Mean pancreatic islet area (n=5/genotype) and 
representative image of insulin immunostaining of pancreas at 18-week 
of age, scale bar=50μm. All panels except E, F, H and I: data are 
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expressed as mean ± SEM. *p<0.05, **p<0.01, ***p<0.001, two-way 
ANOVA with Tukey’s post-hoc test. For panel E, F, H and I: *p<0.05 
between Rptorob
-/-











 and Ctrl, two-way ANOVA with 
Tukey’s post-hoc test. 
Page 96 Figure 3.6B was amended to include quantification of protein of 
interest at the basal levels. 
Page 97 Figure 3.7B was amended to include quantification of protein of 
interest at the basal levels. 
Page 107 Based on the data generated herein, the mechanisms underlying the 
obesity-resistance phenotype of Rptorob
-/-
 mice likely include (i) their 
ability to switch substrate oxidation during the light and dark period, 
and (ii) their ability to increase browning of iWAT via upregulation of 
Ucp1 expression. 
Page 110 Supplementary Figure 3.1 and 3.2 were swapped.  
Page 111 Supplementary Figure 3.2 was amended to include body length (panel 
A), body mass index (panel B) and percentage of lean mass (panel D) 
and the legend have been updated as follows: 
Supplementary Fig. 3.2 Daily food intake, physical activities and % 
of fecal lipid are normal in HFD-fed Rptorob
-/-
 mice. (A) Body length 
of 18-week old mice, as measured from nose to anus (n=4-5/genotype). 
(D) Body mass index (BMI) (n=4-5/genotype). (B-D) DXA analysis of 
total lean mass and % lean mass in male and female HFD-fed mice 
(n=4-5/genotype). (E-F) Lean organ weights, normalised to total body 
weight, in 18-week-old HFD-fed male and female mice (n=4-
9/genotype). (G) %lipid content of 1g faeces collected from male and 
female HFD-fed mice (n=9-10/genotype). (E-F) Food intake 
normalised to lean mass (kcal/g lean mass), measured over a 48-h 
period (left) and per 12-h light/dark cycle (right) in HFD-fed male and 
female mice (n=5-7/genotype). (H-I) Total activity (distance of 
movement) measured over a 48-h period (left) and per 12-h light/dark 
cycle (right) in HFD-fed male and female mice (n=5-7/genotype). All 
panels: data are expressed as mean ± SEM. *p<0.05, two-way ANOVA 
with Tukey’s post-hoc test. Panels E-H: shaded regions represent dark 
cycle. 
 
 
 
